US20230416383A1 - MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 - Google Patents
MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 Download PDFInfo
- Publication number
- US20230416383A1 US20230416383A1 US18/308,778 US202318308778A US2023416383A1 US 20230416383 A1 US20230416383 A1 US 20230416383A1 US 202318308778 A US202318308778 A US 202318308778A US 2023416383 A1 US2023416383 A1 US 2023416383A1
- Authority
- US
- United States
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 title claims abstract description 248
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 title claims abstract description 177
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 title description 104
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 title description 7
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 title description 3
- 108091008324 binding proteins Proteins 0.000 claims abstract description 252
- 239000000427 antigen Substances 0.000 claims abstract description 144
- 241000282414 Homo sapiens Species 0.000 claims abstract description 143
- 102000036639 antigens Human genes 0.000 claims abstract description 142
- 108091007433 antigens Proteins 0.000 claims abstract description 142
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 123
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 116
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 116
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 83
- 102000050738 human NCR1 Human genes 0.000 claims abstract description 81
- 102000052088 human IL3RA Human genes 0.000 claims abstract description 74
- 108010073807 IgG Receptors Proteins 0.000 claims abstract description 71
- 102000009490 IgG Receptors Human genes 0.000 claims abstract description 70
- 238000011282 treatment Methods 0.000 claims abstract description 57
- 230000002265 prevention Effects 0.000 claims abstract description 31
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 857
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 392
- 229920001184 polypeptide Polymers 0.000 claims description 388
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 388
- 210000004027 cell Anatomy 0.000 claims description 274
- 102000023732 binding proteins Human genes 0.000 claims description 250
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 76
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 75
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 54
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 54
- 230000000295 complement effect Effects 0.000 claims description 45
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 150000007523 nucleic acids Chemical class 0.000 claims description 43
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 30
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 30
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 20
- 238000012258 culturing Methods 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 12
- 230000004988 N-glycosylation Effects 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 201000005787 hematologic cancer Diseases 0.000 claims description 8
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 claims description 5
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 5
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims description 5
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims description 4
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 239000000203 mixture Substances 0.000 abstract description 18
- 230000002062 proliferating effect Effects 0.000 abstract description 6
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 104
- 210000000822 natural killer cell Anatomy 0.000 description 96
- 230000014509 gene expression Effects 0.000 description 42
- 235000001014 amino acid Nutrition 0.000 description 40
- 229940024606 amino acid Drugs 0.000 description 39
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 35
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 35
- 230000000694 effects Effects 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 29
- 239000012634 fragment Substances 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 27
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 26
- 229940027941 immunoglobulin g Drugs 0.000 description 26
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 25
- 241000282693 Cercopithecidae Species 0.000 description 24
- 102000004127 Cytokines Human genes 0.000 description 24
- 108090000695 Cytokines Proteins 0.000 description 24
- 230000003013 cytotoxicity Effects 0.000 description 23
- 231100000135 cytotoxicity Toxicity 0.000 description 23
- 102000004889 Interleukin-6 Human genes 0.000 description 22
- 108090001005 Interleukin-6 Proteins 0.000 description 22
- 210000003651 basophil Anatomy 0.000 description 22
- 238000001802 infusion Methods 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 19
- 230000003213 activating effect Effects 0.000 description 19
- 238000003556 assay Methods 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 230000007774 longterm Effects 0.000 description 19
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 17
- 238000000684 flow cytometry Methods 0.000 description 16
- 230000003211 malignant effect Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 241001529936 Murinae Species 0.000 description 14
- 235000018417 cysteine Nutrition 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 11
- 102000003814 Interleukin-10 Human genes 0.000 description 11
- 108090000174 Interleukin-10 Proteins 0.000 description 11
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 11
- 230000001472 cytotoxic effect Effects 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 238000002513 implantation Methods 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 230000002147 killing effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 241000282567 Macaca fascicularis Species 0.000 description 9
- 230000006051 NK cell activation Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- -1 CD32a/b Proteins 0.000 description 8
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 8
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 8
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 8
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 8
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 8
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 7
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 7
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 7
- 238000011579 SCID mouse model Methods 0.000 description 7
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 102000053350 human FCGR3B Human genes 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 206010052015 cytokine release syndrome Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 108020001019 DNA Primers Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 4
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 150000001945 cysteines Chemical class 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 230000006240 deamidation Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 102000057266 human FCGR3A Human genes 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 206010066476 Haematological malignancy Diseases 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 239000007836 KH2PO4 Substances 0.000 description 3
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 101710138747 Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 210000003969 blast cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000014564 chemokine production Effects 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000607 toxicokinetics Toxicity 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 2
- 101000917821 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-c Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052754 neon Inorganic materials 0.000 description 2
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 101000797614 Arabidopsis thaliana Protein MEI2-like 5 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- SJUXYGVRSGTPMC-IMJSIDKUSA-N Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O SJUXYGVRSGTPMC-IMJSIDKUSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010021470 Fc gamma receptor IIC Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 description 1
- 101100396742 Homo sapiens IL3RA gene Proteins 0.000 description 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
- 101000604993 Homo sapiens Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 1
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102000018883 Interleukin-3 Receptor alpha Subunit Human genes 0.000 description 1
- 108010052781 Interleukin-3 Receptor alpha Subunit Proteins 0.000 description 1
- 102000010786 Interleukin-5 Receptors Human genes 0.000 description 1
- 108010038484 Interleukin-5 Receptors Proteins 0.000 description 1
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 101150040801 Ncr1 gene Proteins 0.000 description 1
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 102100025369 Runt-related transcription factor 3 Human genes 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- MYVYPSWUSKCCHG-JQWIXIFHSA-N Trp-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 MYVYPSWUSKCCHG-JQWIXIFHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000276 dose-dependent cytotoxicity Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000008274 immunosurveillance mechanism Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Definitions
- V 1A is V L1 and V 1B is V H1 .
- V 2A is V H2 and V 2B is V L2 .
- V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;
- V L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9;
- V H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15;
- V L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 27; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 28;
- V H1 and V L1 corresponds to the amino acid sequences of SEQ ID NO: 41 and 43 respectively or corresponds to the amino acid sequences of SEQ ID NO: 42 and 44 respectively;
- V H2 and V L2 corresponds to the amino acid sequences of SEQ ID NO: 45 and 53 respectively; the amino acid sequences of SEQ ID NO: 46 and 54 respectively; the amino acid sequences of SEQ ID NO: 47 and 55 respectively; the amino acid sequences of SEQ ID NO: 48 and 56 respectively; the amino acid sequences of SEQ ID NO: 49 and 57 respectively; the amino acid sequences of SEQ ID NO: 50 and 58 respectively; the amino acid sequences of SEQ ID NO: 51 and 59 respectively; or the amino acid sequences of SEQ ID NO: 52 and 60 respectively.
- polypeptide (I) comprises an amino acid sequence of SEQ ID NO: 64; polypeptide (II) comprises an amino acid sequence of SEQ ID NO: 65; and polypeptide (III) comprises an amino acid sequence of SEQ ID NO: 66.
- the disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising the binding protein defined above, and a pharmaceutically acceptable carrier.
- the disclosure relates to an expression vector comprising the nucleic acid molecule defined above.
- the disclosure relates to an isolated cell comprising the nucleic acid molecule defined above.
- the disclosure relates to an isolated cell comprising the expression vector defined above.
- the host cell is a mammalian cell.
- the disclosure relates to a method for making the binding protein defined above, comprising the steps of: (a) introducing the expression vector defined above into a host cell; (b) culturing the host cell under conditions suitable for expressing the binding protein; and (c) optionally recovering the expressed binding protein.
- the disclosure relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a binding protein as defined above, and characterized in that it comprises a first and a second antigen binding domain (ABD) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABD comprises an immunoglobulin heavy chain variable domain (V H ) and an immunoglobulin light chain variable domain (V L ), wherein each V H and V L comprises three complementary determining regions (CDR-1 to CDR-3); wherein:
- the disclosure relates to an expression vector comprising a nucleic acid molecule comprising a nucleotide sequence that encodes of or more polypeptide chains of the binding protein, as defined above.
- the disclosure relates to an isolated cell comprising the nucleic acid molecule as defined above.
- the disclosure relates to an isolated cell comprising the expression vector as defined above.
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method of treating or preventing a blood cancer, the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- the disclosure relates to a method of treating or preventing a myelodysplastic syndrome (MDS) or a lymphoproliferative disorder, the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- MDS myelodysplastic syndrome
- lymphoproliferative disorder the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- the disclosure relates to a method of treating or preventing an Acute Myeloid Leukemia (AML), the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- AML Acute Myeloid Leukemia
- the disclosure relates to a method of treating or preventing a CD64-positive and CD64-negative Acute Myeloid Leukemia (AML), the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- AML Acute Myeloid Leukemia
- the disclosure relates to a method of treating or preventing a CD64-positive Acute Myeloid Leukemia (AML), the method comprising administering to a subject in need of said treatment or prevention a binding protein comprising a first and a second antigen binding domain (ABD) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123, the second ABD binds specifically to human NKp46, and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc- ⁇ receptor.
- AML Acute Myeloid Leukemia
- binding proteins of the present disclosure are oriented with the amino terminal direction (“N-terminal end” or “N-term”) on the left-hand side and the carboxyl-terminal direction (“C-terminal end” or “C-term”) on the right-hand side, in accordance with standard usage and convention.
- FIG. 1 Tri-dimensional schematic representation of the F25 format which is a variant of the bispecific F5 format, including one human NKp46 binding site and one human CD123 binding site.
- the C-term of the polypeptide is on the left-hand side and the N-term is on the right-hand side.
- FIG. 2 A - FIG. 2 D show two-dimensional schematic representations of the F25, F5, F26 and F6 formats respectively including the relevant domains for each polypeptide chain.
- the C-term of the polypeptide is on the left-hand side and the N-term is on the right-hand side.
- the human NKp46 binding domain is formed by the VH/VL pair on the left side.
- the human CD123 binding domain is formed by the VH/VL pair on the right side.
- FIG. 2 A shows a two-dimensional schematic representation of the F25 format. This representation represents the claimed “NKp46-CD123_F25” binding protein.
- FIG. 2 B shows a two-dimensional schematic representation of the F5 format.
- the F5 differs in that the C L and C H pair of the NKp46 binding domain are swapped, with the third polypeptide chain comprising a C H 1 domain and a V L domain.
- FIG. 2 D shows a two-dimensional schematic representation of the F6 format. This F6 differs from F5 of FIG. 2 B in that it includes a Fc-silent N297S mutation on each C H 2 domain.
- FIG. 2 E shows a two-dimensional detailed representation of a variant of the F25 format. This F25 format representation corresponds to the one in FIG. 2 A .
- FIG. 3 shows a proposed mechanism of action of a NK Cell Engager (NKCE) for killing, following joint binding of a tumor cell (i.e. an AML cell line; i.e. MOLM-13) expressing CD123 and a NK cell expressing NKp46 and a Fc ⁇ receptor (CD16a).
- a tumor cell i.e. an AML cell line; i.e. MOLM-13
- NKp46 a NK Cell Engager
- Fc ⁇ receptor CD16a
- FIG. 4 A - FIG. 4 B report the in vitro cytotoxicity of the NKp46-CD123_F25 binding protein of the present disclosure against AML cell line (MOLM-13) or primary AML blast cells respectively.
- FIG. 4 A shows the in vitro cytotoxicity of the NKp46-CD123_F25 binding protein of the present disclosure and negative isotype control variant of format F25 binding NKp46 only (NKp46-IC_F25) against AML cell line (MOLM-13).
- FIG. 4 A shows the in vitro cytotoxicity of the NKp46-CD123_F25 binding protein of the present disclosure and negative isotype control variant of format F25 binding NKp46 only (NKp46-IC_F25) against AML cell line (MOLM-13).
- FIG. 5 provides in-vitro cytotoxicity data using fresh healthy donor NK cells against MOLM-13 AML cell line (EC 50 data) of the NKp46-CD123_F25 binding protein of the present disclosure which is capable of activating human NK cells by engaging both NKp46 and CD16a, inducing ADCC activity with its Fc competent format (F25), and a NKp46-CD123_F6 binding protein activating human NK cells by engaging NKp46 only and not CD16a, inducing reduced ADCC-activity with its Fc silent format (F6).
- FIGS. 7 A - FIG. 7 B report the ex vivo induction of NK degranulation measured through the percentage of CD107a-positive NK cells against primary AML blasts from two different donors.
- Primary AML blasts from donor #1 are CD64(+) ( FIG. 7 A ) and primary AML blasts from donor #2 are CD64( ⁇ ) ( FIG. 7 B ).
- the tested binding proteins are the NKp46-CD123_F25 binding protein of the present disclosure, an anti-CD123 ADCC-enhanced antibody with no specificity for NKp46 (Reference-1), a negative isotype control variant of format F25 not binding CD123 but binding NKp46 and CD16a (NKp46-IC_F25) and a negative isotype control Fc-optimized antibody with increased ADCC activity with no specificity for NKp46 nor CD123 (IC_hIgG1-ADCC-enh).
- FIG. 8 reports dose-dependent anti-tumor activity with the muNKp46-huCD123_F25 binding protein (carrying anti-murineNKp46 and anti-humanCD123 binding domains and also known as moNKp46-huCD123) against MOLM-13 human cells in a Severe Combined ImmunoDeficient mice (SCID) mouse model.
- SCID Severe Combined ImmunoDeficient mice
- FIG. 9 A - FIG. 9 C report the CD123-positive basophil depletion for up to 28 days after the administration NKp46-CD123_F25 binding protein of the present disclosure in non-human primates (M1, M2, M3, M4 and M6) at 3000 ⁇ g/kg or 3 mg/kg ( FIG. 9 A ), at 3 ⁇ g/kg ( FIG. 9 B ), and at 0.5 ⁇ g/kg ( FIG. 9 C ).
- M1, M2, M3, M4 and M6 non-human primates
- FIG. 10 A - FIG. 10 B reports the in-vitro cytotoxicity of two NKp46-CD123 NKCE Fc-competent binding proteins (the NKp46-CD123_F25 of the present disclosure and NKp46-CD123_F5) and a control variant of format F5 binding CD123 and CD16a but not binding NKp46 (CD123-IC_F5) against two AML cell lines, MOLM-13 ( FIG. 10 A ) and THP-1 ( FIG. 10 B ) in presence of NK cell healthy donor sample (D648).
- Central panel reports NKp46-CD123_F25 maximum depletion activity at the highest dose tested (10 ⁇ g/mL, 68 nM).
- Right panel reports the EC 50 (pM) for CD123-positive basophil depletion calculated from NKp46-CD123_F25 dose responses for the PBMCs of six healthy donors.
- TCE tool bispecific T Cell Engager tool
- FIG. 14 A displays the cytotoxicity of NKp46-CD123_F25 binding protein of the present disclosure as compared to an anti-CD123 ADCC-enhanced antibody with no specificity for NKp46 (Reference-1) and a negative isotype control Fc-optimized antibody with increased ADCC activity and no specificity for NKp46 nor CD123 (IC-hIgG1-ADCC-enh) against AML blasts from patients expressing (#AML5, #AML6) or not (#AML1, #AML2) CD64. Malignant cells from AML patients were used as targets and purified healthy donor NK cells were used as effectors. Results are shown for all healthy donor NK cells tested.
- FIG. 14 B reports the phenotype of the malignant AML cells from patients used in FIG. 14 A showing the expression of CD33, CD123, CD32a/b, and CD64 by flow cytometry analysis.
- FIG. 16 A is a flow cytometric analysis of NK and malignant cells from AML patients (AML #8-#10).
- Upper panels display the expression of CD123 on AML blasts (gated on the CD33-positive population); middle panels display the expression of CD64 (CD64 staining in black and isotype control in gray) on CD123-positive AML blasts; and lower panels display expression of NKp46 and CD16a on NK AML sample NK cells.
- FIG. 16 B is an analysis of CD107a/b expression by NK cells after the overnight treatment with NKp46-CD123_F25 (CD123-NKCE), anti-CD123 ADCC-enhanced antibody with no specificity for NKp46 (Reference-1 or CD123-IgG1+ in the graph), a control isotype NKp46-IC_F25 not binding CD123 but binding NKp46 and CD16a (600 and 120 ng/mL) (IC-NKCE) and an IgG1 isotype control (600 ng/ml) (IC-IgG1+) on PBMCs from AML patient samples expressing CD64 (AML #8 and #9) and not expressing CD64 (AML #10) at the cell surface of their blasts.
- NKp46-CD123_F25 CD123-NKCE
- anti-CD123 ADCC-enhanced antibody with no specificity for NKp46 Reference-1 or CD123-IgG1+ in the graph
- FIG. 19 evaluates the impact of NK depletion on the in vivo efficacy of surrogate muNKp46-huCD123_F25 bispecific antibody in SCID mice bearing disseminated human MOLM-13 tumor cells.
- NK depletion was induced by 2 intraperitoneal administrations of anti-asialo GM1 serum one day before tumor cell implantation and at day 5 after implantation.
- MOLM-13 cells were injected intravenously at day 0 in a single administration. Treatments were administered intraperitoneally on day 1 post tumor implantation.
- FIG. 20 B displays the numbers of circulating CD123-positive basophils (open symbols) and total CD123-positive leukocytes (close symbols) at time of study in monkeys M1 (orange) and M2 (purple) treated with 3 mg/kg as single 1-hour intravenous infusion, and monkeys M3 (red) and M4 (blue) treated with 3 ⁇ g/kg as single 1-hour intravenous infusion.
- FIG. 20 C reports cytokine production in cynomolgus monkeys treated with the high and low doses of 3 mg/kg and 3 ⁇ g/kg as single 1-hour intravenous infusion, respectively. Plasma IL-6 and IL-10 concentrations are shown before dosing (0), and 1.5, 5 and 24 hours after the start of the treatment.
- FIG. 20 D reports the plasma NKp46-CD123_F25 (CD123-NKCE) concentration monitored 1.5, 5, 24, 48, 72, 168, 240, 336, 504 and 672 hours (i.e., 0.04, 0.06, 0.21, 1, 2, 3, 7, 10, 14, 21 and 28 days) after the start of the 1-hour infusion of cynomolgus monkeys treated with the high and low doses of 3 mg/kg and 3 ⁇ g/kg.
- the lower limit of quantification (LLOQ; 0.25 ng/mL) is indicated by the horizontal dotted line.
- FIG. 21 B is an analysis of the interleukin-6 production in monkey M5 weekly treated with the high dose of 3 mg/kg/administration for four weeks. Plasma IL-6 concentrations were monitored before dosing and 1, 1.5, 5 and 24 hours after the start of the one-hour infusion on days 1, 8, 15 and before dosing and 1, 1.5, 5, 24, and 168 hours after the start of the last fourth one-hour infusion on day 22.
- FIG. 21 C quantifies the number of circulating CD123-positive basophils (open symbols) and total CD123-positive leukocytes (closed symbols) in blood (left panel) or bone marrow (right panel), by timepoint in the study, for monkey M5, treated at a dose of 3 mg/kg/week.
- FIG. 22 graphically depicts THP1 cytotoxic activity in an assay with human peripheral blood mononuclear cells (PBMC) from 2 healthy donors (HD).
- PBMC peripheral blood mononuclear cells
- HD healthy donors
- NK cells and THP1 GFP target cells were incubated in presence of NKp46-CD123_F25 or its isotype control IC-CD123_F6 engaging CD123 and inducing reduced ADCC-activity with its Fc silent format (F6) at 0.1, 1, 10 and 100 ng/mL.
- F6 Fc silent format
- the disclosure provides multifunctional binding proteins that bind one surface biomarker on immune NK cells, i.e., NKp46 and one antigen of interest on tumoral target cells i.e., CD123 and is capable of redirecting NK cells to lyse a target cell that expresses the CD123 surface biomarker.
- the multifunctional binding proteins of the present disclosure further comprises all or part of a Fc region or variant thereof which binds a Fc- ⁇ receptor (Fc ⁇ R), in particular an activating Fc- ⁇ receptor (Fc ⁇ R), for example Fc ⁇ RIIIa also called CD16a.
- the exemplified multifunctional binding proteins of the present disclosure also possess a dimeric Fc domain that comprises N-linked glycosylation and bind an activating Fc- ⁇ receptor (Fc ⁇ R) such as receptor CD16a thereby providing advantageous immune enhancing activity.
- Fc ⁇ R activating Fc- ⁇ receptor
- the inventors provide experimental evidence that optimal NK cell modulation, in particular NK cell activation, can be achieved with a better safety profile, both in vitro on AML cell lines MOLM-13 and THP1 and ex vivo on primary samples from AML patients (e.g., peripheral blood lymphocytes from AML patients), by engaging NKp46, a Fc ⁇ R such as CD16a, and the cell surface biomarker CD123.
- the in vitro cytotoxic activity of the NKp46-CD123 binding protein of the present disclosure characterized by a format reported herein as the “F25” and comprising a central Fragment crystallizable (Fc) region retaining binding to a human CD16 polypeptide, was reproduced ex vivo.
- the inventors provide experimental support of the therapeutic properties of a bispecific NKp46/CD16-CD123 binding protein in particular for use in treating and preventing AML and other proliferative disorders.
- the inventors further provide experimental evidence that NKp46-CD123 binding protein activate NK cells in primary samples from AML patients irrespective of their CD64 expression status.
- NKp46/CD16 engagement of NK cells through the binding of cell surface markers NKp46/CD16 is validated as a robust and reproducible strategy for use as a medicament.
- the “CD123” marker, or “Cluster of Differentiation 123” is also known as “Interleukin 3 receptor, alpha (IL3RA)” or “IL3R”, “IL3RX”, “IL3RY”, “IL3RAY”, “hIL-3Ra” and denotes an interleukin 3 specific subunit of a heterodimeric cytokine receptor.
- the functional interleukin 3 receptor is a heterodimer that comprises a specific alpha chain (IL-3A; CD123) and the IL-3 receptor beta chain ( ⁇ ; CD131) that is shared with the receptors for granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin 5 (IL-5).
- CD123 is a type I integral transmembrane protein with a deduced Molecular Weight of about 43 kDa containing an extracellular domain involved in IL-3 binding, a transmembrane domain and a short cytoplasmic tail of about 50 amino acids.
- the extracellular domain is composed of two regions: a N-terminal region of about 100 amino acids, the sequence of which exhibits similarity to equivalent regions of the GM-CSF and IL-5 receptor alpha-chains; and a region proximal to the transmembrane domain that contains four conserved cysteine residues and a motif, common to other members of this cytokine receptor family.
- the IL-3 binding domain comprises about 200 amino acid residue cytokine receptor motifs (CRMs) made up of two Ig-like folding domains.
- CCMs cytokine receptor motifs
- the extracellular domain of CD123 is highly glycosylated, with N-glycosylation necessary for both ligand binding and receptor signaling.
- the protein family gathers three members: IL3RA (CD123A), CSF2RA and IL5RA. The overall structure is well conserved between the three members, but sequence homologies are very low.
- One 300 amino-acid long isoform of CD123 has been discovered so far, but only on the RNA level which is accessible on the Getentry database under the accession number ACM241 16.1.
- CD123 the interleukin-3 receptor alpha chain IL-3Ra
- CD123 is a tumor antigen overexpressed in a variety of hematological neoplasms. The majority of AML blasts express surface CD123 and this expression does not vary by subtype of AML. Higher expression of CD123 on AML at diagnosis has been reported to be associated with poorer prognosis. CD123 expression has been reported in other hematological malignancies including myelodysplasia, systemic mastocytosis, blastic plasmacytoid dendritic cell neoplasm (BPDCN), ALL and hairy cell leukemia.
- BPDCN blastic plasmacytoid dendritic cell neoplasm
- NK cells refers to a sub-population of lymphocytes that is involved in non-conventional immunity.
- NK cells can be identified by virtue of certain characteristics and biological properties, such as the expression of specific surface antigens including CD16, CD56 and/or CD57, NKp46 for human NK cells, the absence of the alpha/beta or gamma/delta TCR complex on the cell surface, the ability to bind to and kill cells that fail to express “self” MHC/HLA antigens by the activation of specific cytolytic machinery, the ability to kill tumor cells or other diseased cells that express a ligand for NK activating receptors, and the ability to release protein molecules called cytokines that stimulate or inhibit the immune response.
- NK cells any of these characteristics and activities can be used to identify NK cells, using methods well known in the art. Any subpopulation of NK cells will also be encompassed by the term NK cells.
- active NK cells designate biologically active NK cells, including NK cells having the capacity of lysing target cells or enhancing the immune function of other cells.
- NK cells can be obtained by various techniques known in the art, such as isolation from blood samples, cytapheresis, tissue or cell collections, etc.
- Useful protocols for assays involving NK cells can be found in Natural Killer Cells Protocols (edited by Campbell K S and Colonna M). Human Press. pp. 219-238 (2000).
- NKp46 Natural cytotoxicity triggering receptor 1
- CD335 also known as “CD335” or “NKP46” or “NK-p46” or “LY94” refers to a protein—or polypeptide—encoded by the Ncr1 gene.
- a reference sequence of full-length human NKp46 protein is available from the NCBI database under the accession number NP_004820.
- the human NKp46 extracellular domain (ECD) corresponds to the amino acid sequence of SEQ ID NO: 84.
- the human NKp46 mRNA sequence is described in NCBI accession number NM_004829.
- Fc- ⁇ receptor or “Fc ⁇ R” or “Fc-gamma receptor” may refer to both activating and inhibitory Fc ⁇ Rs.
- Fc-gamma receptors are cellular receptors for the Fc region of an Immunoglobulin G (IgG). Upon binding of complexed IgG, Fc ⁇ Rs can modulate cellular immune effector functions, thereby linking the adaptive and innate immune systems, including ADCC-mediated immune responses.
- IgG Immunoglobulin G
- Fc ⁇ Rs can modulate cellular immune effector functions, thereby linking the adaptive and innate immune systems, including ADCC-mediated immune responses.
- six classic Fc ⁇ Rs are currently reported: one high-affinity receptor (Fc ⁇ RI) and five low-to-medium-affinity Fc ⁇ Rs (Fc ⁇ RIIA, -B and -C.
- Fc ⁇ RIIIA and -B All Fc ⁇ Rs bind the same region on IgG Fc, yet with differing high (FcgRI) and low (FcgRII and FcgRIII) affinities. On a functional level, most of the Fc ⁇ Rs are activating receptors that can induce the cellular responses mentioned above, including ADCC-mediated immune response. Whereas Fc ⁇ RI, Fc ⁇ RIIa, Fc ⁇ RIIc, and Fc ⁇ RIIIa are activating receptors characterized by an intracellular immunoreceptor tyrosine-based activation motif (ITAM), Fc ⁇ RIIb has an inhibition motif (ITIM) and is therefore inhibitory.
- ITAM immunoreceptor tyrosine-based activation motif
- Fc ⁇ Rs encompasses activating receptors, including Fc ⁇ RT (CD64), Fc ⁇ RIIA (CD32a), Fc ⁇ RIIa (CD16a) and Fc ⁇ RIIIb (CD16b), and preferably Fc ⁇ RIIIa (CD16a).
- Fc ⁇ RIIIa (CD16a)” or “Fc ⁇ RIIIa” or “CD16a” or “CD16” or “Cluster of Differentiation 16” may refer to a 50-65 kDa cell surface molecule expressed on mast cells, macrophages, and natural killer cells as a transmembrane receptor.
- Fc ⁇ RIIIa is an activating receptor containing immunoreceptor tyrosine activating motifs (ITAMs) in the associated FcR ⁇ -chain, ITAMs being necessary for receptor expression, surface assembly and signaling.
- CD16a is a low affinity receptor for IgG and is an important receptor mediating ADCC (antibody dependent cell mediated cytotoxicity) by NK cells.
- the high affinity receptor CD16a is preferentially found on NK cells and monocytes and induces antibody-dependent cellular cytotoxicity (ADCC) upon IgG binding.
- ADCC antibody-dependent cellular cytotoxicity
- Fc ⁇ RII CD32 As used herein, the term “Fc ⁇ RII CD32”, “Fc ⁇ RII”, “FCGR2” or “CD32a” or “CD32A” or “CD32” or “cluster of differentiation 32” is a surface receptor glycoprotein belonging to the Ig gene superfamily. CD32A is expressed on all myeloid cells but not on lymphocytes. CD32 has a low-affinity for the Fc region of IgG antibodies in monomeric form, but high affinity for IgG immune complexes. CD32 has two major functions: cellular response regulation, and the uptake of immune complexes. Cellular responses regulated by CD32 include phagocytosis, cytokine stimulation, and endocytic transport.
- Dysregulated CD32 is associated with different forms of autoimmunity, including systemic lupus erythematosus. In humans, there are three major CD32 subtypes: CD32A, CD32B, and CD32C. While CD32A and CD32C are involved in activating cellular responses, CD32B is inhibitory and balances the activating properties of CD32A.
- CD32A is an activating subtype of CD32 that can be found on a variety of immune cells.
- CD32A Fc ⁇ RIIA
- hFc ⁇ RICD64 As used herein, the term “hFc ⁇ RICD64”, “hFc ⁇ RI”, or “CD64” or “Cluster of Differentiation 64” is a surface receptor expressed constitutively only on monocytes and macrophages, but is upregulated on granulocytes upon cytokine stimulation.
- Form 5 or “F5”, “Format 25” or “F25”, “Format F6” or “F6” and “Format 26” or “F26” refer to specific binding protein configurations of bispecific or multispecific antibodies specifically designed to engineer multiple antigen binding domains into a single antibody molecule.
- the multifunctional binding proteins of the present disclosure which comprise a NKp46-binding domain and a CD123-binding domain, are made based on the F25 format, as exemplified in FIG. 1 and FIG. 2 .
- F25 and format F26 respectively differ from format F5 and F6 in that one C H 1/C L pair between the second and third polypeptide chain are swapped to form a C L /C H 1 pair.
- the F5 and F6 format have been previously described in the international patent application WO2017114694, incorporated herein by reference.
- bispecific binding protein refers to a binding protein that specifically binds to two different antigen targets (e.g. human NKp46 and human CD123) through two distinct antigen-binding domains (ABDs).
- two different antigen targets e.g. human NKp46 and human CD123
- ABSDs antigen-binding domains
- the term “specifically binds to” or “binds specifically to” refers to the ability of an antigen-binding domain (ABD) to bind to an antigen (e.g. human NKp46 and/or human CD123) containing an epitope with an Kd of at least about 1 ⁇ 10 ⁇ 6 M, 1 ⁇ 10 ⁇ 7 M, 1 ⁇ 10 ⁇ 8 M, 1 ⁇ 10 ⁇ 9 M, 1 ⁇ 10 ⁇ 10 M, 1 ⁇ 10 ⁇ 11 M, 1 ⁇ 10 ⁇ 12 M, or more, and/or to bind to an epitope with an affinity that is at least twofold greater than its affinity for a nonspecific antigen.
- ABS antigen-binding domain
- the term “specifically binds to human NK46 polypeptide” may refer to a specific binding toward a polypeptide comprising an amino acid sequence of SEQ ID NO: 84.
- the term “specifically to a human CD123 polypeptide” may refer to a specific binding toward a polypeptide comprising an amino acid sequence of SEQ ID NO: 86.
- binds to a human Fc- ⁇ receptor polypeptide may refer to a binding toward a polypeptide comprising an amino acid sequence of SEQ ID NO: 87 or SEQ ID NO: 88.
- Binding specificity can be quantitatively determined by an affinity constant KA (or KA) and a dissociation constant KD (or K D ).
- affinity concentration (EC50) or the equilibrium dissociation constant (KD) means the strength of the binding of an antibody or polypeptide to an epitope.
- the affinity of an antibody is given by a specific type of equilibrium constant, which is the dissociation constant KD, defined as [Ab] ⁇ [Ag]/[Ab-Ag], where [Ab-Ag] is the molar concentration of the antibody-antigen complex, [Ab] is the molar concentration of the unbound antibody and [Ag] is the molar concentration of the unbound antigen.
- KD dissociation constant
- the affinity constant KA is defined by 1/KD.
- a K D of less than 50 nM as determined by SPR, and under physiological conditions may generally be considered as indicative of specificity of binding for antigen-antigen binding domain (ABD) interactions.
- binding proteins reported herein comprise:
- treating refers to a therapeutic use (i.e., on a subject having a given disease) and means reversing, alleviating, inhibiting the progress of one or more symptoms of such disorder or condition. Therefore, treatment does not only refer to a treatment that leads to a complete cure of the disease, but also to treatments that slow down the progression of the disease and/or prolong the survival of the subject.
- preventing means a prophylactic use (i.e., on a subject susceptible of developing a given disease and encompasses the treatment of relapsed AML patient.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific polypeptide employed; the specific composition employed, the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific polypeptide employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts. For example, it is well known within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- a plurality of may thus include «two» or «two or more».
- the constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans-placental mobility, complement binding, and binding to Fc receptors (FcR).
- the Fv fragment is the N-terminal part of the antigen-binding fragment (Fab) of an immunoglobulin and consists of the variable portions of one light chain and one heavy chain.
- multifunctional binding protein encompass a multichain protein, including but not limited to antibody-like polypeptide or protein formats, which comprises at least one first variable region (e.g. a first immunoglobulin heavy chain variable domain (V H ) and/or an immunoglobulin light chain variable domain (V L )) binding specifically to a human CD123 polypeptide, and at least one second variable region (e.g. a second immunoglobulin heavy chain variable domain (V H ) and/or immunoglobulin light chain variable domain (V L )) binding specifically to a human NKp46 poly peptide.
- first variable region e.g. a first immunoglobulin heavy chain variable domain (V H ) and/or an immunoglobulin light chain variable domain (V L )
- V H immunoglobulin heavy chain variable domain
- V L immunoglobulin light chain variable domain
- domain may be any region of a protein, generally defined on the basis of sequence homologies or identities, which is related to a specific structural or functional entity. Accordingly, the term “region”, as used in the context of the present disclosure, is broader in that it may comprise additional regions beyond the corresponding domain.
- amino acid linkers may optionally comprise all or part of an immunoglobulin polypeptide chain, such as all or part of a hinge region of an immunoglobulin.
- the amino acid linker may comprise a polypeptide sequence that is not derived from a hinge region of an immunoglobulin, or even that is not derived from an immunoglobulin heavy or light polypeptide chain.
- an immunoglobulin hinge region or a fragment thereof, may thus be considered as a particular type of linker, which is derived from an immunoglobulin polypeptide chain.
- hinge region refers to a generally flexible region and born by the corresponding heavy chain polypeptides, and which separates the Fc and Fab portions of certain isotypes of immunoglobulins, more particularly of the IgG, IgA or IgD isotypes.
- Such hinge regions are known in the Art to depend upon the isotype of immunoglobulin which is considered.
- the hinge region thus separates the C H 1 domain and the C H 2 domain and is generally cleaved upon papain digestion.
- the region corresponding to the hinge in IgM and IgE heavy chains is generally formed by an additional constant domain with lower flexibility.
- the hinge region may comprise one or more cysteines involved in interchain disulfide bonds.
- the hinge region may also comprise one or more binding sites to a Fc ⁇ receptor, in addition to Fc ⁇ R binding sites born by the C H 2 domain, when applicable.
- the hinge region may comprise one or more post-translational modification, such as one or more glycosylated residues depending on the isotype which is considered.
- the hinge regions which are still particularly considered comprise all or part of a hinge from an immunoglobulin belonging to one isotype selected from: the IgG isotype, the IgA isotype and the IgD isotype; in particular the IgG isotype.
- CH domain or “C H domain”, or “constant domain” can be used interchangeably and refer to any one or more heavy chain immunoglobulin constant domain(s).
- C H domains are natively folded as immunoglobulin-like domains, although they may be partly disordered in an isolated form (e.g., C H 1 domains when not associated with the constant domain of a light chain (C L )). Unless instructed otherwise, the term may thus refer to a C H 1 domain, a C H 2 domain, a C H 3 domain; or any combinations thereof.
- C H 1 domain or “C H 1 domain”, or “constant domain 1”, can be used interchangeably and refer to the corresponding heavy chain immunoglobulin constant domain 1.
- CH2 domain or “C H 2 domain”, or “constant domain 2” can be used interchangeably and refer to the corresponding heavy chain immunoglobulin constant domain 2.
- CH3 domain or “C H 3 domain”, or “constant domain 3” can be used interchangeably and refer to the corresponding heavy chain immunoglobulin constant domain 3.
- C H 2-C H 3 refers to a polypeptide sequence comprising an immunoglobulin heavy chain constant domain 2 (C H 2) and an immunoglobulin heavy chain constant domain 3 (C H 3).
- C L domain can be used interchangeably and refer to the corresponding light chain immunoglobulin constant domain. Unless instructed otherwise, this term may thus encompass a C L domain of the kappa ( ⁇ or K ) or lambda ( ⁇ ) class of immunoglobulin light chains, including all known subtypes (e.g. ⁇ 1 , ⁇ 2 , ⁇ 3 , and ⁇ 7 ) In particular, when the C L domain is of the kappa class, it may also be referred herein as a C ⁇ or C K or C k domain.
- each C H 1 and C L domain forming the pairs will be selected so that they are formed between complementary C H 1 and C L domains.
- Examples of complementary C H 1 and C L domains have been previously described in the international patent applications WO2006064136 or WO2012089814 or WO2015197593A1.
- Fc region or “fragment crystallizable region”, or alternatively “Fc portion.”, encompasses all or parts of the “Fc domain”, which may thus include all or parts of an immunoglobulin hinge region (which natively bears a first binding site to Fc ⁇ Rs), a C H 2 domain (which natively bears a second binding site to Fc ⁇ Rs), and a C H 0 domain of an immunoglobulin (e.g. of an IgG, IgA or IgD immunoglobulin), and/or when applicable of a C H 4 domain of an immunoglobulin (e.g. for IgM and IgE).
- an immunoglobulin hinge region which natively bears a first binding site to Fc ⁇ Rs
- C H 2 domain which natively bears a second binding site to Fc ⁇ Rs
- C H 0 domain of an immunoglobulin e.g. of an IgG, IgA or IgD immunoglobulin
- C H 4 domain of an immunoglobulin
- the number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 13 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgGA1, and IgGA2).
- class e.g., IgG, IgA, and IgE
- subclass e.g., IgG1, IgG2, IgG3, IgGA1, and IgGA2
- Fc variant refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the receptor, FcRn (neonatal Fc receptor). Exemplary Fc variants, and their interaction with the receptor, are known in the art. Thus, the term “Fc variant” can comprise a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises regions that can be removed because they provide structural features or biological activity that are not required for the antibody-like binding proteins of the invention.
- native and variant Fc regions considered herein generally comprise a domain (i.e., a C H 2 domain) capable of binding to human CD16, e.g., a human Fc domain comprising N-linked glycosylation at amino acid residue N297 (according to EU numbering).
- a domain i.e., a C H 2 domain
- human Fc domain comprising N-linked glycosylation at amino acid residue N297 (according to EU numbering).
- Fc-competent thus refers to a binding protein that is capable of binding specifically to a Fc ⁇ R, in particular of an activating Fc ⁇ R, in particular to one selected from Fc ⁇ RI (CD64a), Fc ⁇ RIIa (CD32a), and Fc ⁇ RIIIa (CD16a), and more particularly to Fc ⁇ RIIa (CD16a).
- variable refers to certain portions of the relevant binding protein which differ extensively in sequence between and among antibodies and are used in the specific recognition and binding of a particular antibody for its particular target.
- variability is not evenly distributed throughout the entire variable domains of antibodies.
- the variability is concentrated in three segments called complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) also known as hypervariable regions, both in the light chain and the heavy chain variable domains.
- CDRs complementarity determining regions
- FR framework
- VH domain As used herein, the term “VH domain”, or “V H domain” can be used interchangeably and refer to the corresponding heavy chain immunoglobulin variable domain.
- V H 1 or V L 1 When the VH or VL domains are associated to a first antigen-binding domain (ABD) or to a second antigen-binding domain, they may also be respectively referred herein as “V H 1” and “V L 1”, or “V H 2” and “V L 2”.
- binding pair V VH/VL
- V H /V L pair V H /V L pair
- V L /V H pair V L /V H pair
- (V L /V H ) pair Heavy chain and light chain variable domain can pair in parallel to form the antigen binding domains (ABDs).
- Each binding pair includes both a V H and a V L region. Unless instructed otherwise, these terms do not specify which immunoglobulin variable regions are V H or V L regions and which ABD will bind specifically the protein expressed on the surface of an immune effector cell or a target cell (e.g., NKp46 and CD123).
- CDRs refer to amino acid sequences that together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site.
- the light and heavy chains of an immunoglobulin each have three CDRs, designated CDR-L1, CDR-L2, CDR-L3 and CDR-H1, CDR-H2, CDR-H3, respectively.
- a conventional antibody antigen-binding domain therefore, includes six CDRs, comprising the CDR set from each of a heavy and a light chain variable region.
- the light chain variable domain may thus be designated as (FR-L1)-(CDR-L1)-(FR-L2)-(CDR-L2)-(FR-L3)-(CDR-L3)-(FR-L4) and the heavy chain variable domain may thus be designated as (FR-H1)-(CDR-H1)-(FR-H2)-(CDR-H2)-(FR-H3)-(CDR-H)-(FR4-H3).
- a heavy chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of CDR H2 and inserted residues (e.g., residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82.
- the Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence.
- CDRs are as defined by EU, Kabat, Chotia or IMGT numbering. Correspondances between those classifications are known in the Art, by reference to the IMGT®, or international ImMunoGeneTics information System® (CNRS and affiliated University), and as further detailed in Lefranc (Biomolecules; 2014; 4, 1102-1139) and Dondelinger (Frontiers in Immunology; 2018; 9, 2278).
- the numbering of residues will be considered herein by reference to the EU, Kabat, Chotia or IMGT numbering convention. In case of conflict regarding the exact position of hypervariable regions within a reference sequence, the Kabat numbering convention will prevail. In case of conflict regarding the exact position of constant regions within a reference sequence, the EU numbering convention will prevail.
- cytotoxicity refers to the quality of a compound, such as the multifunctional binding protein according to the present disclosure, to be toxic to tumoral cells. Cytotoxicity may be induced by different mechanisms of action and can thus be divided into cell-mediated cytotoxicity, apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) or complement-dependent cytotoxicity (CDC).
- ADCC antibody-dependent cell-mediated cytotoxicity
- ADCP antibody-dependent cellular phagocytosis
- CDC complement-dependent cytotoxicity
- ADCC antibody-dependent cell-mediated cytotoxicity
- proliferative disorders include cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases, but also include blood cancers, including tumors of the hematopoietic and lymphoid tissues, such as lymphomas, myelomas, and leukemias.
- Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
- AML acute myelogenous leukemia
- AML-LSCs Leukemic Stem Cells
- AML-LSCs Leukemic Stem Cells
- These progenitors generate the large numbers of leukemic blasts readily detectable in patients at diagnosis and relapse, leading ultimately to mortality.
- AML-LSC have been commonly reported as quiescent cells, in contrast to rapidly dividing clonogenic progenitors.
- relapse may in particular be defined as the reoccurrence of AML after complete remission.
- complete remission or “CR” may be defined as follows: normal values for neutrophil (>1.0*10 9 /L), haemoglobin level of 10 g/dl and platelet count (>100*10 9 /L) and independence from red cell transfusion; blast cells less than 5%, no clusters or collections of blasts, and absence of Auer rods on bone marrow examination; and normal maturation of blood cells (morphology; myelogramme) and absence of extramedullary leukemia.
- MDS myelodysplastic syndromes
- preleukemia formerly known as preleukemia
- MDS myelodysplastic syndromes
- AML acute myeloid leukemia
- IMS International Prognostic Scoring System
- a “pharmaceutically acceptable carrier” is intended to include any and all carrier (such as any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like) which is compatible with pharmaceutical administration, in particular parenteral administration.
- carrier such as any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
- the use of such media and agents for pharmaceutically active substances are known. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the present disclosure.
- preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents examples include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- pharmaceutically acceptable carriers include, but are not limited to, 0.01-0.1M (e.g., 0.05M) phosphate buffer or 0.8% saline.
- Other common parenteral vehicles include sodium phosphate solutions, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like. More particularly, pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In such cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal and the like.
- isotonic agents are included, for example, sugars, polyalcohols, such as mannitol, sorbitol, or sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- the term “at least one” may encompass “one or more”, or even “two or more” (or “a plurality”). For instance, it may encompass 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or more than 100.
- the term “less than . . . ” may encompass all values from 0 to the corresponding threshold, For instance, it may encompass less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or less than 100, when applicable.
- the term “cell” may encompass any prokaryotic cell or eukaryotic cell.
- Cell types which are particularly considered are those suitable for the production and/or engineering of recombinant antibodies, or fragments, or polypeptide chains thereof.
- such cells may be selected from the group consisting of: bacterial cells, yeast cells, mammalian cells, non-mammalian cells, insect cells, and plant cells.
- host cell refers to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
- Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
- a host cell is any type of cellular system that can be used to generate binding proteins of the present disclosure.
- Host cells may thus include cultured cells, e.g., mammalian cultured cells, such as CHO cells, HEK cells, BHK cells, NSO cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, bacterial cells, yeast cells, insect cells, and plant cells, to name only a few.
- mammalian cultured cells such as CHO cells, HEK cells, BHK cells, NSO cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, bacterial cells, yeast cells, insect cells, and plant cells, to name only a few.
- isolated nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment.
- a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present disclosure.
- Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution.
- vector or “expression vector” is intended to mean the vehicle by which a nucleic acid, in particular a DNA or RNA sequence (e.g., a foreign gene), can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence.
- a nucleic acid in particular a DNA or RNA sequence (e.g., a foreign gene)
- promote expression e.g., transcription and translation
- the binding protein is characterized in that it comprises:
- the binding protein is characterized in that it comprises:
- the binding protein is characterized in that it comprises:
- the binding protein is characterized in that it comprises:
- the binding protein is characterized in that the first ABD binds specifically to human CD123 and comprises an immunoglobulin light chain variable domain (V L ) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to SEQ ID NO: 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to SEQ ID NO: 12 respectively.
- V L immunoglobulin light chain variable domain
- the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (V H ) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 13 to SEQ ID NO: 15 respectively.
- V H immunoglobulin heavy chain variable domain
- the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (V H ) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 16 to SEQ ID NO: 18 respectively.
- V H immunoglobulin heavy chain variable domain
- the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (V H ) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 19 to SEQ ID NO: 21 respectively.
- V H immunoglobulin heavy chain variable domain
- the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (V H ) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 16, SEQ ID NO: 25 and SEQ ID NO: 26 respectively.
- V H immunoglobulin heavy chain variable domain
- the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (V L ) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 30 to SEQ ID NO: 32 respectively.
- V L immunoglobulin light chain variable domain
- the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (V L ) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 33 to SEQ ID NO: 35 respectively.
- V L immunoglobulin light chain variable domain
- the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (V L ) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 36 to SEQ ID NO: 38 respectively.
- V L immunoglobulin light chain variable domain
- the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (V L ) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 39, SEQ ID NO: 31 and SEQ ID NO: 40 respectively.
- V L immunoglobulin light chain variable domain
- the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (V H ) and an immunoglobulin light chain variable domain (V L ), wherein each V H and V L comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
- binding protein may consist of one single polypeptide chain, or be a multimeric binding protein, and hence comprise a plurality (two or more) polypeptide chains.
- the binding protein is a multimeric binding protein, and the two antigen-binding domains may be born at least in part by distinct polypeptide chains.
- the binding protein comprises a plurality of polypeptide chains, (e.g., two or three polypeptide chains), some of those polypeptide chains may be linked covalently.
- the covalent linker(s) may advantageously be selected from disulfide bridges, or any other covalent linker, including peptide bond(s) bridging one polypeptide chain with another, and/or linker peptide(s) bridging one polypeptide chain with another.
- the binding protein is characterized in that it comprises three polypeptide chains (I), (II) and (III) that form two ABDs:
- the (C H 2-C H 3) A and (C H 2-C H 3) B comprise each at least one identical C H 2 domain, such as a C H 2 domain corresponding to the amino acid sequence of SEQ ID NO: 71.
- the (C H 2-C H 3) A and (C H 2-C H 3) B are identical or different and may comprise a polypeptide sequence selected from amino acid sequences of SEQ ID NO: 69 or SEQ ID NO: 70.
- L 1 , L 2 , L 3 and L 4 may be identical or different, and may comprise all or part of an amino acid sequence selected from SEQ ID NO: 74 to SEQ ID NO: 79; for example, one or more than four consecutive amino acids of an amino acid sequence selected from SEQ ID NO: 74 to SEQ ID NO: 79.
- L 1 , L 2 , L 3 and L 4 may be identical or different, and may comprise all or part of an immunoglobulin hinge region, such as one selected from amino acid sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79; for example four or more than four consecutive amino acids of an immunoglobulin hinge region, such as one selected from amino acid sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79.
- an immunoglobulin hinge region such as one selected from amino acid sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79.
- L 2 , L 3 and L 4 may be identical or different, and may comprise all or part of an immunoglobulin hinge region, such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79; for example, four or more than four consecutive amino acids of an immunoglobulin hinge region, such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79.
- an immunoglobulin hinge region such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79.
- L 2 , L 3 and L 4 may be identical or different, and may comprise all or part of an immunoglobulin hinge region, such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79 (for example four or more than four consecutive amino acids of an immunoglobulin hinge region, such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79), and L 1 may comprise all or part of the linker which corresponds to the amino acid sequence of SEQ ID NO: 76.
- an immunoglobulin hinge region such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79
- L 1 may comprise all or part of the linker which corresponds to the amino acid sequence of SEQ
- the binding protein is characterized in that it comprises three polypeptide chains (I), (II) and (III) that form two ABDs, as defined below:
- the binding protein is characterized in that it comprises three polypeptide chains (I), (II) and (III) that form two ABDs, as defined below:
- V 1B -C 1B -Hinge 2 -(C H 2-C H 3) B -L 1 -V 2A -C 2A -Hinge 3 (II)
- V 1B -C 1B -Hinge 2 -(C H 2-C H 3) B -L 1 -V 2A -C 2A -Hinge 3 (II)
- polypeptide chains (I), (II) and (III) are characterized in that:
- polypeptide chains (I), (II) and (III) are characterized in that:
- polypeptide chains (I), (II) and (III) are characterized in that:
- polypeptide chains (I), (II) and (III) are characterized in that:
- V 1A is a V H and V 1B is a V L .
- V 1A is a V L and V 1B is a V H .
- V 1A is a V L and V 1B is a V H ; and V 2A is a V H and V 2B is a V L .
- V 1A is a V H and V 1B is a V L ; and V 2A is a V L and V 2B is a V H .
- V 1A is V L1 and V 1B is V H1 ; and V 2A is V H2 and V 2B is V L2 .
- V 2A is V H2 and V 2B is V L2 .
- polypeptide chains (I), (II) and (III) are characterized in that:
- L 1 corresponds to the amino acid sequence of SEQ ID NO: 76.
- polypeptide chains (I), (II) and (III) are characterized in that:
- the binding protein comprises at least two polypeptide chains linked by at least one disulfide bridge.
- polypeptide chains (I), (II) and (III) are characterized in that: polypeptide chain (I) is covalently linked to polypeptide chain (II), in particular covalently liked to polypeptide (II) by one or more disulfide bonds.
- polypeptide chains (I), (II) and (III) are characterized in that: polypeptide chain (II) is covalently linked to polypeptide chain (III), by one or more disulfide bonds.
- the binding protein is characterized in that the residue N297 of the Fc region or variant thereof according to EU numbering comprises a N-linked glycosylation.
- the binding protein is characterized in that all or part of the Fc region or variant thereof binds to a human Fc- ⁇ receptor polypeptide. In some embodiments, the binding protein is characterized in that all or part of the Fc region or variant thereof binds to a human CD16A (Fc ⁇ RIII) polypeptide.
- the binding protein comprises:
- the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 61, a polypeptide comprising a sequence SEQ ID NO: 62 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or a variant thereof with at least 80% of sequence identity.
- the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide comprising an amino acid sequence of SEQ ID NO: 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 66 or a variant thereof with at least 80% of sequence identity.
- the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide comprising a amino acid sequence of SEQ ID NO: 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 66 or a variant thereof with at least 90% of sequence identity.
- the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 61, a polypeptide comprising an amino acid sequence of SEQ ID NO: 62 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or a variant thereof with at least 95% of sequence identity.
- the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide comprising a amino acid sequence of SEQ ID NO: 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 66 or a variant thereof with at least 95% of sequence identity.
- the binding protein comprises: a polypeptide (I) comprising an amino acid sequence of SEQ ID NO: 61, a polypeptide (II) comprising an amino acid sequence of SEQ ID NO: 62 and a polypeptide (III) comprising an amino acid sequence of SEQ ID NO: 63.
- the binding protein comprises:
- the binding protein comprises: a polypeptide (I) comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide (II) comprising an amino acid sequence of SEQ ID NO: 65 and a polypeptide (III) comprising an amino acid sequence of SEQ ID NO: 66.
- the binding protein comprises:
- the binding protein comprises polypeptide sequences derived from immunoglobulins chains (in particular immunoglobulins of the IgG type), and/or amino acid sequences selected from any one of SEQ ID NO: 1 to SEQ ID NO: 79, which may thus include any variant sequence with conservative substitutions, and/or any variant with a degree of percent sequence identity with a reference sequence; especially a reference sequence derived from an immunoglobulin chain.
- the binding protein comprises polypeptide sequences derived from immunoglobulins chains of the IgG type, in particular of the IgG1, IgG2, IgG3 or IgG4 type, preferably of the IgG1 type.
- variants of polypeptide sequences include CDR polypeptide sequences (e.g., CDR1, CDR2, and CDR3 from either one of a V H or V L domain), it will be understood herein that those variants do not have modifications on their CDR polypeptide sequences.
- the binding protein comprises a amino acid sequence having at least 90% of sequence identity with an amino acid sequence selected from SEQ ID NO: 67 to 73.
- the multispecific binding proteins of the present disclosure are bispecific binding proteins.
- the disclosure further relates to a pharmaceutical composition
- a pharmaceutical composition comprising a binding protein as defined above, and a pharmaceutically acceptable carrier.
- the binding protein according to the disclosure, and pharmaceutical compositions thereof are sterile and suitable for parenteral use.
- the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (V H ) and an immunoglobulin light chain variable domain (V L ), wherein each V H and V L comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
- the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (V H ) and an immunoglobulin light chain variable domain (V L ), wherein each V H and V L comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
- the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (V H ) and an immunoglobulin light chain variable domain (V L ), wherein each V H and V L comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
- the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (V H ) and an immunoglobulin light chain variable domain (V L ), wherein each V H and V L comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
- the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (V H ) and an immunoglobulin light chain variable domain (V L ), wherein each V H and V L comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
- the disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament.
- the disclosure further relates to a use of the above-mentioned binding proteins as a medicament.
- the disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of cancer.
- the disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of cancer characterized by tumor cells that express CD123 at their surface.
- the disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of blood cancer.
- the disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of blood cancer characterized by tumor cells that express CD123 at their surface.
- the disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of a myelodysplastic syndrome (MDS) or of a lymphoproliferative disorder.
- MDS myelodysplastic syndrome
- the disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of Acute Myeloid Leukemia (AML).
- AML Acute Myeloid Leukemia
- the disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of CD64-positive and CD64-negative Acute Myeloid Leukemia (AML).
- AML Acute Myeloid Leukemia
- a method for treating a cancer characterized by tumor cells that express CD123 and CD64 at their surface comprising administering to and individual having such cancer a binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc- ⁇ receptor polypeptide.
- a binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglob
- a hematological malignancy e.g. AML
- the method comprising administering to the individual a binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc- ⁇ receptor polypeptide.
- ABS first antigen-binding domain
- ABS second antigen-binding domain
- the provided means may refer to the making of a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
- the disclosure relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a binding protein of the present disclosure.
- the disclosure relates to an expression vector comprising a nucleic acid molecule comprising a nucleotide sequence that encodes the binding protein of the present disclosure.
- the disclosure relates to an isolated cell comprising the expression vector of the present disclosure.
- the cell is an eukaryotic cell, in particular an insect cell or a mammalian cell.
- the cell is a mammalian cell and the expression vector is a mammalian expression vector.
- the disclosure relates to a method for making the binding protein of the present disclosure, comprising a step of making a binding protein comprising (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc- ⁇ receptor polypeptide.
- a binding protein comprising (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the disclosure relates to a method for making the binding protein, comprising a step of:
- Methods for making the binding protein of the disclosure may further include a prior step of providing host cell(s) with a nucleic acid, in particular an isolated nucleic acid (i.e., a recombinant nucleic acid), encoding all or part(s) of the said binding protein.
- a prior step of providing host cell(s) with a nucleic acid, in particular an isolated nucleic acid (i.e., a recombinant nucleic acid), encoding all or part(s) of the said binding protein.
- such step may comprise or consist of transfecting said host cell(s) with a nucleic acid, in particular an isolated nucleic acid, encoding all or part(s) of the said binding protein.
- the disclosure relates to a method for making the binding protein, comprising a step of:
- the method for making the binding protein of the present disclosure comprises a step of
- the method for making the binding protein of the present disclosure comprises a step of
- a method of making the binding protein of the present disclosure comprises:
- binding protein of the disclosure may encompass the production and assembly of some or all of the above-mentioned polypeptides, polypeptide chains and/or regions (e.g. variable regions and Fc region or variants thereof) within one or more host cell(s), as part of an in vitro method of production.
- the method may encompass the production of some or all of the above-mentioned polypeptides, polypeptide chains and/or regions within one or more host cell(s), and their assembly outside of the host cell(s).
- the step of bringing into contact said polypeptides, polypeptide chains and/or regions can thus be achieved simultaneously or sequentially.
- one or more of said regions may be present in distinct polypeptide chain(s) or fragments thereof.
- the disclosure relates to a method for making the binding protein of the present disclosure, comprising a step of bringing into contact (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, said variable region comprising at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 1 to 6 and at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 7 to 12, (ii) a second antigen-binding domain (ABD) comprising a variable region suitable which binds specifically to a human NKp46 polypeptide, said variable region comprising at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 13 to 26 and at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 27 to 40, and (iii) all or
- the disclosure relates to a method for making the binding protein of the present disclosure, comprising a step of bringing into contact (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, said variable region comprising at least two complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 1 to 6 and at least two complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 7 to 12, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, said variable region comprising at least two complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 13 to 26 and at least two complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 27 to 40, and (iii) all or
- the disclosure relates to a method for making the binding protein related to the present disclosure, comprising a step of bringing into contact (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, said variable region comprising three complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 1 to 6 and three complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 7 to 12, (ii) a second antigen-binding domain (ABD) comprising variable region which binds specifically to a human NKp46 polypeptide, said variable region comprising three complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 13 to 26 and three complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 27 to 40, and (iii) all or part of an immunoglobulin Fc
- All or parts of the above-mentioned antigen-binding domain(s) and immunoglobulin Fc region or variant thereof may be expressed in vitro, through recombinant means, in an isolated cell or population of cells, in particular in a eukaryotic cell, and preferably in a mammalian or insect cell. Most preferably, the expression system relates to a mammalian cell.
- the disclosure relates to a method for making the binding protein related to the present disclosure, which comprises the steps of:
- the method for making the binding protein comprises the steps of:
- first antigen-binding domain and/or said second antigen-binding domain and/or said all or part of immunoglobulin Fc region or variant thereof are expressed in different isolated cells or population of cells, they may be brought into contact after the recovery step.
- the sequences encoding each polypeptide chain of NKp46-CD123_F25 binding proteins of the present disclosure were inserted into the pTT-5 vector between the HindIII and BamHI restriction sites.
- the three vectors (made as endotoxin-free midipreps) were used to cotransfect EXPI-293F cells (Life Technologies) in the presence of PEI (37° C., 5% CO2, 150 rpm).
- the cells were used to seed culture flasks at a density of 1 ⁇ 106 cells per ml (EXP1293 medium, Gibco).
- PBMC Peripheral mononuclear cells
- AML samples from patients were provided by Institut Paoli-Calmettes (Marseille, SA-IPH-MImAbs Contract).
- CD123 expressing Acute myeloid leukemia (AML) cell line MOLM-13 and THP-1 were purchased at ATCC.
- Cells were cultured in complete RPMI medium (RPMI-1640 containing 10% FBS, 2 mM L-Glutamine, 1 mM Sodium pyruvate and non-essential amino-acids 1 ⁇ ).
- 25 mM HEPES were added in the culture medium for THP-1 cells.
- THP-1 CD64KO and THP-1 CD32KO cells were generated with CRISPR/Cas endonucleases.
- THP-1 cells were cultured in RPMI-1640, 10% SVF, 2 mM L-Glu, 1 mM sodium pyruvate, 0.1 mM non-essential amino acid.
- CD64 deficient THP-1 cells 2,5.106 cells were nucleofected (Neon Transfection System, 100 ul tip, 1700V, 20 ms, 1 pulse) with two sgRNAs (CD64.1: CUUGAGGUGUCAUGCGUGGA (SEQ ID NO: 80); CD64.2: AAGCAUCGCUACACAUCAGC (SEQ ID NO: 81; Synthego) at a CAS9:sgRNA ratio of 1:9 (Alt-RTM S.p. Cas9 Nuclease 3NLS, Integrated DNA Technology). Lack of CD64 expression was monitored by flow cytometry and cells were either sorted or sub-cloned.
- KO THP-1 cells To generate CD32-knockout (KO) THP-1 cells, 2.5 ⁇ 10 6 cells were nucleofected (Neon Transfection System, 100 ⁇ L tip, 1700 V, 20 ms, 1 pulse) with a couple of sgRNAs (CD32A: AUGUAUGUCCCAGAAACCUG (SEQ ID NO: 105); CD32B: AAGCAUAUGACCCCAAGGCU (SEQ ID NO: 106) (Integrated DNA Technologies)) at a CAS9:sgRNA ratio of 1:9 (Alt-RTM S.p. Cas9 Nuclease 3NLS, Integrated DNA Technology).
- the THP-1 CD32KO cells were cell sorted only. Following cell sorting, absence of CD32 expression was monitored by flow cytometry.
- Target cells were loaded with 51 Cr (for MOLM-13, THP-1 or THP-1 CD64KO, THP-1 CD32KO cells) or with CalceinAM (Life technologies, ref: C3100MP or equivalent) for AML blasts from patient samples.
- Tested antibodies, labelled target cells and fresh or overnight-rested human NK cells from healthy donors were successively added in each well of round bottom 96-well plates to obtain a 10:1 (E:T) ratio. After 4 h of co-incubation, the supernatant was transferred into a Lumaplate (for 51 Cr) or into a flat bottom culture plate (for CalceinAM).
- REU relative fluorescence units
- ER experimental release
- SR spontaneous release
- CD32, CD64 and CD123 were controlled by flow cytometry using Anti-human CD33-BB515 (BD Biosciences 564588 Clone WM53), Anti-human CD45-Viogreen (Miltenyi 130-096-906 Clone 5B1), Anti-human CD123-AF647 (BD Biosciences 563599 Clone 9F5), Anti-human CD32-PE (Beckman Coulter IM1935 Clone 2E1), Anti-human CD64-PE (Beckman Coulter IM3601U Clone 22), Anti-human CD123-PE (Biolegend 306006 Clone 6H6), and cognate isotype control antibodies mIgG1-PE (IC-1; BD Biosciences 555749 Clone MOPC-21), and mIgG2a-PE (IC-2a; Beckman Coulter A09142 Clone 7T4-1F5).
- Anti-human CD33-BB515 BD Biosciences 564588 Clone WM53
- Target cells were saturated with normal mouse serum diluted at 1/10e in staining buffer (SB) and then mix with antibodies coupled to dyes. Cells were fixed in BD Cellfix diluted at 1/10e in H2O during 30 min after staining and analyzed by flow cytometry with a FACS Canto II.
- FSC-A, FSC-H, SSC-A, SSC-H, FL2-A, FL4-A and FL7-A or FSC-A, FSC-H, SSC-A, SSC-H, FL1-A, FL2-A, FL3-A, FL5-A and FL8-A (for AML samples derived from patient blood) parameters were recorded and the analyses were done with FlowJo software. The phenotyping results are shown in FIG. 6 A , FIG. 6 B , and FIG. 14 B .
- NK cell activation As in FIG. 7 , tested antibodies, AML blast and autologous NK cells derived from AML patients were successively added in each well of round bottom 96-well plates. After overnight co-incubation with the NKp46-CD123_F25 binding proteins of the present disclosure, anti-human CD107a and CD107b antibodies were added in each well for 4 hours. Cells were then washed and stained with the following mix: markers of viability, APC-coupled anti-human CD45, BB515-coupled anti-human CD33, PeCy7-coupled anti-human CD56, BV510-coupled anti-human CD3 antibodies. Cells were then washed, fixed and analyzed by flow cytometry. Obtained data were analyzed by using Flowjo Software to analyze NK cell degranulation through the expression of CD107 on NK cells identified as alive CD45 + CD33 ⁇ CD56 + CD3 ⁇ cells.
- flow cytometric analysis was performed using the following antibody markers: CD69, CD107a/b, IFN ⁇ , TNF ⁇ , MIP1 ⁇ .
- Flow cytometry was performed on a LSR FortessaTM X-20, equipped with BD FACSDiva acquisition software measuring FSC-A, FSC-H, SSC-A, SSC-H, FL-1, FL-3, FL-6, FL-7, FL-9, FL-13 and FL-16 parameters. All data were analyzed with FlowJo software.
- NK cell sample Marker percent of NK cell sample was done using GraphPad prism. Top of activation values corresponded to the observed maximum activation. Half maximal effective concentration (EC 50 ) values were calculated using 4 parameter logistics non-linear regression model corresponding to the following equation:
- NK ⁇ cell ⁇ activation ⁇ ( % ) calculated ⁇ bottom + calculated ⁇ top - calculated ⁇ bottom 1 + 10 ( log ( EC ⁇ 50 ) - log ⁇ ( concentration ) ) slope
- the sequence encoding the Extracellular Domain (ECD) of human NKp46 (Gln22-Asn255, NCBI Reference: NM_004829.5) was inserted into the SLX192 vector (Selexis) between the HindIII and XbaI restriction sites.
- a C-terminal 6 ⁇ His tag (SEQ ID NO: 107) was added for purification.
- the following primers were used for PCR on human PBMCs: 5′ TACGACTCACAAGCTTGCCGCCACCATGTCTTCCACACTCCCTGC 3′ (SEQ ID NO: 82) and 5′ CCGCCCCGACTCTAGATCAATGGTGATGGTGGTGATGATTCTGGGCAGTGTGA TCCC 3′ (SEQ ID NO: 83).
- the sequence of the amplicon was checked.
- the vector was then used to transfect a CHO cell line and a clone producing the protein was selected.
- the protein was purified from the culture supernatant with Ni-NTA beads (Qiagen, #1018244) and 5200 size exclusion chromatography was performed to ensure the elimination of aggregates prior to characterization of binding kinetics with surface plasmon resonance (SPR).
- SPR surface plasmon resonance
- the sequence encoding the ECD of Cynomolgus NKp46 (Gln17-Asn254, NP_001271509.1) was cloned into the SLX192 vector between the HindIII and XbaI restriction sites. A C-terminal Flag-M2 tag was added for purification.
- the primers used to amplify the expected sequence from cynomolgus PBMC were: 5′ TACGACTCACAAGCTTGCCGCCACCATGTCTTCCACACTCCGTGC 3′ (SEQ ID NO: 89) and 5′ CCGCCCCGACTCTAGATCACTTGTCATCGTCATCTTTGTAATCATTCTGGGCAG TGTGGTCC 3′ (SEQ ID NO: 90).
- the beads were then washed with PBS1X and the elution is performed with elution peptide at 150 ng/ ⁇ l in PBS1X.
- the proteins are then dialyzed against PBS1X.
- the next batches (161003CDe batch 1 and 161116CDe batch 2) were purified by affinity chromatography by coupling the anti-NKp46 antibody HUX1-M-H46-17E1 to the AminoLink Coupling Resin according to the manufacturer's instructions (GE Healthcare, #20381, batch QB213815).
- the beads were then incubated with the supernatant containing the recombinant protein overnight.
- the beads were then washed with PBS1X and the elution is performed using Glycine 0.1M pH2.5.
- the proteins are then dialyzed against TBS buffer pH7.5 and concentrated to perform a preparative size exclusion chromatography on a Superdex 200 Increase 10/300 GL column.
- a Biacore T200 instrument (Cytiva, Uppsala, Catalog No. 28975001) was used with a Series S CM5 sensor chip (Cytiva, Uppsala, Catalog No. 29149603).
- HBS-EP+ buffer (Cytiva, Uppsala, Catalog No. BR1006-69) was prepared by mixing 100 mL 10 ⁇ HBS-EP+ buffer with 900 mL of purified water. Affinity capture of the bispecific Ab sample was achieved using the human antibody capture kit (Cytiva, Uppsala, Catalog No. BR1008-39). The anti-Fc capture antibody was diluted in running buffer 1:20 and coupled to the CM5 chip (Cytiva, Uppsala, Catalog No. 29149603) using standard amine coupling to yield approximately 8000 response units (RU) using the amine coupling kit (Cytiva, Uppsala, Catalog No.
- HBS-EP+ buffer (Cytiva, Uppsala, Catalog No. BR1006-69) was prepared by mixing 100 mL 10 ⁇ HBS-EP+ buffer with 900 mL of purified water. Affinity capture of the human CD16a proteins was achieved using the His capture kit (Cytiva, Uppsala, Catalog No. 28995056). The anti-His capture antibody was diluted in running buffer 1:20 and coupled to the CM5 chip (Cytiva, Uppsala, Catalog No. 29149603) using standard amine coupling to yield approximately 8000 response units (RU) using the amine coupling kit (Cytiva, Uppsala, Catalog No. BR-100-50).
- MSD SULFO-TAG electrochemiluminescent labels
- ECL elctrochemiluminescence
- ECLIA Electromoluminescence Assay
- MSD Mesoscale
- NHS Proinflammatory Panell
- K15056D Proinflammatory Panell
- Animals were identified as M1 and M2 for males dosed at 0.1 mg/kg/administration, F3 and F4 for females dosed at 0.1 mg/kg/administration, M5 and M6 for males dosed at 3 mg/kg/administration, and F7 and F8 for females dosed at 0.1 mg/kg/administration, respectively. Dosing was performed on Days 1, 8, 15 and 22. The potential delayed onset toxicity and/or the reversibility of potential toxicity was assessed one week (Day 29) and up to 4 weeks (Day 50) after the last (4th) administration. M2, F4, M6 and F8 were euthanized and necropsied on Day 29.
- CD123-NKCE concentrations were determined in plasma using a dedicated immunoassay method where CD123-NKCE were captured by biotin-coupled CD123 recombinant proteins and revealed by a monkey absorbed alexa-goat anti-human IgG, with a Lower Limit of Quantification (LLOQ) value of 0.250 ng/mL.
- LLOQ Lower Limit of Quantification
- the first polypeptide chain (or “polypeptide chain (I)” or “Fragment I” or “Fragment 1”) comprises from N-term to C-term, the V L (CD123-binding) domain corresponding to the amino sequence of SEQ ID NO:43, a native C K (or C ⁇ ) domain derived from human IgG1, a modified human IgG1 hinge region (“DKTHTCPPCP (SEQ ID NO: 74)”) wherein residue D (position according to EU numbering) is connected to the C-terminal cysteine of the human C K domain.
- the Fc region or variant thereof is further derived from a native human IgG1 antibody comprising a C H 2-C H 3 domain. Disulfide bridges are potentially formed extracellularly with the second polypeptide chain (“chain II”) with native cysteines.
- the second polypeptide chain (“polypeptide chain (II)” or “Fragment II” or “Fragment 2”) comprises, from N-term to C-term, the V H (CD123-binding) domain corresponding to the amino sequence of SEQ ID NO:41, a native C H 1 domain derived from human IgG1, an unmodified human IgG1 hinge region (“EPKSCDKTHTCPPCP (SEQ ID NO: 75)”), and a Fc region or variant thereof derived from a human IgG1 including a C H 2-C H 3 domain wherein the last residue of the C H 3 domain is removed and replaced by a small four amino-acid “STGS (SEQ ID NO: 76)” linker, a V H (NKp46-binding) domain corresponding to the amino sequence of SEQ ID NO:45, a second native C H 1 domain which is identical to the C H 1 domain of the first polypeptide chain, and a C-terminal hinge sequence from human IgG1.
- NKp46-CD123_F25 binding protein comprises four predicted interchain disulfide bridges:
- NKp46-CD123_F25 binding protein of the present disclosure comprising polypeptide (I), (II) and (III); wherein the polypeptide (I) consists of an amino acid sequence of SEQ ID NO: 64, the polypeptide (II) consists of an amino acid sequence of SEQ ID NO: 65, and the polypeptide (III) consists of an amino acid sequence of SEQ ID NO: 66.
- NKp46-CD123_F25 binding protein (NKp46-CD123_F25) was tested by SPR in order to confirm its affinity toward a set of human Fc ⁇ receptors, including CD64 and two variants of the CD16a receptor.
- the human CD16a-V receptor refers to a polypeptide construct comprising a fragment of the CD16 human receptor binding to a Fc region of a natural antibody, mediating antibody-dependent cellular cytotoxicity and bearing a Valine (V) on position 158, which is also reported in the literature as allotype CD16a V158.
- the human CD16a-F receptor refers to a polypeptide construct comprising a fragment of the CD16 human receptor binding to a Fc region of a natural antibody, mediating antibody-dependent cellular cytotoxicity and bearing a Phenylalanine (F) on position 158, which is also reported in the literature as allotype CD16a F158.
- FIG. 4 reports in vitro cytotoxicity against MOLM-13 AML cells ( FIG. 4 A ). The same experiment is reproduced against ex vivo patient blast samples as target cells ( FIG. 4 B ). Cytotoxicity is assessed as a function of the tested NKp46-CD123_F25 binding protein (NKp46-CD123_F25) concentration in the experiment.
- NKp46-CD123_F25 is responsible for dose-dependent cytotoxicity in both in vitro and ex vivo tested samples.
- the observed cytotoxicity is also higher than the one observed with an anti-CD123 antibody ADCC-enhanced with no specificity for NKp46 (Reference-1).
- a negative control variant of format F25 binding NKp46 only shows little cytotoxicity under the tested conditions.
- the experiments support a synergistic effect of the dual binding toward both CD123 and NKp46 in a Fc-competent construct (F25) to lead to cytotoxicity against CD123-positive tumor cells.
- FIG. 5 provides data based on EC 50 on a MOLM-13 cell line. Improvement of in vitro cytotoxicity (which translates into a decreased EC 50 ) is observed with the NKp46-CD123_F25 binding protein (NKp46-CD123_F25). In contrast, the F6 control (NKp46-CD123_F6), which lacks N-glycosylation on residue 297, provides a decreased cytotoxicity since it activates NK cells by engaging NKp46 only and not CD16a. Hence, this second experiment provides evidence of the synergistic effect observed through binding and activation of NKp46 and CD16a NK cell markers.
- NKp46-CD123_F25 specific lysis was illustrated with NKp46-CD123_F25, and with an anti-CD123 antibody ADCC-enhanced with no specificity for NKp46 (Reference-1) in the presence of human NK cells against CD123-positive MOLM-13 AML cells.
- the EC 50 value is established based on the variation of cell lysis over the concentration of binders. The results are shown hereafter.
- NKp46-CD123_F25 cytotoxicity experiments were performed using different AML cell lines expressing CD123 as targets.
- Reference-1 antibody efficiently killed MOLM-13 cells but was not active against THP-1 cells ( FIG. 6 A -upper panels).
- NKp46-CD123_F25 demonstrated comparable killing activity on both AML cell lines ( FIG. 6 A -upper panels).
- FIG. 6 A -lower panels show that MOLM-13 and THP-1 cells differ for the expression of CD32a/b and CD64 Fc ⁇ Rs at the cell surface as analyzed by flow cytometry.
- FIG. 6 B Killing experiments performed on THP-1 sub-clones expressing CD32a/b but not CD64 or expressing CD64 but not CD32a/b ( FIG. 6 B ) demonstrated that CD64 expression on THP-1 was responsible for the inhibition of Reference-1 ADCC activity as killing of this antibody was restored only on sub-clones inactivated for CD64 expression. Accordingly, these results indicate that cis capture of antibody FC by Fc ⁇ R, CD64, at the surface of AML cells interfere with ADCC probably by competing with the binding of CD16a to NK cells.
- FIG. 14 A-B confirm that Reference-1 activity is negatively impacted by expression of CD64 on AML cells.
- AML #5-AML #6, (Reference-1-non-responders) have higher staining levels of CD32 and CD64 than AML #1 and AML #2 (Reference-1 responders)( FIG. 14 B , right panels, compare peak shifts in CD64 and CD32 from controls in both groups).
- this experiment supports the capacity of the NKp46-CD123_F25 binding protein of the present disclosure to activate NK cells ex vivo, both with respect to CD64(+) and CD64( ⁇ ) AML cells.
- NKp46-CD123_F25 binding protein of the present disclosure are able to engage NK cells in the presence of CD64(+) cells at a much lower concentration than what is observed in the presence of Reference-1.
- the NKp46-CD123_F25 binding protein related to the present disclosure showed a dose-dependent anti-tumor in-vivo activity with a robust activity at 0.5 mg/kg.
- NKCE pro-inflammatory cytokine release in human PBMCs in vitro was further confirmed in two dedicated pharmacokinetic, pharmacodynamic and safety studies performed on NHPs. Cynomolgus monkeys were selected as a relevant species for preclinical pharmacokinetics, pharmacodynamics and toxicological studies on (1) the basis of their tissue distributions of NKp46 and CD123, which are similar to those in humans (Walzer et al. PNAS; 2007; 104:3384-3398 and ChiChili et al.
- FIG. 9 further shows a complete and sustained CD123-positive basophil depletion at 3 ⁇ g/kg for up to 20 days after the injection of the NKp46-CD123_F25 binding protein related to the present disclosure (NKp46-CD123_F25), and up to 5 hours at 0.5 ⁇ g/kg for non-human primates.
- CD123-positive immune cell depletion is a hallmark of in vivo activity of the NKp46-CD123_F25 binding proteins in non-human primate. It is found that rapid and sustained depletion of CD123-positive basophils is observed, which occurs at about 1.5 hours from start of infusion, and is maintained up to Day 7, with cell number returning to baseline on Day 28.
- this example reports the variation of specific lysis for three distinct binding proteins: (i) a NKp46-CD123_F5 binding protein in the F5 format (NKp46-CD123_F5), (ii) a NKp46-CD123_F25 binding protein in the F25 format (NKp46-CD123_F25), and (iii) a negative isotype control variant of format F5 binding CD123 only (CD123-IC_F5).
- NKp46-CD123 NKCEs-Induced CD123-Positive Basophil Depletion is Associated to Low Cytokine Release when Compared to T-Cells Engager Tool
- FIGS. 11 and 12 demonstrate that the treatment of PBMCs with CD123-NKCEs promoted a depletion of CD123′ basophils but induced much lower levels of IL-6, IL-1 ⁇ , TNF- ⁇ and IFN- ⁇ release than treatment with CD3-CD123 antibody molecule.
- NKp46-CD123_F25 binding protein related to the present disclosure has shown its ability to engage primary NK cells to target and kill CD123+ primary normal mononuclear blood cells associated with minor cytokine release and may have a better benefit/risk profile than TCEs for the treatment of AML.
- FIG. 13 A - FIG. 13 F show that very low cytokine release (IL6 and IL10) was observed in all treated animals (male Cynomolgus monkeys) after the start of the injection of NKp46-CD123_F25 binding protein related to the present disclosure (NKp46-CD123_F25), without any associated clinical signs. No IL-2 nor IFN ⁇ cytokine release were detected. More particularly, transient IL6 and IL10 peaks are detected in non-human primates after a single intravenous injection of F25 constructs at 3 mg/kg. This transient peak occurs from 1 hour to 5 hours and returns to baseline within 1 or 2 days.
- IL-6 and IL-10 cytokine release are not associated with clinical signs up to 3 mg/kg dose. This indicates that such NK cell engagers possess a good safety profile in non-human primates.
- NKp46-CD123 NK Cell Engagers Promote NK-Cell Activation In Vitro that is Commensurate with Cytokine/Chemokine Production
- NKp46-CD123_F25 binding proteins promoted NK-cell activation only when CD123 expressing target cells are present.
- mice underwent an NK cell depletion regimen during the experimental set-up outlined in B.8.
- the control group treated showed a median survival time (MST) of 29 days and no long-term survivors.
- the muNKp46-IC isotype control did not show activity with an ILS of 7% and no long-term survivors. No impact of the NK depletion is observed on the group treated with muNKp46-IC isotype control with no increased lifespan and 10% of long-term survivors.
- the IC-huCD123 isotype control was statistically significantly active with an ILS of 28% and 20% of long-term survivors. A statistically significant impact of the depletion was observed on the group treated with IC-huCD123 isotype control with no increased lifespan and no long-term survivors.
- the muNKp46-huCD123_F25 was statistically significantly active with an ILS of 84% and 40% of long-term survivors. A statistically significant impact of the depletion was observed on the group treated with muNKp46-huCD123_F25 with an ILS of 14% and no long-term survivors.
- the NK depletion impacted the anti-tumoral activity of muNKp46-huCD123_F25 confirming the NK involvement as effector cells in muNKp46-huCD123_F25 NKCE in vivo efficacy.
- NKp46-CD123 NK Cell Engagers are Safe and Efficient in NHPs
- CD123-NKCE Treatment with CD123-NKCE promoted a sustained and complete depletion of CD123 + cells in the blood of all monkeys, for more than 10 days, at both the 3 mg/kg and 3 ⁇ g/kg doses (as exemplified for CD123 + basophils and total CD123 + cells in FIG. 20 A and FIG. 20 B ), with only very small amounts ( ⁇ 50 ⁇ g/mL) of the pro-inflammatory cytokines IL-6 and IL-10 released ( FIG. 20 C ) without any associated clinical signs.
- the preclinical safety profile of CD123-NKCE was further interrogated through an exploratory repeat-dose toxicity study in which four monkeys (2/sex/dose) were treated weekly, for four weeks, at a dose of 3 mg/kg/administration or 0.1 mg/kg/administration, administered by intravenous infusion for one hour ( FIG. 21 ).
- a dose of 3 mg/kg/administration or 0.1 mg/kg/administration administered by intravenous infusion for one hour
- FIG. 21 In all monkeys (except one of the monkeys, monkey M5, male No. 5; FIG. 21 ), exposure to CD123-NKCEs lasted for at least two weeks, at both tested doses, with the presence of Anti-Drug Antibody (ADA) detected (data not shown) from the third administration (Day 15) (Table 6).
- ADA Anti-Drug Antibody
- Table 6 below displays individual CD123-NKCE plasma concentration values after a weekly repeat 1-hour intravenous infusion at 0.1 and 3 mg/kg/administration for 4 weeks (on Days 1, 8, 15 and 22) to cynomolgus monkeys.
- TABLE 8 displays the individual absolute counts of basophils and total CD123- positive cells in blood and bone marrow after a weekly repeat 1-hour intravenous infusion of CD123-NKCE at 0.1 and 3 mg/kg/administration for 4 weeks to cynomolgus monkeys.
- NKp46-CD123_F25 and its isotype control IC-CD123_F6 were tested in an in vitro tumor cell killing assay with NK cells taken from 2 different healthy donors (HD).
- PBMC Human peripheral blood mononuclear cells
- HD healthy donors
- NK cells were purified from these PBMCs with MACSxpress® Whole Blood NK cells isolation kit (Miltenyi Biotec). The NK cells were rested overnight in RPMI1640 (Gibco) supplemented with 10% SVF (BioWest) and 1% L-Glutamine (Gibco).
- THP1 cells (CD123+. CD64+) were chosen for this study based on their expression of CD123. Before the experiment, THP1 cells were infected with Incucyte® Nuclight Green Lentivirus (Sartorius) to express the Green Fluorescent Protein (GFP).
- Incucyte® Nuclight Green Lentivirus (Sartorius) to express the Green Fluorescent Protein (GFP).
- NK cells and THP1 GFP target cells were incubated in presence of NKp46-CD123_F25 or its isotype control IC-CD123_F6 at 0.1, 1, 10 and 100 ng/mL at 37° C.
- the ratio effector:target cells was 1:1.
- the medium used was the same as for NK cell culture.
- the target cells were monitored by florescence imaging over 74 h using Incucyte Live Cell Analysis system (EssenBioscience). The number of live target cells was quantified using IncucyteS3 software (2020B version).
- NKp46-CD123_F25 at different concentrations (1, 10 and 100 ng/mL) enhances the cytotoxic activity of HD NK cells against THP1 GFP AML cells over time at the effector:target cells ratio of 1:1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- This application is a division of U.S. patent application Ser. No. 17/566,142, filed Dec. 30, 2021, which claims priority to European Patent Application No. 20306717.8, filed Dec. 31, 2020, and U.S. Provisional Patent Application Ser. No. 63/256,950, filed Oct. 18, 2021, the entire disclosures of which are hereby incorporated herein by reference.
- The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML file, created on Apr. 27, 2023, is named 742634_SA9-309DIV_ST26.xml and is 148,093 bytes in size.
- The disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor.
- The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
- Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are heterogeneous clonal neoplastic diseases, which are thought to arise from subpopulations of leukemic stem cells, which tend to be resistant to conventional chemotherapy, and which may be further responsible for disease relapse.
- Natural killer (NK) cells are a subpopulation of lymphocytes that are involved in non-conventional immunity. NK cells provide an efficient immunosurveillance mechanism by which undesired cells such as tumor- or virally-infected cells can be eliminated. Characteristics and biological properties of NK cells include the expression of surface antigens including CD16, CD56 and/or CD57, the absence of the α/β or γ/δ TCR complex on the cell surface, the ability to bind to and kill cells in a MHC-unrestrictive manner and in particular cells that fail to express “self” MHC/HLA antigens by the activation of specific cytolytic enzymes, the ability to kill tumor cells or other diseased cells that express a ligand for NK activating receptors, and the ability to release protein molecules called cytokines that stimulate the immune response.
- Interest has also focused on natural killer (NK) cells due to their potential anti-tumor properties.
- Still, there is an urgent need for active agents for treating or preventing proliferative disorders such as Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
- There is also a need for novel NK engagers with a therapeutic effect.
- There is also a need for novel compounds which are easier to manufacture and/or administer, with no or decreased side-effects. In particular, there is a need for novel compounds with no or decreased risk of cytokine release syndrome in patients (e.g. no or decreased IL-6 associated cytokine release).
- In one embodiment, the disclosure relates to a binding protein comprising a first and a second antigen binding domain (ABD) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABD comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor.
- (i) the first ABD binds specifically to human CD123 and comprises:
- In certain embodiments, the binding protein comprises three polypeptide chains (I), (II) and (III) that form two ABDs, as defined below:
-
V1A-C1A-Hinge1-(CH2-CH3)A (I) -
V1B-C1B-Hinge2-(CH2-CH3)B-L1-V2A-C2A-Hinge3 (II) -
V2B-C2B (III) - wherein:
-
- V1A and V1B form a binding pair V1 (VH1/VL1);
- V2A and V2B form a binding pair V2 (VH2/VL2);
- C1A and C1B form a pair C1 (
C H1/CL) and C2A and C2B form a pair C2 (C H1/CL) whereinC H1 is an immunoglobulin heavy chainconstant domain 1 and CL is an immunoglobulin light chain constant domain; - Hinge1, Hinge2 and Hinge3 are identical or different and correspond to all or part of an immunoglobulin hinge region;
- (CH2-CH3)A and (CH2-CH3)B are identical or different, and comprise an immunoglobulin heavy chain constant domain 2 (CH2) and an immunoglobulin heavy chain constant domain 3 (CH3);
- L1 is an amino acid linker.
- In certain embodiments, C1B is an immunoglobulin heavy chain constant domain 1 (CH1); C2A is an immunoglobulin heavy chain constant domain 1 (CH1); CL corresponds to an immunoglobulin kappa light chain constant domain (C); (CH2-CH3)A corresponds to the amino acid sequence of SEQ ID NO: 69; (CH2-CH3)B corresponds to the amino acid sequence of SEQ ID NO: 70; Hinge1 corresponds to the amino acid sequence of SEQ ID NO:74; Hinge2 corresponds to the amino acid sequence of SEQ ID NO:75; Hinge3 corresponds to the amino acid sequence of SEQ ID NO: 77; L1 corresponds to the amino acid sequence of SEQ ID NO: 76.
- In certain embodiments, the residue N297 of the Fc region or variant thereof according to EU numbering comprises a N-linked glycosylation.
- In certain embodiments, the all or part of the Fc region or variant thereof binds to a human CD16A (FcγRIII) polypeptide.
- In certain embodiments, the binding protein comprises at least two polypeptide chains linked by at least one disulfide bridge.
- In certain embodiments, the polypeptide chains (I) and (II) are linked by at least one disulfide bridge between C1A and Hinge2 and/or wherein the polypeptide chains (II) and (III) are linked by at least one disulfide bridge between Hinge3 and C2B.
- In certain embodiments, V1A is VL1 and V1B is VH1. In certain embodiments, V2A is VH2 and V2B is VL2.
- In certain embodiments, (a) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 27; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 28; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 29; (b) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 18; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 30; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 32; (c) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 33; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 34; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 35; (d) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 22; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 23; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 24; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 37; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 38; (e) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 39; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 40; (f) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 27; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 28; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 29; (g) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 18; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 30; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 32; (h) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 33; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 34; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 35; (i) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 22; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 23; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 24; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 37; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 38; or (j) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 39; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 40.
- In certain embodiments, (a) VH1 and VL1 corresponds to the amino acid sequences of SEQ ID NO: 41 and 43 respectively or corresponds to the amino acid sequences of SEQ ID NO: 42 and 44 respectively;
- and/or (b) VH2 and VL2 corresponds to the amino acid sequences of SEQ ID NO: 45 and 53 respectively; the amino acid sequences of SEQ ID NO: 46 and 54 respectively; the amino acid sequences of SEQ ID NO: 47 and 55 respectively; the amino acid sequences of SEQ ID NO: 48 and 56 respectively; the amino acid sequences of SEQ ID NO: 49 and 57 respectively; the amino acid sequences of SEQ ID NO: 50 and 58 respectively; the amino acid sequences of SEQ ID NO: 51 and 59 respectively; or the amino acid sequences of SEQ ID NO: 52 and 60 respectively.
- In certain embodiments,
-
- (a) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 45; VL2 comprises the amino acid sequence of SEQ ID NO: 53;
- (b) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 46; VL2 comprises the amino acid sequence of SEQ ID NO: 54;
- (c) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 47; VL2 comprises the amino acid sequence of SEQ ID NO: 55;
- (d) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 48; VL2 comprises the amino acid sequence of SEQ ID NO: 56;
- (e) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 49; VL2 comprises the amino acid sequence of SEQ ID NO: 57;
- (f) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 50; VL2 comprises the amino acid sequence of SEQ ID NO: 58;
- (g) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 51; VL2 comprises the amino acid sequence of SEQ ID NO: 59;
- (h) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 52; VL2 comprises the amino acid sequence of SEQ ID NO: 60;
- (i) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 45; VL2 comprises the amino acid sequence of SEQ ID NO: 53;
- (j) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 46; VL2 comprises the amino acid sequence of SEQ ID NO: 54;
- (k) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 47; VL2 comprises the amino acid sequence of SEQ ID NO: 55;
- (l) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 48; VL2 comprises the amino acid sequence of SEQ ID NO: 56;
- (m) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 49; VL2 comprises the amino acid sequence of SEQ ID NO: 57;
- (n) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 50; VL2 comprises the amino acid sequence of SEQ ID NO: 58.
- (o) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 51; VL2 comprises the amino acid sequence of SEQ ID NO: 59;
- (p) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 52; VL2 comprises the amino acid sequence of SEQ ID NO: 60.
- In certain embodiments, polypeptide (I) comprises an amino acid sequence of SEQ ID NO: 64; polypeptide (II) comprises an amino acid sequence of SEQ ID NO: 65; and polypeptide (III) comprises an amino acid sequence of SEQ ID NO: 66.
- In certain embodiments, polypeptide (I) consists of an amino acid sequence of SEQ ID NO: 64; polypeptide (II) consists of an amino acid sequence of SEQ ID NO: 65; and polypeptide (III) consists of an amino acid sequence of SEQ ID NO: 66.
- In one embodiment, the disclosure relates to a pharmaceutical composition comprising the binding protein defined above, and a pharmaceutically acceptable carrier.
- In one embodiment, the disclosure relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes the binding protein defined above.
- In one embodiment, the disclosure relates to an expression vector comprising the nucleic acid molecule defined above.
- In one embodiment, the disclosure relates to an isolated cell comprising the nucleic acid molecule defined above.
- In one embodiment, the disclosure relates to an isolated cell comprising the expression vector defined above. In certain embodiments, the host cell is a mammalian cell.
- In one embodiment, the disclosure relates to a method for making the binding protein defined above, comprising the steps of: (a) introducing the expression vector defined above into a host cell; (b) culturing the host cell under conditions suitable for expressing the binding protein; and (c) optionally recovering the expressed binding protein.
- In one embodiment, the disclosure relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a binding protein as defined above, and characterized in that it comprises a first and a second antigen binding domain (ABD) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABD comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor.
- (i) the first ABD binds specifically to human CD123 and comprises:
- In one embodiment, the disclosure relates to an expression vector comprising a nucleic acid molecule comprising a nucleotide sequence that encodes of or more polypeptide chains of the binding protein, as defined above.
- In one embodiment, the disclosure relates to an isolated cell comprising the nucleic acid molecule as defined above.
- In one embodiment, the disclosure relates to an isolated cell comprising the expression vector as defined above.
- In one embodiment, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for expressing a plurality of recombinant polypeptides, said plurality comprising (i) a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, and (ii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 65, and (iii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 66;
- (b) optionally recovering the expressed recombinant polypeptides.
- In one embodiment, the disclosure relates to a method of treating or preventing a blood cancer, the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- In one embodiment, the disclosure relates to a method of treating or preventing a myelodysplastic syndrome (MDS) or a lymphoproliferative disorder, the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- In one embodiment, the disclosure relates to a method of treating or preventing an Acute Myeloid Leukemia (AML), the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- In one embodiment, the disclosure relates to a method of treating or preventing a CD64-positive and CD64-negative Acute Myeloid Leukemia (AML), the method comprising administering to a subject in need of said treatment or prevention the pharmaceutical composition defined above.
- In one embodiment, the disclosure relates to a method of treating or preventing a CD64-positive Acute Myeloid Leukemia (AML), the method comprising administering to a subject in need of said treatment or prevention a binding protein comprising a first and a second antigen binding domain (ABD) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123, the second ABD binds specifically to human NKp46, and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor.
- If not specified otherwise, the binding proteins of the present disclosure are oriented with the amino terminal direction (“N-terminal end” or “N-term”) on the left-hand side and the carboxyl-terminal direction (“C-terminal end” or “C-term”) on the right-hand side, in accordance with standard usage and convention.
-
FIG. 1 . Tri-dimensional schematic representation of the F25 format which is a variant of the bispecific F5 format, including one human NKp46 binding site and one human CD123 binding site. OnFIG. 1 , the C-term of the polypeptide is on the left-hand side and the N-term is on the right-hand side. -
FIG. 2A -FIG. 2D show two-dimensional schematic representations of the F25, F5, F26 and F6 formats respectively including the relevant domains for each polypeptide chain. In theFIGS. 2A to 2D , the C-term of the polypeptide is on the left-hand side and the N-term is on the right-hand side. The human NKp46 binding domain is formed by the VH/VL pair on the left side. The human CD123 binding domain is formed by the VH/VL pair on the right side. -
FIG. 2A shows a two-dimensional schematic representation of the F25 format. This representation represents the claimed “NKp46-CD123_F25” binding protein. -
FIG. 2B shows a two-dimensional schematic representation of the F5 format. When compared to F25, the F5 differs in that the CL and CH pair of the NKp46 binding domain are swapped, with the third polypeptide chain comprising aC H1 domain and a VL domain. -
FIG. 2C shows a two-dimensional schematic representation of the F26 format. This F26 differs from F25 ofFIG. 2A in that it includes a Fc-silent N297S mutation on eachC H2 domain. -
FIG. 2D shows a two-dimensional schematic representation of the F6 format. This F6 differs from F5 ofFIG. 2B in that it includes a Fc-silent N297S mutation on eachC H2 domain. -
FIG. 2E shows a two-dimensional detailed representation of a variant of the F25 format. This F25 format representation corresponds to the one inFIG. 2A . -
FIG. 3 shows a proposed mechanism of action of a NK Cell Engager (NKCE) for killing, following joint binding of a tumor cell (i.e. an AML cell line; i.e. MOLM-13) expressing CD123 and a NK cell expressing NKp46 and a Fcγ receptor (CD16a). Reproduced and adapted from Gauthier, L. et al. (“Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity”. Cell 177, 1701-1713 (2019)). -
FIG. 4A -FIG. 4B report the in vitro cytotoxicity of the NKp46-CD123_F25 binding protein of the present disclosure against AML cell line (MOLM-13) or primary AML blast cells respectively.FIG. 4A shows the in vitro cytotoxicity of the NKp46-CD123_F25 binding protein of the present disclosure and negative isotype control variant of format F25 binding NKp46 only (NKp46-IC_F25) against AML cell line (MOLM-13).FIG. 4B reproduces the same experiment with ex vivo patient samples where the cytotoxicity of NKp46-CD123_F25, NKp46-IC_F25, an anti-CD123 ADCC-enhanced antibody with no specificity for NKp46 (Reference-1) and a negative isotype control Fc-optimized antibody with increased ADCC activity and no specificity for NKp46 nor CD123 (IC-hIgG1-ADCC-enh) is assessed against primary AML blast cells. -
FIG. 5 provides in-vitro cytotoxicity data using fresh healthy donor NK cells against MOLM-13 AML cell line (EC50 data) of the NKp46-CD123_F25 binding protein of the present disclosure which is capable of activating human NK cells by engaging both NKp46 and CD16a, inducing ADCC activity with its Fc competent format (F25), and a NKp46-CD123_F6 binding protein activating human NK cells by engaging NKp46 only and not CD16a, inducing reduced ADCC-activity with its Fc silent format (F6). -
FIGS. 6A -FIG. 6B upper panels report the in vitro cytotoxicity of the NKp46-CD123_F25 binding protein of the present disclosure, an anti-CD123 ADCC-enhanced antibody with no binding for NKp46 (Reference-1) and a negative isotype control Fc-optimized antibody with increased ADCC activity with no specificity for NKp46 nor CD123 (IC_hIgG1-ADCC-enh) against different AML cell lines. The AML cell lines tested are: THP-1, a cell line expressing CD64(+) and CD32(+) (FIG. 6A ); MOLM-13, a cell line not expressing CD64(−) but expressing CD32(+) (FIG. 6A ), THP-1 CD64KO, a cell line knockout for CD64(−) expressing CD32(+) (FIG. 6B ); and THP-1 CD32KO, a cell line expressing CD64(+) and knockout for CD32(−) (FIG. 6B ).FIGS. 6A and 6B lower panels reports the phenotype of the malignant AML cell lines and sub-clones and the expression of CD123, CD64, CD32a/b by flow cytometry analysis. Background staining of AML cells with mouse-IgG2a (IC mouse IgG2a) and mouse-IgG1 (IC mouse IgG1) isotype controls is also shown. -
FIGS. 7A -FIG. 7B report the ex vivo induction of NK degranulation measured through the percentage of CD107a-positive NK cells against primary AML blasts from two different donors. Primary AML blasts fromdonor # 1 are CD64(+) (FIG. 7A ) and primary AML blasts fromdonor # 2 are CD64(−) (FIG. 7B ). The tested binding proteins are the NKp46-CD123_F25 binding protein of the present disclosure, an anti-CD123 ADCC-enhanced antibody with no specificity for NKp46 (Reference-1), a negative isotype control variant of format F25 not binding CD123 but binding NKp46 and CD16a (NKp46-IC_F25) and a negative isotype control Fc-optimized antibody with increased ADCC activity with no specificity for NKp46 nor CD123 (IC_hIgG1-ADCC-enh). -
FIG. 8 reports dose-dependent anti-tumor activity with the muNKp46-huCD123_F25 binding protein (carrying anti-murineNKp46 and anti-humanCD123 binding domains and also known as moNKp46-huCD123) against MOLM-13 human cells in a Severe Combined ImmunoDeficient mice (SCID) mouse model. -
FIG. 9A -FIG. 9C report the CD123-positive basophil depletion for up to 28 days after the administration NKp46-CD123_F25 binding protein of the present disclosure in non-human primates (M1, M2, M3, M4 and M6) at 3000 μg/kg or 3 mg/kg (FIG. 9A ), at 3 μg/kg (FIG. 9B ), and at 0.5 μg/kg (FIG. 9C ). -
FIG. 10A -FIG. 10B reports the in-vitro cytotoxicity of two NKp46-CD123 NKCE Fc-competent binding proteins (the NKp46-CD123_F25 of the present disclosure and NKp46-CD123_F5) and a control variant of format F5 binding CD123 and CD16a but not binding NKp46 (CD123-IC_F5) against two AML cell lines, MOLM-13 (FIG. 10A ) and THP-1 (FIG. 10B ) in presence of NK cell healthy donor sample (D648). -
FIG. 11 left panel reports CD123-positive basophil depletion in healthy donor PBMCs (N=10) in vitro induced by the treatment with NKp46-CD123_F25 (CD123-NKCE; dose range 0.001 to 10 μg/mL), NKCE isotype control NKp46-IC_F25 (IC-NKCE; not binding CD123 but binding NKp46 and CD16a) (dose range 0.001 to 10 μg/mL), or CD3-CD123 bispecific T-cell engager (CD123-TCE tool; 0.001 to 0.1 μg/mL). Central panel reports NKp46-CD123_F25 maximum depletion activity at the highest dose tested (10 μg/mL, 68 nM). Right panel reports the EC50 (pM) for CD123-positive basophil depletion calculated from NKp46-CD123_F25 dose responses for the PBMCs of six healthy donors. -
FIG. 12 displays the IL-1β, TNF-α, IFN-γ (written as INFg on the graph), and IL-6 cytokine release in vitro by healthy donor PBMCs (N=10) following the treatment with NKp46-CD123_F25, NKCE isotype control NKp46-IC_F25 (not binding CD123 but binding NKp46 and CD16a) at doses of 0.1, 1 and 10 μg/mL or a bispecific T Cell Engager tool (TCE tool) co-targeting CD123 and CD3 binding sites at dose of 0.1 μg/mL. -
FIG. 13A -FIG. 13F show the individual IL-6 and IL-10 plasma concentration versus time profiles in correlation with NKp46-CD123_F25 binding protein concentrations at 3000 μg/kg (FIG. 13A andFIG. 13B ), 3 μg/kg (FIG. 13C andFIG. 13D ), 0.5 μg/kg (FIG. 13E ) and <0.5 μg/kg (FIG. 13F ) for 6 male Cynomolgus monkeys (M1 to M6). -
FIG. 14A displays the cytotoxicity of NKp46-CD123_F25 binding protein of the present disclosure as compared to an anti-CD123 ADCC-enhanced antibody with no specificity for NKp46 (Reference-1) and a negative isotype control Fc-optimized antibody with increased ADCC activity and no specificity for NKp46 nor CD123 (IC-hIgG1-ADCC-enh) against AML blasts from patients expressing (#AML5, #AML6) or not (#AML1, #AML2) CD64. Malignant cells from AML patients were used as targets and purified healthy donor NK cells were used as effectors. Results are shown for all healthy donor NK cells tested. -
FIG. 14B reports the phenotype of the malignant AML cells from patients used inFIG. 14A showing the expression of CD33, CD123, CD32a/b, and CD64 by flow cytometry analysis. -
FIG. 15A is a comparison of the cytotoxicities of NKCEs targeting CD123 on tumor cells and not engaging NK cells (IC-CD123_F6) or engaging NK cells by CD16a only (IC-CD123_F25) or NKp46 only (NKp46-CD123_F6) or co-engaging NKp46+CD16 (NKp46-CD123_F25). MOLM-13 cells were used as the target cells and purified resting healthy donor NK cells as effectors. Two NK donors are shown. -
FIG. 15B reports the cytotoxicity of NKp46-CD123_F25 binding protein of the present disclosure as compared to a negative isotype control NKCE molecule not binding to CD123 (NKp46-IC_F25) against AML cell line MOLM-13. Results for five healthy NK-cell donors are shown. -
FIG. 16A is a flow cytometric analysis of NK and malignant cells from AML patients (AML #8-#10). Upper panels display the expression of CD123 on AML blasts (gated on the CD33-positive population); middle panels display the expression of CD64 (CD64 staining in black and isotype control in gray) on CD123-positive AML blasts; and lower panels display expression of NKp46 and CD16a on NK AML sample NK cells. -
FIG. 16B is an analysis of CD107a/b expression by NK cells after the overnight treatment with NKp46-CD123_F25 (CD123-NKCE), anti-CD123 ADCC-enhanced antibody with no specificity for NKp46 (Reference-1 or CD123-IgG1+ in the graph), a control isotype NKp46-IC_F25 not binding CD123 but binding NKp46 and CD16a (600 and 120 ng/mL) (IC-NKCE) and an IgG1 isotype control (600 ng/ml) (IC-IgG1+) on PBMCs from AML patient samples expressing CD64 (AML # 8 and #9) and not expressing CD64 (AML #10) at the cell surface of their blasts. -
FIG. 17 shows percent of marker expression (CD107, CD69, TNF-α, IFN-γ, and MIP-10) expression by NK cells treated with increasing concentrations of NKp46-CD123_F25 in comparison to controls, including one engaging NKp46 and CD16 only (NKp46-IC_F25) in an experimental setting using NK cells co-cultured or not with MOLM-13 cells (NK+MOLM-13 versus NK alone). Results for three NK cell donors are shown. -
FIG. 18 shows the activity of the surrogate muNKp46-huCD123_F25 bispecific antibody (also known as moNKp46-huCD123) against disseminated human AML, MOLM-13, in SCID mice. MOLM-13 cells were injected intravenously atday 0 in a single administration. Treatments were administered onday 1 post tumor implantation by intraperitoneal route. An isotype control antibody binding muNKp46 and murine FcγRs but not huCD123 (muNKp46-IC) was administered at 0.5 mg/kg. muNKp46-huCD123_F25 and Reference-1 were administered at 5, 0.5, 0.25 and 0.05 mg/kg. The control group was left untreated. Graphs represent Kaplan-Meier curves for animals treated by muNKp46-huCD123_F25 bispecific antibody, Reference-1 and controls at 5, 0.5, 0.25 and 0.05 mg/kg. ***: p<0.001 vs control group; **: p<0.01 vs control group; *: p<0.05 vs control group; ###: p<0.001 vs Reference-1; #: p<0.05 vs Reference-1. n=5 to 10 mice/group. -
FIG. 19 evaluates the impact of NK depletion on the in vivo efficacy of surrogate muNKp46-huCD123_F25 bispecific antibody in SCID mice bearing disseminated human MOLM-13 tumor cells. NK depletion was induced by 2 intraperitoneal administrations of anti-asialo GM1 serum one day before tumor cell implantation and atday 5 after implantation. MOLM-13 cells were injected intravenously atday 0 in a single administration. Treatments were administered intraperitoneally onday 1 post tumor implantation. Controls including an isotype control antibody binding muNKp46 and murine FcγRs but not huCD123 (muNKp46-IC) and a second isotype control antibody binding huCD123 and murine FcγRs but not murine NKp46 (IC-huCD123) were also evaluated. Graphs represent Kaplan-Meier curves for animals treated by muNKp46-huCD123_F25 bispecific antibody and controls (muNKp46-IC, IC-huCD123) at 0.5, 0.25 and 0.05 mg/kg. n=10 mice/group. ***: p<0.001 vs control group; **: p<0.01 vs control group; ###: p<0.001 vs same treatment+NK depletion; #: p<0.05 vs same treatment+NK depletion. -
FIG. 20A depicts the depletion of CD123-positive basophils from the blood of monkeys M3 and M4 treated at the low dose of 3 μg/kg as single 1-hour intravenous infusion. Blood samples were collected before dosing (pre-dose) and 24 hours after the start of the infusion and analyzed by flow cytometry. CD123-positive basophils are shown in the gate. -
FIG. 20B displays the numbers of circulating CD123-positive basophils (open symbols) and total CD123-positive leukocytes (close symbols) at time of study in monkeys M1 (orange) and M2 (purple) treated with 3 mg/kg as single 1-hour intravenous infusion, and monkeys M3 (red) and M4 (blue) treated with 3 μg/kg as single 1-hour intravenous infusion. -
FIG. 20C reports cytokine production in cynomolgus monkeys treated with the high and low doses of 3 mg/kg and 3 μg/kg as single 1-hour intravenous infusion, respectively. Plasma IL-6 and IL-10 concentrations are shown before dosing (0), and 1.5, 5 and 24 hours after the start of the treatment. -
FIG. 20D reports the plasma NKp46-CD123_F25 (CD123-NKCE) concentration monitored 1.5, 5, 24, 48, 72, 168, 240, 336, 504 and 672 hours (i.e., 0.04, 0.06, 0.21, 1, 2, 3, 7, 10, 14, 21 and 28 days) after the start of the 1-hour infusion of cynomolgus monkeys treated with the high and low doses of 3 mg/kg and 3 μg/kg. The lower limit of quantification (LLOQ; 0.25 ng/mL) is indicated by the horizontal dotted line. -
FIG. 21A shows the toxicokinetics (TK) of the NKp46-CD123_F25 (CD123-NKCE) molecule in male monkey M5 weekly treated at a dose of 3 mg/kg/administration for four weeks (onDays days day 22. Values below the lower limit of quantification (LLOQ: 0.25 ng/mL) are not reported on the graphs. Infusion days are indicated by vertical dotted lines. -
FIG. 21B is an analysis of the interleukin-6 production in monkey M5 weekly treated with the high dose of 3 mg/kg/administration for four weeks. Plasma IL-6 concentrations were monitored before dosing and 1, 1.5, 5 and 24 hours after the start of the one-hour infusion ondays day 22. -
FIG. 21C quantifies the number of circulating CD123-positive basophils (open symbols) and total CD123-positive leukocytes (closed symbols) in blood (left panel) or bone marrow (right panel), by timepoint in the study, for monkey M5, treated at a dose of 3 mg/kg/week. -
FIG. 22 graphically depicts THP1 cytotoxic activity in an assay with human peripheral blood mononuclear cells (PBMC) from 2 healthy donors (HD). NK cells and THP1 GFP target cells were incubated in presence of NKp46-CD123_F25 or its isotype control IC-CD123_F6 engaging CD123 and inducing reduced ADCC-activity with its Fc silent format (F6) at 0.1, 1, 10 and 100 ng/mL. - The disclosure provides multifunctional binding proteins that bind one surface biomarker on immune NK cells, i.e., NKp46 and one antigen of interest on tumoral target cells i.e., CD123 and is capable of redirecting NK cells to lyse a target cell that expresses the CD123 surface biomarker. The multifunctional binding proteins of the present disclosure further comprises all or part of a Fc region or variant thereof which binds a Fc-γ receptor (FcγR), in particular an activating Fc-γ receptor (FcγR), for example FcγRIIIa also called CD16a.
- The exemplified multifunctional binding proteins of the present disclosure also possess a dimeric Fc domain that comprises N-linked glycosylation and bind an activating Fc-γ receptor (FcγR) such as receptor CD16a thereby providing advantageous immune enhancing activity.
- The inventors provide experimental evidence that optimal NK cell modulation, in particular NK cell activation, can be achieved with a better safety profile, both in vitro on AML cell lines MOLM-13 and THP1 and ex vivo on primary samples from AML patients (e.g., peripheral blood lymphocytes from AML patients), by engaging NKp46, a FcγR such as CD16a, and the cell surface biomarker CD123.
- Importantly, the in vitro cytotoxic activity of the NKp46-CD123 binding protein of the present disclosure, characterized by a format reported herein as the “F25” and comprising a central Fragment crystallizable (Fc) region retaining binding to a human CD16 polypeptide, was reproduced ex vivo.
- Accordingly, the inventors provide experimental support of the therapeutic properties of a bispecific NKp46/CD16-CD123 binding protein in particular for use in treating and preventing AML and other proliferative disorders.
- The inventors further provide experimental evidence that NKp46-CD123 binding protein activate NK cells in primary samples from AML patients irrespective of their CD64 expression status.
- Hence, engagement of NK cells through the binding of cell surface markers NKp46/CD16 is validated as a robust and reproducible strategy for use as a medicament.
- As used herein, the “CD123” marker, or “Cluster of Differentiation 123” is also known as “
Interleukin 3 receptor, alpha (IL3RA)” or “IL3R”, “IL3RX”, “IL3RY”, “IL3RAY”, “hIL-3Ra” and denotes aninterleukin 3 specific subunit of a heterodimeric cytokine receptor. Thefunctional interleukin 3 receptor is a heterodimer that comprises a specific alpha chain (IL-3A; CD123) and the IL-3 receptor beta chain (βθ; CD131) that is shared with the receptors for granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin 5 (IL-5). CD123 is a type I integral transmembrane protein with a deduced Molecular Weight of about 43 kDa containing an extracellular domain involved in IL-3 binding, a transmembrane domain and a short cytoplasmic tail of about 50 amino acids. The extracellular domain is composed of two regions: a N-terminal region of about 100 amino acids, the sequence of which exhibits similarity to equivalent regions of the GM-CSF and IL-5 receptor alpha-chains; and a region proximal to the transmembrane domain that contains four conserved cysteine residues and a motif, common to other members of this cytokine receptor family. The IL-3 binding domain comprises about 200 amino acid residue cytokine receptor motifs (CRMs) made up of two Ig-like folding domains. The extracellular domain of CD123 is highly glycosylated, with N-glycosylation necessary for both ligand binding and receptor signaling. The protein family gathers three members: IL3RA (CD123A), CSF2RA and IL5RA. The overall structure is well conserved between the three members, but sequence homologies are very low. One 300 amino-acid long isoform of CD123 has been discovered so far, but only on the RNA level which is accessible on the Getentry database under the accession number ACM241 16.1. A reference sequence of full-length human CD123 protein, including signal peptide, is available from the NCBI database under the accession number NP_002174.1 and under the Uniprot accession number P26951. The extracellular domain of human CD123 (ECD) consists of the amino acid sequence of SEQ ID NO: 86. CD123 (the interleukin-3 receptor alpha chain IL-3Ra) is a tumor antigen overexpressed in a variety of hematological neoplasms. The majority of AML blasts express surface CD123 and this expression does not vary by subtype of AML. Higher expression of CD123 on AML at diagnosis has been reported to be associated with poorer prognosis. CD123 expression has been reported in other hematological malignancies including myelodysplasia, systemic mastocytosis, blastic plasmacytoid dendritic cell neoplasm (BPDCN), ALL and hairy cell leukemia. - As used herein, “Natural killer” or “NK cells” refers to a sub-population of lymphocytes that is involved in non-conventional immunity. NK cells can be identified by virtue of certain characteristics and biological properties, such as the expression of specific surface antigens including CD16, CD56 and/or CD57, NKp46 for human NK cells, the absence of the alpha/beta or gamma/delta TCR complex on the cell surface, the ability to bind to and kill cells that fail to express “self” MHC/HLA antigens by the activation of specific cytolytic machinery, the ability to kill tumor cells or other diseased cells that express a ligand for NK activating receptors, and the ability to release protein molecules called cytokines that stimulate or inhibit the immune response. Any of these characteristics and activities can be used to identify NK cells, using methods well known in the art. Any subpopulation of NK cells will also be encompassed by the term NK cells. Within the context herein “active” NK cells designate biologically active NK cells, including NK cells having the capacity of lysing target cells or enhancing the immune function of other cells. NK cells can be obtained by various techniques known in the art, such as isolation from blood samples, cytapheresis, tissue or cell collections, etc. Useful protocols for assays involving NK cells can be found in Natural Killer Cells Protocols (edited by Campbell K S and Colonna M). Human Press. pp. 219-238 (2000).
- As used herein, the “NKp46” marker, or “Natural
cytotoxicity triggering receptor 1”, also known as “CD335” or “NKP46” or “NK-p46” or “LY94” refers to a protein—or polypeptide—encoded by the Ncr1 gene. A reference sequence of full-length human NKp46 protein is available from the NCBI database under the accession number NP_004820. The human NKp46 extracellular domain (ECD) corresponds to the amino acid sequence of SEQ ID NO: 84. The human NKp46 mRNA sequence is described in NCBI accession number NM_004829. - As used herein, the term “Fc-γ receptor” or “FcγR” or “Fc-gamma receptor” may refer to both activating and inhibitory FcγRs. Fc-gamma receptors (FcγR) are cellular receptors for the Fc region of an Immunoglobulin G (IgG). Upon binding of complexed IgG, FcγRs can modulate cellular immune effector functions, thereby linking the adaptive and innate immune systems, including ADCC-mediated immune responses. In humans, six classic FcγRs are currently reported: one high-affinity receptor (FcγRI) and five low-to-medium-affinity FcγRs (FcγRIIA, -B and -C. FcγRIIIA and -B). All FcγRs bind the same region on IgG Fc, yet with differing high (FcgRI) and low (FcgRII and FcgRIII) affinities. On a functional level, most of the FcγRs are activating receptors that can induce the cellular responses mentioned above, including ADCC-mediated immune response. Whereas FcγRI, FcγRIIa, FcγRIIc, and FcγRIIIa are activating receptors characterized by an intracellular immunoreceptor tyrosine-based activation motif (ITAM), FcγRIIb has an inhibition motif (ITIM) and is therefore inhibitory. Unless specified otherwise, the term FcγRs encompasses activating receptors, including FcγRT (CD64), FcγRIIA (CD32a), FcγRIIa (CD16a) and FcγRIIIb (CD16b), and preferably FcγRIIIa (CD16a).
- As used herein, the term “FcγRIIIa (CD16a)” or “FcγRIIIa” or “CD16a” or “CD16” or “Cluster of
Differentiation 16” may refer to a 50-65 kDa cell surface molecule expressed on mast cells, macrophages, and natural killer cells as a transmembrane receptor. FcγRIIIa is an activating receptor containing immunoreceptor tyrosine activating motifs (ITAMs) in the associated FcR γ-chain, ITAMs being necessary for receptor expression, surface assembly and signaling. CD16a is a low affinity receptor for IgG and is an important receptor mediating ADCC (antibody dependent cell mediated cytotoxicity) by NK cells. The high affinity receptor CD16a is preferentially found on NK cells and monocytes and induces antibody-dependent cellular cytotoxicity (ADCC) upon IgG binding. - As used herein, the term “FcγRII CD32”, “FcγRII”, “FCGR2” or “CD32a” or “CD32A” or “CD32” or “cluster of
differentiation 32” is a surface receptor glycoprotein belonging to the Ig gene superfamily. CD32A is expressed on all myeloid cells but not on lymphocytes. CD32 has a low-affinity for the Fc region of IgG antibodies in monomeric form, but high affinity for IgG immune complexes. CD32 has two major functions: cellular response regulation, and the uptake of immune complexes. Cellular responses regulated by CD32 include phagocytosis, cytokine stimulation, and endocytic transport. Dysregulated CD32 is associated with different forms of autoimmunity, including systemic lupus erythematosus. In humans, there are three major CD32 subtypes: CD32A, CD32B, and CD32C. While CD32A and CD32C are involved in activating cellular responses, CD32B is inhibitory and balances the activating properties of CD32A. CD32A is an activating subtype of CD32 that can be found on a variety of immune cells. Notably, CD32A (FcγRIIA) mediates effector functions of granulocytes, monocytes, B cells, platelets, and dendritic cells upon low affinity binding of aggregated IgG. When bound to an IgG immune complex, the cytosolic ITAM can promote phagocytic activity and cytokine secretion in neutrophils and macrophages. - As used herein, the term “hFcγRICD64”, “hFcγRI”, or “CD64” or “Cluster of Differentiation 64” is a surface receptor expressed constitutively only on monocytes and macrophages, but is upregulated on granulocytes upon cytokine stimulation.
- As used herein, the terms “
Format 5” or “F5”, “Format 25” or “F25”, “Format F6” or “F6” and “Format 26” or “F26” refer to specific binding protein configurations of bispecific or multispecific antibodies specifically designed to engineer multiple antigen binding domains into a single antibody molecule. The multifunctional binding proteins of the present disclosure which comprise a NKp46-binding domain and a CD123-binding domain, are made based on the F25 format, as exemplified inFIG. 1 andFIG. 2 . F25 and format F26 respectively differ from format F5 and F6 in that oneC H1/CL pair between the second and third polypeptide chain are swapped to form a CL/C H1 pair. The F5 and F6 format have been previously described in the international patent application WO2017114694, incorporated herein by reference. - As used herein the term “bispecific binding protein” refers to a binding protein that specifically binds to two different antigen targets (e.g. human NKp46 and human CD123) through two distinct antigen-binding domains (ABDs).
- As used herein, the term “specifically binds to” or “binds specifically to” refers to the ability of an antigen-binding domain (ABD) to bind to an antigen (e.g. human NKp46 and/or human CD123) containing an epitope with an Kd of at least about 1×10−6 M, 1×10−7 M, 1×10−8 M, 1×10−9 M, 1×10−10 M, 1×10−11 M, 1×10−12 M, or more, and/or to bind to an epitope with an affinity that is at least twofold greater than its affinity for a nonspecific antigen.
- As used herein, the term “specifically binds to human NK46 polypeptide” may refer to a specific binding toward a polypeptide comprising an amino acid sequence of SEQ ID NO: 84.
- As used herein, the term “specifically to a human CD123 polypeptide” may refer to a specific binding toward a polypeptide comprising an amino acid sequence of SEQ ID NO: 86.
- As used herein, the term “binds to a human Fc-γ receptor polypeptide” may refer to a binding toward a polypeptide comprising an amino acid sequence of SEQ ID NO: 87 or SEQ ID NO: 88.
- Competitive binding assays and other methods for determining specific binding are further described below and are well known in the art. Expressions such as “specifically binds to”, or “with specificity for” are used interchangeably. Those terms are not construed to refer exclusively to those antibodies, polypeptides and/or multichain polypeptides which actually bind to the recited target/binding partner, but also to those which, although provided in a non-bound form, retain the specificity to the recited target. Binding specificity can be quantitatively determined by an affinity constant KA (or KA) and a dissociation constant KD (or KD).
- As used herein, the term “affinity”, concentration (EC50) or the equilibrium dissociation constant (KD) means the strength of the binding of an antibody or polypeptide to an epitope. The affinity of an antibody is given by a specific type of equilibrium constant, which is the dissociation constant KD, defined as [Ab]×[Ag]/[Ab-Ag], where [Ab-Ag] is the molar concentration of the antibody-antigen complex, [Ab] is the molar concentration of the unbound antibody and [Ag] is the molar concentration of the unbound antigen. The affinity constant KA is defined by 1/KD. Preferred methods for determining the affinity of mAbs can be found in Harlow, et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988), Coligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992, 1993), and Muller, Meth. Enzymol. 92:589-601 (1983), which references are entirely incorporated herein by reference. One preferred and standard method well known in the art for determining the affinity of mAbs is the use of surface plasmon resonance (SPR) screening (such as by analysis with a BIAcore™ SPR analytical device). In a non-limitative manner, a KD of less than 50 nM as determined by SPR, and under physiological conditions (e.g. at a pH ranging from 6 to 8 under normal buffer conditions), may generally be considered as indicative of specificity of binding for antigen-antigen binding domain (ABD) interactions. As an illustration, and according to some particular and exemplified embodiments, binding proteins reported herein comprise:
-
- an antigen binding domain which binds specifically to human CD123 with a KD of less than 10 nM, in particular with a KD of less than 0.5 nM, as determined by SPR, under physiological conditions;
- an antigen binding domain which binds specifically to human NKp46 with a KD of less than 50 nM, in particular with a KD of less than 20 nM, as determined by SPR, under physiological conditions.
- As used herein, the term “and/or” is a grammatical conjunction that is to be interpreted as encompassing that one or more of the cases it connects may occur. For example, the wording “such native sequence proteins can be made using standard recombinant and/or synthetic methods” indicates that native sequence proteins can be made using standard recombinant and synthetic methods or native sequence proteins can be made using standard recombinant methods or native sequence proteins can be made using synthetic methods.
- As used herein, “treating” refers to a therapeutic use (i.e., on a subject having a given disease) and means reversing, alleviating, inhibiting the progress of one or more symptoms of such disorder or condition. Therefore, treatment does not only refer to a treatment that leads to a complete cure of the disease, but also to treatments that slow down the progression of the disease and/or prolong the survival of the subject.
- As used herein, “preventing” means a prophylactic use (i.e., on a subject susceptible of developing a given disease and encompasses the treatment of relapsed AML patient.
- As used herein, the terms “therapeutically effective amount” of the multifunctional binding protein or pharmaceutical composition thereof is meant a sufficient amount of the antibody-like multifunctional binding protein to treat said cancer disease, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the polypeptides and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific polypeptide employed; the specific composition employed, the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific polypeptide employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts. For example, it is well known within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- As used herein, the term “subject” or “individual” or “patient” are used interchangeably and may encompass a human or a non-human mammal, rodent or non-rodent. The term includes, but is not limited to, mammals, e.g., humans including man, woman and child, other primates (monkey), pigs, rodents such as mice and rats, rabbits, guinea pigs, hamsters, cows, horses, cats, dogs, sheep and goats.
- As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a pharmaceutically acceptable carrier” encompasses a plurality of pharmaceutically acceptable carriers, including mixtures thereof.
- As used herein, “a plurality of” may thus include «two» or «two or more».
- As used herein, “antibody” or “immunoglobulin” may refer to a natural or conventional antibody in which two heavy chains are linked to each other by disulfide bonds and each heavy chain is linked to a light chain by a disulfide bond. There are two types of light chain, lambda (λ) and kappa (κ). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each chain contains distinct sequence domains. The light chain includes two domains or regions, a variable domain (VL) and a constant domain (CL). The heavy chain generally includes four domains, a variable domain (VH) and three constant domains (
C H1,C H2 andC H3, collectively referred to as CH). In particular, classes IgG, IgA, and IgD have three heavy chain constant region domains, which are designated CH1C H2, andC H3; and the IgM and IgE classes have four heavy chain constant region domains,C H1,C H2,C H3, andC H4. The variable regions of both light (VL) and heavy (VH) chains determine binding recognition and specificity to the antigen. The constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans-placental mobility, complement binding, and binding to Fc receptors (FcR). The Fv fragment is the N-terminal part of the antigen-binding fragment (Fab) of an immunoglobulin and consists of the variable portions of one light chain and one heavy chain. - As used herein, when referring to “IgG” or “Immunoglobulin G” in general, IgG1, IgG2, IgG3 and IgG4 are included, unless defined otherwise. In particular, IgG is IgG1.
- As used herein, the term “antibody-like” or “immunoglobulin-like” polypeptide may also refer to non-conventional or synthetic antigen-binding polypeptides or binding protein, including single domain antibodies and fragments thereof, in particular variable heavy chain of single domain antibodies, and chimeric, humanized, bispecific or multimeric antibodies.
- As used herein, the term “multifunctional binding protein” encompass a multichain protein, including but not limited to antibody-like polypeptide or protein formats, which comprises at least one first variable region (e.g. a first immunoglobulin heavy chain variable domain (VH) and/or an immunoglobulin light chain variable domain (VL)) binding specifically to a human CD123 polypeptide, and at least one second variable region (e.g. a second immunoglobulin heavy chain variable domain (VH) and/or immunoglobulin light chain variable domain (VL)) binding specifically to a human NKp46 poly peptide. Although not limited specifically to a particular type of construct, one general embodiment is particularly considered throughout the specification: the polypeptide constructs reported in WO2015197593 and WO2017114694, each of which is incorporated herein by reference. In particular, the multifunctional binding protein such as those reported in WO2015197593 and WO2017114694, may encompass any construct comprising one or more polypeptide chains.
- As used herein, the term “humanized”, as in “humanized antibody” refers to a polypeptide (i.e., an antibody or an antibody-like polypeptide) which is wholly or partially of non-human origin and which has been modified to replace certain amino acids, in particular in the framework regions of the heavy and light chains, in order to avoid or minimize an immune response in humans. The constant domains of a humanized antibody are most of the time human CH and CL domains. Numerous methods for humanization of an antibody sequence are known in the art; see e.g., the review by Almagro & Fransson (2008) Front Biosci. 13: 1619-1633. One commonly used method is CDR grafting, or antibody reshaping, which involves grafting of the CDR sequences of a donor antibody, generally a mouse antibody, into the framework scaffold of a human antibody of different specificity.
- For chimeric antibodies, humanization typically involves modification of the framework regions of the variable region sequences. Amino acid residues that are part of a CDR will typically not be altered in connection with humanization, although in certain cases it may be desirable to alter individual CDR amino acid residues, for example to remove a glycosylation site, a deamidation site or an undesired cysteine residue. N-linked glycosylation occurs by attachment of an oligosaccharide chain to an asparagine residue in the tripeptide sequence Asn-X-Ser or Asn-X-Thr, where X may be any amino acid except Pro. Removal of an N-glycosylation site may be achieved by mutating either the Asn or the Ser/Thr residue to a different residue, in particular by way of conservative substitution. Deamidation of asparagine and glutamine residues can occur depending on factors such as pH and surface exposure. Asparagine residues are particularly susceptible to deamidation, primarily when present in the sequence Asn-Gly, and to a lesser extent in other dipeptide sequences such as Asn-Ala. When such a deamidation site, in particular Asn-Gly, is present in a CDR sequence, it may therefore be desirable to remove the site, typically by conservative substitution to remove one of the implicated residues. Substitution in a CDR sequence to remove one of the implicated residues is also intended to be encompassed by the claimed multifunctional binding protein.
- As used herein, the term “conservative amino acid substitution” refers to substitutions in which an amino acid residue is replaced with an amino acid residue having a side chain with similar physicochemical properties. Families of amino acid residues having similar side chains are known in the art, and include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan). When an amino acid belongs to two different classes (i.e., tyrosine & phenylalanine), both can be accepted. As a reference, the following classification will be followed throughout the specification, unless stated otherwise.
-
Conservative Substitution Type of Amino acid Ala, Val, Leu, Ile, Met, Pro, Amino acids with non-polar side chains Phe, Trp Ser, Thr, Tyr, Asn, Gln, Cys, Amino acids with uncharged polar side chains Gly Asp, Glu Amino acids with acidic side chains Lys, Arg, His Amino acids with basic side chains Tyr, Phe, Trp, Aromatic amino acids - As used herein, the term “domain” may be any region of a protein, generally defined on the basis of sequence homologies or identities, which is related to a specific structural or functional entity. Accordingly, the term “region”, as used in the context of the present disclosure, is broader in that it may comprise additional regions beyond the corresponding domain.
- As used herein, the terms “linker region”, “linker peptide” or “linker polypeptide” or “amino acid linker” or “linker” refer to any amino acid sequence suitable for covalently linking two polypeptide domains, such as two antigen-binding domains together and/or a Fc region to one or more variable regions, such as one or more antigen-binding domains. Although the term is not limited to a particular size or polypeptide length, such amino acid linkers are generally less than 50 amino acids in length, preferably less than 30 amino acids in length, for
instance 20 or less than 20 amino acids in length, forinstance 15 or less than 15 amino acids in length. Such amino acid linkers may optionally comprise all or part of an immunoglobulin polypeptide chain, such as all or part of a hinge region of an immunoglobulin. Alternatively, the amino acid linker may comprise a polypeptide sequence that is not derived from a hinge region of an immunoglobulin, or even that is not derived from an immunoglobulin heavy or light polypeptide chain. - As used herein, an immunoglobulin hinge region, or a fragment thereof, may thus be considered as a particular type of linker, which is derived from an immunoglobulin polypeptide chain.
- As used herein, the term “hinge region” or “hinge” refers to a generally flexible region and born by the corresponding heavy chain polypeptides, and which separates the Fc and Fab portions of certain isotypes of immunoglobulins, more particularly of the IgG, IgA or IgD isotypes. Such hinge regions are known in the Art to depend upon the isotype of immunoglobulin which is considered. For native IgG, IgA and IgD isotypes, the hinge region thus separates the
C H1 domain and theC H2 domain and is generally cleaved upon papain digestion. On the other hand, the region corresponding to the hinge in IgM and IgE heavy chains is generally formed by an additional constant domain with lower flexibility. Additionally, the hinge region may comprise one or more cysteines involved in interchain disulfide bonds. The hinge region may also comprise one or more binding sites to a Fcγ receptor, in addition to FcγR binding sites born by theC H2 domain, when applicable. Additionally, the hinge region may comprise one or more post-translational modification, such as one or more glycosylated residues depending on the isotype which is considered. Thus, it will be readily understood that the reference to the term “hinge” throughout the specification is not limited to a particular set of hinge sequences or to a specific location on the structure. Unless instructed otherwise, the hinge regions which are still particularly considered comprise all or part of a hinge from an immunoglobulin belonging to one isotype selected from: the IgG isotype, the IgA isotype and the IgD isotype; in particular the IgG isotype. - As used herein, the terms “CH domain”, or “CH domain”, or “constant domain”, can be used interchangeably and refer to any one or more heavy chain immunoglobulin constant domain(s). Such CH domains are natively folded as immunoglobulin-like domains, although they may be partly disordered in an isolated form (e.g.,
C H1 domains when not associated with the constant domain of a light chain (CL)). Unless instructed otherwise, the term may thus refer to aC H1 domain, aC H2 domain, aC H3 domain; or any combinations thereof. - As used herein, the terms “
C H1 domain”, or “C H1 domain”, or “constant domain 1”, can be used interchangeably and refer to the corresponding heavy chain immunoglobulinconstant domain 1. - As used herein, the term “CH2 domain”, or “
C H2 domain”, or “constant domain 2” can be used interchangeably and refer to the corresponding heavy chain immunoglobulinconstant domain 2. - As used herein, the term “CH3 domain”, or “
C H3 domain”, or “constant domain 3” can be used interchangeably and refer to the corresponding heavy chain immunoglobulinconstant domain 3. - As used herein, the term “CH2-
C H3”, as in (CH2-CH3)A and (CH2-CH3)B, thus refers to a polypeptide sequence comprising an immunoglobulin heavy chain constant domain 2 (CH2) and an immunoglobulin heavy chain constant domain 3 (CH3). - As used herein, the term “CL domain” or “CL domain” can be used interchangeably and refer to the corresponding light chain immunoglobulin constant domain. Unless instructed otherwise, this term may thus encompass a CL domain of the kappa (κ or K) or lambda (λ) class of immunoglobulin light chains, including all known subtypes (e.g. λ1, λ2, λ3, and λ7) In particular, when the CL domain is of the kappa class, it may also be referred herein as a Cκ or CK or Ck domain.
- As used herein, the terms “pair C (
C H1/CL)”, or “paired C (C H1/CL)” “refers to one constantheavy chain domain 1 and one constant light chain domain (e.g., a kappa (κ or K) or lambda (λ) class of immunoglobulin light chains) bound to one another by covalent or non-covalent bonds, preferably non-covalent bonds; thus forming a heterodimer. Unless specified otherwise, when the constant chain domains forming the pair are not present on a same polypeptide chain, this term may thus encompass all possible combinations. Preferably, thecorresponding C H1 and CL domains will thus be selected as complementary to each other, such that they form a stable pair C (C H1/CL). - Advantageously, when the binding protein comprises a plurality of paired C domains, such as one “pair C1 (
C H1/CL)” and one “pair C2 (C H1/CL)”, eachC H1 and CL domain forming the pairs will be selected so that they are formed betweencomplementary C H1 and CL domains. Examples ofcomplementary C H1 and CL domains have been previously described in the international patent applications WO2006064136 or WO2012089814 or WO2015197593A1. - Unless instructed otherwise, the terms “pair C1 (
C H1/CL)” or “pair C2 (C H1/CL)” may refer to distinct constant pair domains (C1 and C2) formed by identical or distinct constant heavy 1 domains (CH1) and identical or distinct constant light chain domains (CL). Preferably, the terms “pair C1 (C H1/CL)” or “pair C2 (C H1/CL)” may refer to distinct constant pair domains (C1 and C2) formed by identical constant heavy 1 domains (CH1) and identical constant light chain domains (CL). - As used herein, the term “Fc region” or “fragment crystallizable region”, or alternatively “Fc portion.”, encompasses all or parts of the “Fc domain”, which may thus include all or parts of an immunoglobulin hinge region (which natively bears a first binding site to FcγRs), a
C H2 domain (which natively bears a second binding site to FcγRs), and aC H0 domain of an immunoglobulin (e.g. of an IgG, IgA or IgD immunoglobulin), and/or when applicable of aC H4 domain of an immunoglobulin (e.g. for IgM and IgE). Preferably, the Fc region includes all or parts of, at least, aC H2 domain and aC H3 domain, and optionally all or parts of an immunoglobulin hinge region. The term may thus refer to a molecule comprising the sequence of a non-antigen-binding fragment resulting from digestion of an antibody or produced by other means, whether in monomeric or multimeric form, and can contain the hinge region. The original immunoglobulin source of the native Fc is, in particular, of human origin and can be any of the immunoglobulins, although IgG1 are preferred. Native Fc molecules are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 13 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgGA1, and IgGA2). One example of a native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG. The term “native Fe” as used herein is generic to the monomeric, dimeric, and multimeric forms. Under that terminology, a “Fc region” may thus comprise or consist of CH12-CH3 (e.g., (CH2-CH3)A or (CH2-CH3)B or a binding pair thereof, and optionally all or part of an immunoglobulin hinge region, comprising a binding site to a human FcγR. Unless specified otherwise, the term “Fc region” may refer to either a native or variant Fc region. - The term “Fc variant” as used herein refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the receptor, FcRn (neonatal Fc receptor). Exemplary Fc variants, and their interaction with the receptor, are known in the art. Thus, the term “Fc variant” can comprise a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises regions that can be removed because they provide structural features or biological activity that are not required for the antibody-like binding proteins of the invention. Thus, the term “Fc variant” comprises a molecule or sequence that lacks one or more native Fc sites or residues, or in which one or more Fc sites or residues has be modified, that affect or are involved in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC).
- The fragment crystallizable (Fc) regions (e.g., native or variant) according to the present disclosure retain a capacity to bind to a human Fc-γ receptor polypeptide (Fcγ) which generally occurs on native Fc regions through binding of the antibody Fc-hinge region. As a reference, overall structures of IgG1, IgG2, and IgG4 are similar with more than 90% sequence homology, the major differences residing in the hinge region and
C H2 domain, which form primary binding sites to FcγRs. The hinge region also functions as a flexible linker between the Fab and Fc portion. - Fc regions having one or more amino acid modifications (e.g., substitutions, deletions, insertions) in one or more portions, which modifications increase the affinity and avidity of the variant Fc region for an FcγR (including activating and inhibitory FcγRs) are further considered as Fc regions. In some embodiments, said one or more amino acid modifications increase the affinity of the Fc region for FcγRIIIA and/or FcγRIIA. In another embodiment, the variant Fc region further specifically binds FcγRIIB with a lower affinity than does the Fc region of the reference parent antibody (e.g., an antibody having the same amino acid sequence as the antibody except for the one or more amino acid modifications in the Fc region). Hence, native and variant Fc regions considered herein generally comprise a domain (i.e., a
C H2 domain) capable of binding to human CD16, e.g., a human Fc domain comprising N-linked glycosylation at amino acid residue N297 (according to EU numbering). - As used herein, the term “Fc-competent” thus refers to a binding protein that is capable of binding specifically to a FcγR, in particular of an activating FcγR, in particular to one selected from FcγRI (CD64a), FcγRIIa (CD32a), and FcγRIIIa (CD16a), and more particularly to FcγRIIa (CD16a).
- Alternatively, several modifications are reported to directly affect the binding to FcγRs, including mutation on residues 297 (according to EU numbering), or alternatively on residues 234 and 235 in the lower hinge region (according to the EU numbering system).
- As used herein, the term “Fc-silent” refers to a binding protein with a Fc region, wherein the Fc region lacks a binding site to a FcγR (e.g., a Fc region lacking a
C H2 domain with said binding site and hinge region with said binding site); in particular FcγRI, FcγRIIa, and FcγRIIIa, and more particularly to FcγRIIIa (CD16a). - As used herein, the term “variable”, as in “variable domain”, refers to certain portions of the relevant binding protein which differ extensively in sequence between and among antibodies and are used in the specific recognition and binding of a particular antibody for its particular target. However, the variability is not evenly distributed throughout the entire variable domains of antibodies. The variability is concentrated in three segments called complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) also known as hypervariable regions, both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework (FR) regions or sequences.
- As used herein, the term “VH domain”, or “VH domain” can be used interchangeably and refer to the corresponding heavy chain immunoglobulin variable domain.
- As used herein, the term “VL domain”, or “VL domain” can be used interchangeably and refer to the corresponding light chain immunoglobulin variable domain.
- When the VH or VL domains are associated to a first antigen-binding domain (ABD) or to a second antigen-binding domain, they may also be respectively referred herein as “
V H1” and “V L1”, or “V H2” and “V L2”. - The terms “binding pair V (VH/VL)”, “VH/VL pair” or “(VH/VL) pair” or “VL/VH pair” or “(VL/VH) pair” can be used interchangeably. Heavy chain and light chain variable domain can pair in parallel to form the antigen binding domains (ABDs). Each binding pair includes both a VH and a VL region. Unless instructed otherwise, these terms do not specify which immunoglobulin variable regions are VH or VL regions and which ABD will bind specifically the protein expressed on the surface of an immune effector cell or a target cell (e.g., NKp46 and CD123).
- As used herein, the term “hypervariable region’ when used herein refers to the amino acid residues of an antibody that are responsible for antigen binding. This term may be substituted by the terms “Complementarity Determining Regions” or “CDRs”.
- Thus, as used herein “Complementarity Determining Regions” or “CDRs” refer to amino acid sequences that together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site. The light and heavy chains of an immunoglobulin each have three CDRs, designated CDR-L1, CDR-L2, CDR-L3 and CDR-H1, CDR-H2, CDR-H3, respectively. A conventional antibody antigen-binding domain, therefore, includes six CDRs, comprising the CDR set from each of a heavy and a light chain variable region. Also, as used herein, “Framework Regions” (FRs) refer to amino acid sequences interposed between CDRs, i.e., to those portions of immunoglobulin light and heavy chain variable regions that are relatively conserved among different immunoglobulins in a single species. The light and heavy chains of an immunoglobulin each have four FRs, designated FR-L1, FR-L2, FR-L3, FR-L4, and FR-H1, FR-H2, FR-H3, FR-H4, respectively. Accordingly, the light chain variable domain may thus be designated as (FR-L1)-(CDR-L1)-(FR-L2)-(CDR-L2)-(FR-L3)-(CDR-L3)-(FR-L4) and the heavy chain variable domain may thus be designated as (FR-H1)-(CDR-H1)-(FR-H2)-(CDR-H2)-(FR-H3)-(CDR-H)-(FR4-H3).
- The hypervariable region generally comprises amino acid residues from a “complementarity-determining region” or “CDR” (e.g. residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light-chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy-chain variable domain; Kabat et al. 1991) and/or those residues from a “hypervariable loop” (e.g. residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light-chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy-chain variable domain; Chothia and Lesk, J. Mol. Biol 1987; 196:901-917). The numbering of amino acid residues in this region is performed by the method described in Kabat et al., supra. Accordingly, phrases such as “Kabat position”, “variable domain residue numbering as in Kabat” and “according to Kabat” herein refer to this numbering system for heavy chain variable domains or light chain variable domains. Using the Kabat numbering system, the actual linear amino acid sequence of a peptide may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable domain. For example, a heavy chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of CDR H2 and inserted residues (e.g., residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence.
- Optionally, CDRs are as defined by EU, Kabat, Chotia or IMGT numbering. Correspondances between those classifications are known in the Art, by reference to the IMGT®, or international ImMunoGeneTics information System® (CNRS and Montpellier University), and as further detailed in Lefranc (Biomolecules; 2014; 4, 1102-1139) and Dondelinger (Frontiers in Immunology; 2018; 9, 2278).
- Unless instructed otherwise, the numbering of residues will be considered herein by reference to the EU, Kabat, Chotia or IMGT numbering convention. In case of conflict regarding the exact position of hypervariable regions within a reference sequence, the Kabat numbering convention will prevail. In case of conflict regarding the exact position of constant regions within a reference sequence, the EU numbering convention will prevail.
- As used herein, the term “cytotoxicity” refers to the quality of a compound, such as the multifunctional binding protein according to the present disclosure, to be toxic to tumoral cells. Cytotoxicity may be induced by different mechanisms of action and can thus be divided into cell-mediated cytotoxicity, apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) or complement-dependent cytotoxicity (CDC).
- As used herein, the term “antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to a mechanism of cell-mediated immune defence whereby an effector cell of the immune system actively lyses a target cell, whose membrane-surface antigens have been bound by specific antibodies or the multifunctional binding protein of the present disclosure.
- As used herein, the terms “proliferative disorders”, “hyper-proliferative disorders” and/or “cancer” not only refer to solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases, but also include blood cancers, including tumors of the hematopoietic and lymphoid tissues, such as lymphomas, myelomas, and leukemias. Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
- As used herein, “Acute myelogenous leukemia (AML)” is a clonal disorder clinically presenting as increased proliferation of heterogeneous and undifferentiated myeloid blasts. Without wishing to be bound by the theory, the leukemic hierarchy is maintained by a small population of LSCs (Leukemic Stem Cells) (AML-LSCs), which have the distinct ability for self-renewal, and are able to differentiate into leukemic progenitors. These progenitors generate the large numbers of leukemic blasts readily detectable in patients at diagnosis and relapse, leading ultimately to mortality. AML-LSC have been commonly reported as quiescent cells, in contrast to rapidly dividing clonogenic progenitors.
- Within the context of AML, the term “relapse” may in particular be defined as the reoccurrence of AML after complete remission. In that sense “complete remission” or “CR” may be defined as follows: normal values for neutrophil (>1.0*109/L), haemoglobin level of 10 g/dl and platelet count (>100*109/L) and independence from red cell transfusion; blast cells less than 5%, no clusters or collections of blasts, and absence of Auer rods on bone marrow examination; and normal maturation of blood cells (morphology; myelogramme) and absence of extramedullary leukemia.
- As used herein, “myelodysplastic syndromes” (“MDS”), formerly known as preleukemia, are a collection of hematological conditions that involve ineffective production (or dysplasia) of the myeloid class of blood cells. They represent a spectrum of clonal hematopoietic stem cell disorders characterized by progressive bone marrow failure and increased risk of progression to acute myeloid leukemia (“AML”, also known as “acute myelogenous leukemia”). The International Prognostic Scoring System (“IPSS”) is widely used to identify patients with high-risk features based on the severity of their cytopenias, bone marrow myeloblast percentage, and cytogenetic abnormalities.
- As used herein, a “pharmaceutically acceptable carrier” is intended to include any and all carrier (such as any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like) which is compatible with pharmaceutical administration, in particular parenteral administration. The use of such media and agents for pharmaceutically active substances are known. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the present disclosure. For example, preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. In a non-exhaustive manner, pharmaceutically acceptable carriers include, but are not limited to, 0.01-0.1M (e.g., 0.05M) phosphate buffer or 0.8% saline. Other common parenteral vehicles include sodium phosphate solutions, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like. More particularly, pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In such cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It should be stable under the conditions of manufacture and storage and will in an embodiment be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal and the like. In certain embodiments, isotonic agents are included, for example, sugars, polyalcohols, such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- As used herein, and unless instructed otherwise, the term “at least one” may encompass “one or more”, or even “two or more” (or “a plurality”). For instance, it may encompass 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or more than 100.
- As used herein, and unless instructed otherwise, the term “less than . . . ” may encompass all values from 0 to the corresponding threshold, For instance, it may encompass less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or less than 100, when applicable.
- As used herein, the term “cell” may encompass any prokaryotic cell or eukaryotic cell. Cell types which are particularly considered are those suitable for the production and/or engineering of recombinant antibodies, or fragments, or polypeptide chains thereof. In a non-exhaustive manner, such cells may be selected from the group consisting of: bacterial cells, yeast cells, mammalian cells, non-mammalian cells, insect cells, and plant cells.
- The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. A host cell is any type of cellular system that can be used to generate binding proteins of the present disclosure. Host cells may thus include cultured cells, e.g., mammalian cultured cells, such as CHO cells, HEK cells, BHK cells, NSO cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, bacterial cells, yeast cells, insect cells, and plant cells, to name only a few.
- By “isolated” nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present disclosure. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. An isolated polynucleotide includes a polynucleotide molecule contained in cells that ordinarily contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present disclosure, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present disclosure further include such molecules produced synthetically. In addition, a polynucleotide or a nucleic acid may be or may include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator.
- The term “vector’ or “expression vector” is intended to mean the vehicle by which a nucleic acid, in particular a DNA or RNA sequence (e.g., a foreign gene), can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence.
- In one embodiment, the disclosure relates to a binding protein characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor.
- In some embodiments, the binding protein is characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide and comprising at least one CDR selected from SEQ ID NO: 1 to SEQ ID NO: 12, or a variant thereof with one or more conservative substitution(s);
- (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In some embodiments, the disclosure relates to a binding protein characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide,
- (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide and comprising at least one CDR selected from SEQ ID NO: 13 to SEQ ID NO: 40, or a variant thereof with one or more conservative substitution(s);
- and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In some embodiments, the binding protein is characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide and comprising at least one CDR selected from SEQ ID NO: 1 to SEQ ID NO: 12, or a variant thereof with one or more conservative substitution(s); and
- (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide and comprising at least one CDR selected from SEQ ID NO: 13 to SEQ ID NO: 40, or a variant thereof with one or more conservative substitution(s);
- and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In some embodiments, the binding protein is characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide and comprising three CDRs selected from SEQ ID NO: 1 to SEQ ID NO: 12, or a variant thereof with one or more conservative substitution(s), and
- (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide and comprising three CDRs selected from SEQ ID NO: 13 to SEQ ID NO: 40, or a variant thereof with one or more conservative substitution(s), and
- (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In some embodiments, the binding protein is characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, and comprising an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3 respectively), and
- (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and comprising an immunoglobulin light chain variable region (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3 respectively), and
- (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In some embodiments, the binding protein is characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, and comprising an immunoglobulin heavy chain variable region (VH) with three complementary determining regions, at least one being selected from SEQ ID NO: 1 to SEQ ID NO: 6, and an immunoglobulin light chain variable region (VL) with three complementary determining regions, at least one being selected from SEQ ID NO: 7 to SEQ ID NO: 12;
- (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and comprising an immunoglobulin heavy chain variable region (VH) with three complementary determining regions at least one being selected from SEQ ID NO: 13 to SEQ ID NO: 26, and an immunoglobulin light chain variable region (VL) with three complementary determining regions at least one being selected from SEQ ID NO: 27 to SEQ ID NO: 40;
and - (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In some embodiments, the binding protein is characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, and comprising an immunoglobulin heavy chain variable region (VH) with three complementary determining regions, at least two being selected from SEQ ID NO: 1 to SEQ ID NO: 6, and an immunoglobulin light chain variable region (VL) with three complementary determining regions at least two being selected from SEQ ID NO: 7 to SEQ ID NO: 12;
- (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and comprising an immunoglobulin heavy chain variable region (VH) with three complementary determining regions at least two being selected from SEQ ID NO: 13 to SEQ ID NO: 26, and an immunoglobulin light chain variable region (VL) with three complementary determining regions at least two being selected from SEQ ID NO: 27 to SEQ ID NO: 40;
and - (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In some embodiments, the binding protein is characterized in that it comprises:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, and comprising an immunoglobulin heavy chain variable region (VH) with three complementary determining regions, selected from SEQ ID NO: 1 to SEQ ID NO: 6, and an immunoglobulin light chain variable region (VL) with three complementary determining regions selected from SEQ ID NO: 7 to SEQ ID NO: 12;
- (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and comprising an immunoglobulin heavy chain variable region (VH) with three complementary determining regions selected from SEQ ID NO: 13 to SEQ ID NO: 26, and an immunoglobulin light chain variable region (VL) with three complementary determining regions selected from SEQ ID NO: 27 to SEQ ID NO: 40;
and - (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In some embodiments, the binding protein is characterized in that the first ABD binds specifically to human CD123 and comprises an immunoglobulin heavy chain variable domain (VH) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to SEQ ID NO: 6 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the first ABD binds specifically to human CD123 and comprises an immunoglobulin light chain variable domain (VL) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to SEQ ID NO: 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to SEQ ID NO: 12 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (VH) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 13 to SEQ ID NO: 15 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (VH) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 16 to SEQ ID NO: 18 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (VH) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 19 to SEQ ID NO: 21 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (VH) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 22 to SEQ ID NO: 24 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin heavy chain variable domain (VH) comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 16, SEQ ID NO: 25 and SEQ ID NO: 26 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (VL) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 27 to SEQ ID NO: 29 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (VL) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 30 to SEQ ID NO: 32 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (VL) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 33 to SEQ ID NO: 35 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (VL) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 36 to SEQ ID NO: 38 respectively.
- According to some particular embodiments of this first general object, the binding protein is characterized in that the second ABD binds specifically to human NKp46 and comprises an immunoglobulin light chain variable domain (VL) comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 39, SEQ ID NO: 31 and SEQ ID NO: 40 respectively.
- According to one embodiment, the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to SEQ ID NO: 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to SEQ ID NO: 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to SEQ ID NO: 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO: 13 to SEQ ID NO: 15 respectively;
- the amino acid sequences of SEQ ID NO: 16 to SEQ ID NO: 18 respectively;
- the amino acid sequences of SEQ ID NO: 19 to SEQ ID NO: 21 respectively;
- the amino acid sequences of SEQ ID NO: 22 to SEQ ID NO: 24 respectively; or
- the amino acid sequences of SEQ ID NO: 16, SEQ ID NO: 25 and SEQ ID NO: 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO: 27 to SEQ ID NO: 29 respectively;
- the amino acid sequences of SEQ ID NO: 30 to SEQ ID NO: 32 respectively;
- the amino acid sequences of SEQ ID NO: 33 to SEQ ID NO: 35 respectively;
- the amino acid sequences of SEQ ID NO: 36 to SEQ ID NO: 38 respectively; or
- the amino acid sequences SEQ ID NO: 39, SEQ ID NO: 31 and SEQ ID NO: 40 respectively;
and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor.
- (i) the first ABD binds specifically to human CD123 and comprises:
- It will be readily understood by the skilled in the Art that the above described binding protein may consist of one single polypeptide chain, or be a multimeric binding protein, and hence comprise a plurality (two or more) polypeptide chains.
- According to some particular embodiments, the binding protein is a multimeric binding protein, and the two antigen-binding domains may be born at least in part by distinct polypeptide chains.
- Optionally, when the binding protein comprises a plurality of polypeptide chains, (e.g., two or three polypeptide chains), some of those polypeptide chains may be linked covalently. When two polypeptide chains are linked covalently, the covalent linker(s) may advantageously be selected from disulfide bridges, or any other covalent linker, including peptide bond(s) bridging one polypeptide chain with another, and/or linker peptide(s) bridging one polypeptide chain with another.
- According to some particular embodiments, the binding protein is characterized in that it comprises three polypeptide chains (I), (II) and (III) that form two ABDs:
-
V1A-C1A-L3-(CH2-CH3)A (I) -
V1B-C1B-L4-(CH2-CH3)B-L1-V2A-C2A-L2 (II) -
V2B-C2B (III) - wherein:
-
- V1A and V1B form a binding pair V1 (VH1/VL1);
- V2A and V2B form a binding pair V2 (VH2/VL2);
- C1A and C1B form a pair C1 (
C H1/CL) and C2A and C2B form a pair C2 (C H1/CL) whereinC H1 is an immunoglobulin heavy chainconstant domain 1 and CL is an immunoglobulin light chain constant domain; - (CH2-CH3)A and (CH2-CH3)B are identical or different, and comprise an immunoglobulin heavy chain constant domain 2 (CH2) and an immunoglobulin heavy chain constant domain 3 (CH3);
- L1, L2, L3, L4 are optional independent amino acid linkers, which may be identical or different.
- In some embodiments, the (CH2-CH3)A and (CH2-CH3)B comprise each at least one
identical C H2 domain, such as aC H2 domain corresponding to the amino acid sequence of SEQ ID NO: 71. - In some embodiments, the (CH2-CH3)A and (CH2-CH3)B are identical or different and may comprise a polypeptide sequence selected from amino acid sequences of SEQ ID NO: 69 or SEQ ID NO: 70.
- In some embodiments, some of L1, L2, L3 and L4 may be identical or different, and may comprise all or part of an amino acid sequence selected from SEQ ID NO: 74 to SEQ ID NO: 79; for example, one or more than four consecutive amino acids of an amino acid sequence selected from SEQ ID NO: 74 to SEQ ID NO: 79.
- According to some particular embodiments, some of L1, L2, L3 and L4 may be identical or different, and may comprise all or part of an immunoglobulin hinge region, such as one selected from amino acid sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79; for example four or more than four consecutive amino acids of an immunoglobulin hinge region, such as one selected from amino acid sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79.
- According to some more particular embodiments, L2, L3 and L4 may be identical or different, and may comprise all or part of an immunoglobulin hinge region, such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79; for example, four or more than four consecutive amino acids of an immunoglobulin hinge region, such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79.
- According to some more particular embodiments, L2, L3 and L4 may be identical or different, and may comprise all or part of an immunoglobulin hinge region, such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79 (for example four or more than four consecutive amino acids of an immunoglobulin hinge region, such as one selected from sequences SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78 and/or SEQ ID NO: 79), and L1 may comprise all or part of the linker which corresponds to the amino acid sequence of SEQ ID NO: 76.
- According to some particular embodiments, the binding protein is characterized in that it comprises three polypeptide chains (I), (II) and (III) that form two ABDs, as defined below:
-
V1A-C1A-L3-(CH2-CH3)A (I) -
V1B-C1B-L4-(CH2-CH3)B-L1-V2A-C2A-L2 (II) -
V2B-C2B (III) - wherein:
-
- V1A and V1B form a binding pair V1 (VH1/VL1), which binds specifically to a human CD123 polypeptide;
- V2A and V2B form a binding pair V2 (VH2/VL2), which binds specifically to a human NKp46 polypeptide;
- C1A and C1B form a pair C1 (
C H1/CL) and C2A and C2B form a pair C2 (C H1/CL) whereinC H1 is an immunoglobulin heavy chainconstant domain 1 and CL is an immunoglobulin light chain constant domain; - (CH2-CH3)A and (CH2-CH3)B are identical or different, and comprise an immunoglobulin heavy chain constant domain 2 (CH2) and an immunoglobulin heavy chain constant domain 3 (CH3);
- L1, L2, L3, L4 are optional independent amino acid linkers, which may be identical or different.
- In one embodiment, the binding protein is characterized in that it comprises three polypeptide chains (I), (II) and (III) that form two ABDs, as defined below:
-
V1A-C1A-Hinge1-(CH2-CH3)A (I) -
V1B-C1B-Hinge2-(CH2-CH3)B-L1-V2A-C2A-Hinge3 (II) -
V2B-C2B (III) - wherein:
-
- V1A and V1B form a binding pair V1 (VH1/VL1);
- V2A and V2B form a binding pair V2 (VH2/VL2);
- C1A and C1B form a pair C1 (
C H1/CL) and C2A and C2B form a pair C2 (C H1/CL) whereinC H1 is an immunoglobulin heavy chainconstant domain 1 and CL is an immunoglobulin light chain constant domain; - Hinge1, Hinge2 and Hinge3 are identical or different and correspond to all or part of an immunoglobulin hinge region;
- (CH2-CH3)A and (CH2-CH3)B are identical or different, and comprise an immunoglobulin heavy chain constant domain 2 (CH2) and an immunoglobulin heavy chain constant domain 3 (CH3);
- L1 is an amino acid linker.
- In one embodiment, the binding protein is characterized in that it comprises three polypeptide chains (I), (II) and (III) that form two ABDs, as defined below:
-
V1A-C1A-Hinge1-(CH2-CH3)A (I) -
V1B-C1B-Hinge2-(CH2-CH3)B-L1-V2A-C2A-Hinge3 (II) -
V2B-C2B (III) - wherein:
-
- V1A and V1B form a binding pair V1 (VH1/VL1) which binds specifically to a human CD123 polypeptide;
- V2A and V2B form a binding pair V2 (VH2/VL2) which binds specifically to a human NKp46 polypeptide;
- C1A and C1B form a pair C1 (
C H1/CL) and C2A and C2B form a pair C2 (C H1/CL) whereinC H1 is an immunoglobulin heavy chainconstant domain 1 and CL is an immunoglobulin light chain constant domain; - Hinge1, Hinge2 and Hinge3 are identical or different and correspond to all or part of an immunoglobulin hinge region;
- (CH2-CH3)A and (CH2-CH3)B are identical or different, and comprise an immunoglobulin heavy chain constant domain 2 (CH2) and an immunoglobulin heavy chain constant domain 3 (CH3);
- L1 is an amino acid linker.
- In some embodiments of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that:
-
- C1A comprises a CL domain;
- C1B comprises a
C H1 domain; - C2A comprises a
C H1 domain; - C2B comprises a CL domain.
- In some embodiments of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that:
-
- C1A comprises a
C H1 domain; - C1B comprises a CL domain;
- C2A comprises a CL domain;
- C2B comprises a
C H1 domain.
- C1A comprises a
- According to some of those particular embodiments of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that:
-
- C1A comprises a
C H1 domain; - C1B comprises a CL domain;
- C2A comprises a
C H1 domain; - C2B comprises a CL domain.
- C1A comprises a
- According to some of those particular embodiments of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that:
-
- C1A comprises a CL domain;
- C1B comprises a
C H1 domain; - C2A comprises a CL domain;
- C2B comprises a
C H1 domain.
- In some embodiments, CL and
C H1 domains which form C1A, C1B, C2A, and C2B may be identical or different. Hence in some embodiments of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that: -
- C1A and C2A are identical and comprise a CL domain; or
- C1A and C2B are identical and comprise a CL domain; or
- C1B and C2A are identical and comprise a CL domain; or
- C1B and C2B are identical and comprise a CL domain.
- In some embodiments of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that:
-
- C1A and C2A are identical and comprise a
C H1 domain; or - C1A and C2B are identical and comprise a
C H1 domain; or - C1B and C2A are identical and comprise a
C H1 domain; or - C1B and C2B are identical and comprise a
C H1 domain.
- C1A and C2A are identical and comprise a
- In some embodiments of polypeptide chains (I), (II) and (III): V1A is a VH and V1B is a VL.
- In some embodiments of polypeptide chains (I), (II) and (III): V1A is a VL and V1B is a VH.
- In some embodiments of polypeptide chains (I), (II) and (III): V2A is a VH and V2B is a VL.
- In some embodiments of polypeptide chains (I), (II) and (III): V2A is a VL and V2B is a VH.
- In some embodiments of polypeptide chains (I), (II) and (III): V1A is a VH and V1B is a VL; and V2A is a VH and V2B is a VL.
- In some embodiments of polypeptide chains (I), (II) and (III): V1A is a VL and V1B is a VH; and V2A is a VH and V2B is a VL.
- In some embodiments of polypeptide chains (I), (II) and (III): V1A is a VH and V1B is a VL; and V2A is a VL and V2B is a VH.
- In some embodiments of polypeptide chains (I), (II) and (III): V1A is a VL and V1B is a VH; and V2A is a VL and V2B is a VH.
- In some embodiment of the binding protein, V1A is VL1 and V1B is VH1; and V2A is VH2 and V2B is VL2.
- In some embodiment of the binding protein, V1A is VL1 and V1B is VH1.
- In some embodiment of the binding protein, V2A is VH2 and V2B is VL2.
- In some embodiment of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that:
-
- C1B is an immunoglobulin heavy chain constant domain 1 (CH1);
- C2A is an immunoglobulin heavy chain constant domain 1 (CH1);
- CL corresponds to an immunoglobulin kappa light chain constant domain (CK);
- (CH2-CH3)A corresponds to the amino acid sequence of SEQ ID NO: 69;
- (CH2-CH3)B corresponds to the amino acid sequence of SEQ ID NO: 70;
- L2 or Hinge1 corresponds to the amino acid sequence of SEQ ID NO:74;
- L3 or Hinge2 corresponds to the amino acid sequence of SEQ ID NO:75;
- L4 or Hinge3 corresponds to the amino acid sequence of SEQ ID NO: 77.
- L1 corresponds to the amino acid sequence of SEQ ID NO: 76.
- In some embodiment of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that:
-
- C1B is an immunoglobulin heavy chain constant domain 1 (CH1);
- C2A is an immunoglobulin heavy chain constant domain 1 (CH1);
- CL corresponds to an immunoglobulin kappa light chain constant domain (CK);
- (CH2-CH3)A corresponds to the amino acid sequence of SEQ ID NO: 69;
- (CH2-CH3)B corresponds to the amino acid sequence of SEQ ID NO: 70;
- Hinge1 corresponds to the amino acid sequence of SEQ ID NO:74;
- Hinge2 corresponds to the amino acid sequence of SEQ ID NO:75;
- Hinge3 corresponds to the amino acid sequence of SEQ ID NO: 77;
- L1 corresponds to the amino acid sequence of SEQ ID NO: 76.
- In some embodiment of the binding protein:
-
- (a) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 27; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 28; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 29;
- (b) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 18; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 30; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 32;
- (c) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 33; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 34; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 35;
- (d) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 22; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 23; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 24; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 37; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 38;
- (e) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 39; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 40;
- (f) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 27; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 28; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 29;
- (g) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 18; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 30; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 32;
- (h) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 33; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 34; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 35;
- (i) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 22; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 23; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 24; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 37; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 38;
- (j) VH1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; VL1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; VH2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; VL2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 39; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 40.
- In some embodiments of the binding protein:
-
- (a) VH1 and VL1 corresponds to the amino acid sequences of SEQ ID NO: 41 and 43 respectively or corresponds to the amino acid sequences of SEQ ID NO: 42 and 44 respectively;
and/or - (b) VH2 and VL2 corresponds to
- the amino acid sequences of SEQ ID NO: 45 and 53 respectively;
- the amino acid sequences of SEQ ID NO: 46 and 54 respectively;
- the amino acid sequences of SEQ ID NO: 47 and 55 respectively;
- the amino acid sequences of SEQ ID NO: 48 and 56 respectively;
- the amino acid sequences of SEQ ID NO: 49 and 57 respectively;
- the amino acid sequences of SEQ ID NO: 50 and 58 respectively;
- the amino acid sequences of SEQ ID NO: 51 and 59 respectively; or
- the amino acid sequences of SEQ ID NO: 52 and 60 respectively.
- (a) VH1 and VL1 corresponds to the amino acid sequences of SEQ ID NO: 41 and 43 respectively or corresponds to the amino acid sequences of SEQ ID NO: 42 and 44 respectively;
- In some embodiments of the binding protein:
-
- (a) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 45; VL2 comprises the amino acid sequence of SEQ ID NO: 53;
- (b) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 46; VL2 comprises the amino acid sequence of SEQ ID NO: 54;
- (c) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 47; VL2 comprises the amino acid sequence of SEQ ID NO: 55;
- (d) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 48; VL2 comprises the amino acid sequence of SEQ ID NO: 56;
- (e) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 49; VL2 comprises the amino acid sequence of SEQ ID NO: 57;
- (f) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 50; VL2 comprises the amino acid sequence of SEQ ID NO: 58;
- (g) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 51; VL2 comprises the amino acid sequence of SEQ ID NO: 59;
- (h) VH1 comprises the amino acid sequence of SEQ ID NO: 41; VL1 comprises the amino acid sequence of SEQ ID NO: 43; VH2 comprises the amino acid sequence of SEQ ID NO: 52; VL2 comprises the amino acid sequence of SEQ ID NO: 60;
- (i) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 45; VL2 comprises the amino acid sequence of SEQ ID NO: 53;
- (j) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 46; VL2 comprises the amino acid sequence of SEQ ID NO: 54;
- (k) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 47; VL2 comprises the amino acid sequence of SEQ ID NO: 55;
- (l) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 48; VL2 comprises the amino acid sequence of SEQ ID NO: 56;
- (m) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 49; VL2 comprises the amino acid sequence of SEQ ID NO: 57;
- (n) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 50; VL2 comprises the amino acid sequence of SEQ ID NO: 58.
- (o) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 51; VL2 comprises the amino acid sequence of SEQ ID NO: 59;
- (p) VH1 comprises the amino acid sequence of SEQ ID NO: 42; VL1 comprises the amino acid sequence of SEQ ID NO: 44; VH2 comprises the amino acid sequence of SEQ ID NO: 52; VL2 comprises the amino acid sequence of SEQ ID NO: 60.
- In some embodiments, the binding protein comprises at least two polypeptide chains linked by at least one disulfide bridge.
- In some embodiments of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that: polypeptide chain (I) is covalently linked to polypeptide chain (II), in particular covalently liked to polypeptide (II) by one or more disulfide bonds.
- According to some of those particular embodiments of the binding protein, the polypeptide chains (I), (II) and (III) are characterized in that: polypeptide chain (II) is covalently linked to polypeptide chain (III), by one or more disulfide bonds.
- In some embodiments, the polypeptide chains (I) and (II) are linked by at least one disulfide bridge between C1A and Hinge2 and/or wherein the polypeptide chains (II) and (III) are linked by at least one disulfide bridge between Hinge3 and C2B.
- In some embodiments, the binding protein is characterized in that the Fc region or variant thereof (e.g. (CH2-CH3)A or (CH2-CH3)B or Hinge1-(CH2-CH3)A or Hinge2-(CH2-CH3)B) which binds to a human Fc-γ receptor polypeptide, comprises a
C H2 heavy chain constant domain with a N-linked glycosylation at residue N297 according to EU numbering. - In some embodiments, the binding protein is characterized in that the residue N297 of the Fc region or variant thereof according to EU numbering comprises a N-linked glycosylation.
- In some embodiments, the binding protein is characterized in that all or part of the Fc region or variant thereof binds to a human Fc-γ receptor polypeptide. In some embodiments, the binding protein is characterized in that all or part of the Fc region or variant thereof binds to a human CD16A (FcγRIII) polypeptide.
- In one embodiment, the binding protein comprises:
-
- a polypeptide comprising an amino acid sequence of SEQ ID NO: 61, a polypeptide comprising an amino acid sequence of SEQ ID NO: 62 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 63, or a variant thereof with at least 80% of sequence identity; or
- a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide comprising an amino acid sequence of SEQ ID NO: 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 66 or a variant thereof with at least 80% of sequence identity; and/or
- a polypeptide comprising an amino acid sequence of SEQ ID NO: 61 or 64, a polypeptide comprising an amino acid sequence of SEQ ID NO: 62 or 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or 66, or a variant thereof with at least 80% of sequence identity.
- In some embodiments, the binding protein comprises:
-
- a polypeptide comprising an amino acid sequence SEQ ID NO: 61, a polypeptide comprising an amino acid sequence SEQ ID NO: 62 and a polypeptide comprising an amino acid sequence SEQ ID NO: 63 or a variant thereof with at least 80% of sequence identity; or
- a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide comprising an amino acid sequence of SEQ ID NO: 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 66 or a variant thereof with at least 80% of sequence identity.
- In some embodiments, the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 61, a polypeptide comprising a sequence SEQ ID NO: 62 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or a variant thereof with at least 80% of sequence identity.
- In some embodiments, the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide comprising an amino acid sequence of SEQ ID NO: 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 66 or a variant thereof with at least 80% of sequence identity.
- In some embodiments, the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 61, a polypeptide comprising an amino acid sequence of SEQ ID NO: 62 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or a variant thereof with at least 90% of sequence identity.
- In some embodiments, the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide comprising a amino acid sequence of SEQ ID NO: 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 66 or a variant thereof with at least 90% of sequence identity.
- In some embodiments, the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 61, a polypeptide comprising an amino acid sequence of SEQ ID NO: 62 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or a variant thereof with at least 95% of sequence identity.
- In some embodiments, the binding protein comprises: a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide comprising a amino acid sequence of SEQ ID NO: 65 and a polypeptide comprising an amino acid sequence of SEQ ID NO: 66 or a variant thereof with at least 95% of sequence identity.
- In some embodiments, the binding protein comprises: a polypeptide (I) comprising an amino acid sequence of SEQ ID NO: 61, a polypeptide (II) comprising an amino acid sequence of SEQ ID NO: 62 and a polypeptide (III) comprising an amino acid sequence of SEQ ID NO: 63.
- In some embodiments, the binding protein comprises:
-
- polypeptide (I) consisting of an amino acid sequence of SEQ ID NO: 61;
- polypeptide (II) consisting of an amino acid sequence of SEQ ID NO: 62; and
- polypeptide (III) consisting of an amino acid sequence of SEQ ID NO: 63.
- In some embodiments, the binding protein comprises: a polypeptide (I) comprising an amino acid sequence of SEQ ID NO: 64, a polypeptide (II) comprising an amino acid sequence of SEQ ID NO: 65 and a polypeptide (III) comprising an amino acid sequence of SEQ ID NO: 66.
- In some embodiments, the binding protein comprises:
-
- polypeptide (I) consisting of an amino acid sequence of SEQ ID NO: 64;
- polypeptide (II) consisting of an amino acid sequence of SEQ ID NO: 65; and
- polypeptide (III) consisting of an amino acid sequence of SEQ ID NO: 66.
- In some variants of those embodiments, the binding protein comprises polypeptide sequences derived from immunoglobulins chains (in particular immunoglobulins of the IgG type), and/or amino acid sequences selected from any one of SEQ ID NO: 1 to SEQ ID NO: 79, which may thus include any variant sequence with conservative substitutions, and/or any variant with a degree of percent sequence identity with a reference sequence; especially a reference sequence derived from an immunoglobulin chain.
- In some embodiments, the binding protein comprises polypeptide sequences derived from immunoglobulins chains of the IgG type, in particular of the IgG1, IgG2, IgG3 or IgG4 type, preferably of the IgG1 type.
- When variants of Fc and constant regions and non-CDRs polypeptide sequences from a variable region are considered herein, they may consist of Fc and constant regions and non-CDRs polypeptide sequences having at least 80% of sequence identity with a reference polypeptide sequence; more particularly having at least 90% of sequence identity with a reference polypeptide sequence; and preferably having at least 95% of sequence identity with a reference polypeptide sequence.
- Alternatively, when variants of polypeptide sequences include CDR polypeptide sequences (e.g., CDR1, CDR2, and CDR3 from either one of a VH or VL domain), it will be understood herein that those variants do not have modifications on their CDR polypeptide sequences.
- In some embodiments, the binding protein comprises an amino acid sequence having at least 80% of sequence identity with an amino acid sequence selected from SEQ ID NO: 67 to 73.
- In some embodiments, the binding protein comprises a amino acid sequence having at least 90% of sequence identity with an amino acid sequence selected from SEQ ID NO: 67 to 73.
- In some embodiments, the binding protein comprises an amino acid sequence having at least 95% of sequence identity with an amino acid sequence selected from SEQ ID NO: 67 to 73.
- In some embodiments, the binding protein comprises a Fc region or variant thereof having at least 80% of sequence identity with an amino acid sequence selected from SEQ ID NO: 69 to 73.
- In some embodiments, the binding protein comprises a Fc region or variant thereof having at least 90% of sequence identity with an amino acid sequence selected from SEQ ID NO: 69 to 73.
- In some embodiments, the binding protein comprises a Fc region or variant thereof having at least 95% of sequence identity with an amino acid s sequence selected from SEQ ID NO: 69 to 73.
- In some embodiments, the binding protein comprises a Fc region or variant thereof with a CH2-
C H3 domain having at least 80% of sequence identity with an amino acid sequence selected from SEQ ID NO: 69 or 70; or alternatively comprises a Fc region or variant thereof with aC H2 domain having at least 80% of sequence identity with an amino acid sequence of SEQ ID NO: 71; or alternatively comprises a Fc region or variant thereof with aC H3 domain having at least 80% of sequence identity with an amino acid sequence of SEQ ID NO: 72 or 73. - In some embodiments, the binding protein comprises a Fc region or variant thereof with a CH2-
C H3 domain having at least 90% of sequence identity with an amino acid sequence selected from SEQ ID NO: 69 or 70; or alternatively comprises a Fc region or variant thereof with aC H2 domain having at least 90% of sequence identity with an amino acid sequence SEQ ID NO: 71; or alternatively comprises a Fc region or variant thereof with aC H3 domain having at least 90% of sequence identity with an amino acid sequence of SEQ ID NO: 72 or 73. - In some embodiments, the binding protein comprises a Fc region or variant thereof with a CH2-
C H3 domain having at least 95% of sequence identity with an amino acid sequence selected from SEQ ID NO: 69 or 70; or alternatively comprises a Fc region or variant thereof with aC H2 domain having at least 95% of sequence identity with an amino acid sequence of SEQ ID NO: 71; or alternatively comprises a Fc region or variant thereof with aC H3 domain having at least 95% of sequence identity with an amino acid sequence of SEQ ID NO: 72 or 73. - Preferably, the multispecific binding proteins of the present disclosure are bispecific binding proteins.
- The disclosure further relates to a pharmaceutical composition comprising a binding protein as defined above, and a pharmaceutically acceptable carrier.
- Hence, in one embodiment, the disclosure relates to a pharmaceutical composition comprising a binding protein, and a pharmaceutically acceptable carrier, said binding protein comprising:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin fragment crystallizable (Fc) region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- Hence, in one embodiment, the disclosure relates to a pharmaceutical composition comprising the binding protein defined above, and a pharmaceutically acceptable carrier, said binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor
- (i) the first ABD binds specifically to human CD123 and comprises:
- Preferably, the binding protein according to the disclosure, and pharmaceutical compositions thereof, are sterile and suitable for parenteral use.
- The disclosed binding protein, and compositions thereof, are particularly suitable for use as a medicament. Methods and uses for the preparation of such medicament are further disclosed herein.
- Hence, in one embodiment, the disclosure relates to a binding protein comprising:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin fragment crystallizable (Fc) region which binds to a human Fc-γ receptor polypeptide; for use as a medicament.
- According to some particular embodiments of this third general object, the disclosure relates to a binding protein comprising:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin fragment crystallizable (Fc) region which binds to a human Fc-γ receptor polypeptide; for use in a method for the treatment or prevention of cancer.
- According to some particular embodiments of this third general object, the disclosure relates to a binding protein comprising:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin fragment crystallizable (Fc) region which binds to a human Fc-γ receptor polypeptide; for use in a method for the treatment or prevention of blood cancer.
- According to some particular embodiments of this third general object, the disclosure relates to a binding protein comprising:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin fragment crystallizable (Fc) region which binds to a human Fc-γ receptor polypeptide; for use in a method for the treatment or prevention of a myelodysplastic syndrome (MDS) or of a lymphoproliferative disorder.
- According to some particular embodiments of this third general object, the disclosure relates to a binding protein comprising:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin fragment crystallizable (Fc) region which binds to a human Fc-γ receptor polypeptide; for use in a method for the treatment or prevention of Acute Myeloid Leukemia (AML).
- According to some particular embodiments of this third general object, the disclosure relates to a binding protein comprising:
-
- (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin fragment crystallizable (Fc) region which binds to a human Fc-γ receptor polypeptide; for use in a method for the treatment or prevention of CD64-positive and CD64-negative Acute Myeloid Leukemia (AML).
- In some embodiment, the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor; for use as a medicament.
- (i) the first ABD binds specifically to human CD123 and comprises:
- In some embodiment, the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor; for use in a method for the treatment or prevention of cancer.
- (i) the first ABD binds specifically to human CD123 and comprises:
- According to some particular embodiments of this third main object, the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor; for use in a method for the treatment or prevention of blood cancer.
- (i) the first ABD binds specifically to human CD123 and comprises:
- According to some particular embodiments of this third main object, the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor; for use in a method for the treatment or prevention of a myelodysplastic syndrome (MDS) or of a lymphoproliferative disorder.
- (i) the first ABD binds specifically to human CD123 and comprises:
- According to some particular embodiments of this third main object, the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor; for use in a method for the treatment or prevention of Acute Myeloid Leukemia (AML).
- (i) the first ABD binds specifically to human CD123 and comprises:
- According to some particular embodiments of this third main object, the disclosure relates to a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences of SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor; for use in a method for the treatment or prevention of CD64-positive and CD64-negative Acute Myeloid Leukemia (AML).
- (i) the first ABD binds specifically to human CD123 and comprises:
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament.
- The disclosure further relates to a use of the above-mentioned binding proteins as a medicament.
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of cancer.
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of cancer characterized by tumor cells that express CD123 at their surface.
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of cancer characterized by tumor cells that express CD123 and CD64 at their surface.
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of blood cancer.
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of blood cancer characterized by tumor cells that express CD123 at their surface.
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of blood cancer characterized by tumor cells that express CD123 and CD64 at their surface.
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of a myelodysplastic syndrome (MDS) or of a lymphoproliferative disorder.
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of Acute Myeloid Leukemia (AML).
- The disclosure further relates to a use of the above-mentioned binding proteins for the preparation of a medicament for the treatment or prevention of CD64-positive and CD64-negative Acute Myeloid Leukemia (AML).
- In one aspect, provided is a method for treating a cancer characterized by tumor cells that express CD123 and CD64 at their surface, the method comprising administering to and individual having such cancer a binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In one aspect, provided is method for treating a CD123-expressing tumor (e.g. a hematological malignancy, AML) in an individual who is susceptible to having tumor cells that express CD64 at their surface, the method comprising administering to the individual a binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In one aspect, provided is method for treating a hematological malignancy (e.g. AML) in an individual, the method comprising administering to the individual a binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In another aspect, provided is a method of treating a hematological malignancy (e.g., AML) in an individual, the method comprising: (a) assessing or determining whether malignant cells (e.g. AML cells) from the individual express CD64 at their surface; and (b) if the individual is determined to have malignant cells (e.g., AML cells) expressing CD64 at their surface (e.g., at a predetermined level), administering to the individual a_binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In another aspect, provided is a method for depleting malignant cells in an individual, and/or directing NK cell-mediated cytotoxicity toward CD64-expressing malignant cells (e.g., an individual having AML), the method comprising administering, to an individual having malignant cells (e.g. AML cells) expressing CD64 at their surface, a binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- In another aspect, provided is a method of causing NK cells to eliminate malignant cells that express both CD123 and CD64, the method comprising bringing the malignant cells (e.g. AML cells) into contact, in the presence of NK cells, with_a binding protein comprising: (i) a first antigen-binding domain (ABD) comprising a variable region which binds to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds to a human NKp46 polypeptide, and (iii) all or part of an Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- Assessing the expression of CD64 by malignant cells (e.g., AML cells), e.g. at their surface, can be carried out by any suitable method. Generally, a biological sample from an individual, for example from a blood sample or suitable biopsy, can be obtained and assessed and expression of CD64 in tumor cells can be determined using assays such as immunohistochemistry (IHC) assays, fluorescence activated cell sorting (FACS) assays, for example quantitative FACS, ELISA, immunoblotting (e.g., western blotting, dot blotting, or in-cell western blotting), and other immunoassays. Anti-CD64 antibodies for use in such assays are available in the art.
- Means for making the binding protein of the present disclosure in vitro are further disclosed herein. As used herein, a “binding protein of present disclosure” refers to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor. It also refers to all particular embodiments of the binding protein which are described throughout the disclosure.
- More particularly, the provided means may refer to the making of a binding protein comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein each of said ABDs comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein each VH and VL comprises three complementary determining regions (CDR-1 to CDR-3); and wherein:
-
- (i) the first ABD binds specifically to human CD123 and comprises:
- a VH1 comprising a CDR-H1, H2 and H3 corresponding to the amino acid sequences of SEQ ID NO:1 to 3 respectively or corresponding to the amino acid sequences of SEQ ID NO: 4 to 6 respectively, and
- a VL1 comprising a CDR-L1, L2 and L3 corresponding to the amino acid sequences of SEQ ID NO: 7 to 9 respectively or corresponding to the amino acid sequences of SEQ ID NO: 10 to 12 respectively;
- (ii) the second ABD binds specifically to human NKp46 and comprises:
- a VH2 comprising a CDR-H1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:13 to 15 respectively;
- the amino acid sequences of SEQ ID NO:16 to 18 respectively;
- the amino acid sequences of SEQ ID NO:19 to 21 respectively;
- the amino acid sequences of SEQ ID NO:22 to 24 respectively; or
- the amino acid sequences of SEQ ID NO:16, 25 and 26 respectively;
- and
- a VL2 comprising a CDR-L1, 2 and 3 corresponding to:
- the amino acid sequences of SEQ ID NO:27 to 29 respectively;
- the amino acid sequences of SEQ ID NO:30 to 32 respectively;
- the amino acid sequences of SEQ ID NO:33 to 35 respectively;
- the amino acid sequences of SEQ ID NO:36 to 38 respectively; or
- the amino acid sequences SEQ ID NO:39, 31 and 40 respectively;
- and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-γ receptor.
- (i) the first ABD binds specifically to human CD123 and comprises:
- Hence, in one embodiment, the disclosure relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a binding protein of the present disclosure.
- Hence, in one embodiment, the disclosure relates to an expression vector comprising a nucleic acid molecule comprising a nucleotide sequence that encodes the binding protein of the present disclosure.
- Hence, in one embodiment, the disclosure relates to an isolated cell comprising the nucleic acid molecules of the present disclosure.
- Hence, in one embodiment, the disclosure relates to an isolated cell comprising the expression vector of the present disclosure.
- According to a particular embodiment, the cell is an eukaryotic cell, in particular an insect cell or a mammalian cell. In one embodiment, the cell is a mammalian cell and the expression vector is a mammalian expression vector.
- Hence, in one embodiment, the disclosure relates to a method for making the binding protein of the present disclosure, comprising a step of making a binding protein comprising (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide.
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for expressing one or more recombinant polypeptide(s) comprising (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, and/or (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and/or (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide;
- (b) optionally recovering the expressed recombinant polypeptide(s).
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for expressing one or more recombinant polypeptide(s) comprising (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, and (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide;
- (b) optionally recovering the expressed recombinant polypeptide(s).
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for expressing a plurality of recombinant polypeptides, said plurality comprising (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, and (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide;
- (b) optionally recovering the expressed recombinant polypeptides.
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for expressing a plurality of recombinant polypeptides, said plurality comprising (i) a polypeptide comprising an amino acid sequence of SEQ ID NO: 61 or 64, and (ii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 62 or 65, and (iii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or 66;
- (b) optionally recovering the expressed recombinant polypeptides.
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for expressing a plurality of recombinant polypeptides, said plurality comprising (i) a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, and (ii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 65, and (iii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 66;
- (b) optionally recovering the expressed recombinant polypeptides.
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for co-expressing a plurality of recombinant polypeptides, said plurality comprising (i) a polypeptide comprising an amino acid sequence of SEQ ID NO: 61 or 64, and (ii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 62 or 65, and (iii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or 66;
- (b) optionally recovering the co-expressed recombinant polypeptides.
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for co-expressing a plurality of recombinant polypeptides, said plurality comprising (i) a polypeptide comprising an amino acid sequence of SEQ ID NO: 64, and (ii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 65, and (iii) a polypeptide comprising an amino acid sequence of SEQ ID NO: 66;
- (b) optionally recovering the expressed recombinant polypeptides.
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for expressing a plurality of recombinant polypeptides, said plurality comprising (i) a first polypeptide chain (I), (ii) a second polypeptide chain (II), and (iii) a third polypeptide (III), that form two antigen-binding domains (ABD), one ABD which binds specifically to a human CD123 polypeptide and the one other ABD which binds specifically to a human NKp46 polypeptide; characterized in that it the three polypeptide chains (I), (II) and (III) consist of:
-
V1A-C1A-L3-(CH2-CH3)A (I) -
V1B-C1B-L4-(CH2-CH3)B-L1-V2A-C2A-L2 (II) -
V2B-C2B (III) - wherein:
-
- V1A and V1B form a binding pair V1 (VH1/VL1);
- V2A and V2B form a binding pair V2 (VH2/VL2);
- C1A and C1B form a pair C1 (
C H1/CL) and C2A and C2B form a pair C2 (C H1/CL) whereinC H1 is an immunoglobulin heavy chainconstant domain 1 and CL is an immunoglobulin light chain constant domain; - (CH2-CH3)A and (CH2-CH3)B are identical or different, and comprise an immunoglobulin heavy chain constant domain 2 (CH2) and an immunoglobulin heavy chain constant domain 3 (CH3);
- L1, L2, L3, L4 are optional independent amino acid linkers, which may be identical or different;
- (b) optionally recovering the expressed polypeptide chains (I), (II) and (III).
- According to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for co-expressing a plurality of recombinant polypeptides, said plurality comprising (i) a first polypeptide chain (I), (ii) a second polypeptide chain (II), and (iii) a third polypeptide (III), that form two antigen-binding domains (ABD), one ABD which binds specifically to a human CD123 polypeptide and the one other ABD which binds specifically to a human NKp46 polypeptide; characterized in that it the three polypeptide chains (I), (II) and (III) consist of:
-
V1A-C1A-L3-(CH2-CH3)A (I) -
V1B-C1B-L4-(CH2-CH3)B-L1-V2A-C2A-L2 (II) -
V2B-C2B (III) - wherein:
-
- V1A and V1B form a binding pair V1 (VH1/VL1);
- V2A and V2B form a binding pair V2 (VH2/VL2);
- C1A and C1B form a pair C1 (
C H1/CL) and C2A and C2B form a pair C2 (C H1/CL) whereinC H1 is an immunoglobulin heavy chainconstant domain 1 and CL is an immunoglobulin light chain constant domain; - (CH2-CH3)A and (CH2-CH3)B are identical or different, and comprise an immunoglobulin heavy chain constant domain 2 (CH2) and an immunoglobulin heavy chain constant domain 3 (CH3);
- L1, L2, L3, L4 are optional independent amino acid linkers, which may be identical or different;
- (b) optionally recovering the co-expressed polypeptide chains (I), (II) and (III).
- Hence, according to some particular embodiment, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for expressing a plurality of recombinant polypeptides, said plurality comprising (i) a first polypeptide chain (I) comprising an amino acid sequence of SEQ ID NO: 61 or 64, (ii) a second polypeptide chain (II) comprising an amino acid sequence of SEQ ID NO: 62 or 65, and (iii) a third polypeptide (III) comprising an amino acid sequence of SEQ ID NO: 63 or 66;
- (b) optionally recovering the expressed polypeptide chains (I), (II) and (III).
- Hence, according to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) culturing host cell(s) under conditions suitable for co-expressing a plurality of recombinant polypeptides, said plurality comprising (i) a first polypeptide chain (I) comprising an amino acid sequence of SEQ ID NO: 61 or 64, (ii) a second polypeptide chain (II) comprising an amino acid sequence of SEQ ID NO: 62 or 65, and (iii) a third polypeptide (III) comprising an amino acid sequence of SEQ ID NO: 63 or 66;
- (b) optionally recovering the co-expressed polypeptide chains (I), (II) and (III).
- Methods for making the binding protein of the disclosure, such as those defined above, may further include a prior step of providing host cell(s) with a nucleic acid, in particular an isolated nucleic acid (i.e., a recombinant nucleic acid), encoding all or part(s) of the said binding protein. In particular, such step may comprise or consist of transfecting said host cell(s) with a nucleic acid, in particular an isolated nucleic acid, encoding all or part(s) of the said binding protein.
- Hence, according to some particular embodiments, the disclosure relates to a method for making the binding protein, comprising a step of:
-
- (a) providing host cell(s) with a nucleic acid encoding all or part(s) of the said binding protein;
- (b) culturing said host cell(s) under conditions suitable for expressing one or more recombinant polypeptide(s) comprising (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, and/or (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, and/or (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide;
- (c) optionally recovering the expressed recombinant polypeptide(s).
- In one embodiment, the method for making the binding protein of the present disclosure comprises a step of
-
- (a) providing one or more nucleic acid(s) encoding a first polypeptide chain (I), a second polypeptide chain (II), and a third polypeptide chain (III);
- (b) transfecting host cell(s) with the one or more nucleic acid(s);
- (c) culturing the host cell(s) under conditions suitable to express (or co-express) the said polypeptide chain(s); and
- (d) optionally recovering the expressed (or co-expressed) polypeptide chain(s) (I), (II) and (III).
- In one embodiment, the method for making the binding protein of the present disclosure comprises a step of
-
- (a) providing one or more nucleic acid(s) encoding a first polypeptide chain (I) comprising an amino acid sequence of SEQ ID NO: 61 or 64, a second polypeptide chain (II) comprising an amino acid sequence of SEQ ID NO: 62 or 65, and a third polypeptide chain (III) comprising an amino acid sequence of SEQ ID NO: 63 or 66;
- (b) transfecting host cell(s) with the one or more nucleic acid(s);
- (c) culturing the host cell(s) under conditions suitable to express (or co-express) the said polypeptide chain(s); and
- (d) optionally recovering the expressed (or co-expressed) polypeptide chain(s) (I), (II) and (III).
- In some particular embodiments, a method of making the binding protein of the present disclosure comprises:
-
- (a) providing a first nucleic acid encoding a first polypeptide chain according to any of amino acid sequences of SEQ ID NO: 61 or 64, a second nucleic acid encoding a second polypeptide according to any of amino acid sequences of SEQ ID NO: 62 or 65, and a third nucleic acid encoding a third polypeptide chain according to any of amino acid sequences of SEQ ID NO: 63 or 66; and
- (b) expressing said first, second and third nucleic acids in the one or more host cell(s) to produce a binding protein comprising said first, second and third polypeptide chains, respectively;
- (c) optionally loading the protein produced onto an affinity purification support, optionally a Protein-A support, and recovering the binding protein.
- It will thus be readily understood by the skilled in the Art that such method of making the binding protein of the disclosure may encompass the production and assembly of some or all of the above-mentioned polypeptides, polypeptide chains and/or regions (e.g. variable regions and Fc region or variants thereof) within one or more host cell(s), as part of an in vitro method of production.
- Alternatively, the method may encompass the production of some or all of the above-mentioned polypeptides, polypeptide chains and/or regions within one or more host cell(s), and their assembly outside of the host cell(s). The step of bringing into contact said polypeptides, polypeptide chains and/or regions can thus be achieved simultaneously or sequentially.
- According to some embodiments, one or more of said regions may be present in distinct polypeptide chain(s) or fragments thereof.
- As a reference, the “F25” format of binding proteins which is described herein in the examples section possesses four predicted interchain disulfide bridges:
-
- one disulfide bridge connecting a cysteine within the CL domain of polypeptide (I) to the first cysteine within the Hinge region of polypeptide chain (II);
- two disulfide bridges connecting two cysteines within the Hinge regions of polypeptide chain (I) and (II);
- one disulfide bridge connecting a C-terminal cysteine at the CL domain of polypeptide chain (III) to a C-terminal cysteine on polypeptide chain (II).
- In some embodiment, the disclosure relates to a method for making the binding protein of the present disclosure, comprising a step of bringing into contact (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, said variable region comprising at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 1 to 12, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, said variable region comprising at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 13 to 40 and (iii) all or part of a Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide, especially which binds to a human CD16a Fc-γ receptor polypeptide.
- In some embodiment, the disclosure relates to a method for making the binding protein of the present disclosure, comprising a step of bringing into contact (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, said variable region comprising at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 1 to 6 and at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 7 to 12, (ii) a second antigen-binding domain (ABD) comprising a variable region suitable which binds specifically to a human NKp46 polypeptide, said variable region comprising at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 13 to 26 and at least one complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 27 to 40, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide, especially which binds to a human CD16a Fc-γ receptor polypeptide.
- In some embodiments, the disclosure relates to a method for making the binding protein of the present disclosure, comprising a step of bringing into contact (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, said variable region comprising at least two complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 1 to 6 and at least two complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 7 to 12, (ii) a second antigen-binding domain (ABD) comprising a variable region which binds specifically to a human NKp46 polypeptide, said variable region comprising at least two complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 13 to 26 and at least two complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 27 to 40, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide, especially which binds to a human CD16 Fc-γ receptor polypeptide.
- In some embodiments, the disclosure relates to a method for making the binding protein related to the present disclosure, comprising a step of bringing into contact (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, said variable region comprising three complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 1 to 6 and three complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 7 to 12, (ii) a second antigen-binding domain (ABD) comprising variable region which binds specifically to a human NKp46 polypeptide, said variable region comprising three complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 13 to 26 and three complementary determining region (CDR) selected from the group of amino acid sequences consisting of SEQ ID NO: 27 to 40, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide, especially which binds to a human CD16 Fc-γ receptor polypeptide.
- In some embodiments, the disclosure relates to a method for making the binding protein related to the present disclosure, comprising a step of bringing into contact (i) a first antigen-binding domain (ABD) comprising a variable region which binds specifically to a human CD123 polypeptide, (ii) a second antigen-binding domain (ABD) comprising a variable region suitable which binds specifically to a human NKp46 polypeptide, and (iii) all or part of an immunoglobulin Fc region or variant thereof which binds to a human Fc-γ receptor polypeptide, especially which binds to a human CD16 Fc-γ receptor polypeptide; characterized in that the step of bringing into contact said regions comprises bringing into contact a plurality of polypeptide chains selected from of amino acid sequences SEQ ID NO: 61 to 66.
- All or parts of the above-mentioned antigen-binding domain(s) and immunoglobulin Fc region or variant thereof may be expressed in vitro, through recombinant means, in an isolated cell or population of cells, in particular in a eukaryotic cell, and preferably in a mammalian or insect cell. Most preferably, the expression system relates to a mammalian cell.
- According to alternative embodiments, parts of the above-mentioned antigen-binding domain(s) and Fc region or variant thereof may be expressed in a first population of isolated cells, whereas other parts of the above-mentioned antigen-binding domain(s) and Fc region or variant thereof may be expressed in a second population of isolated cells.
- According to alternative embodiments, all the parts of the above-mentioned antigen-binding domain(s) and immunoglobulin Fc region or variant thereof may be expressed in a same population of isolated cells, and then recovered, thereby brought into contact during or at the end of the recovery step.
- Hence, the method for making the binding protein may comprise the steps of:
-
- (a) expressing at least one of said first antigen-binding domain and/or said second antigen-binding domain and/or said all or part of immunoglobulin Fc region or variant thereof in an isolated cell or population of cells, most preferably in a mammalian cell;
- (b) recovering said first antigen-binding domain and/or said second antigen-binding domain and/or said all or part of Fc region or variant thereof.
- According to one of said preferred embodiment, the disclosure relates to a method for making the binding protein related to the present disclosure, which comprises the steps of:
-
- (a) expressing at least one of said first antigen-binding domain and/or said second antigen-binding domain and/or said all or part of Fc region or variant thereof in an isolated cell or population of cells, most preferably in a mammalian cell;
- (b) recovering said first antigen-binding domain and/or said second antigen-binding domain and/or said all or part of Fc region or variant thereof;
- (c) bringing into contact the said first antigen-binding domain and/or said second antigen-binding domain and/or said all or part of Fc region or variant thereof, steps (b) and (c) being achieved simultaneously or sequentially.
- Preferably, the method for making the binding protein comprises the steps of:
-
- (a) expressing said first antigen-binding domain and said second antigen-binding domain and said all or part of immunoglobulin Fc region or variant thereof in an isolated cell;
- (b) recovering said first antigen-binding domain and said second antigen-binding domain and said all or part of immunoglobulin Fc region or variant thereof;
- (c) bringing into contact the said first antigen-binding domain and said second antigen-binding domain and said all or part of immunoglobulin Fc region or variant thereof, steps (b) and (c) being achieved simultaneously or sequentially.
- Advantageously, when the said first antigen-binding domain and said second antigen-binding domain and said all or part of immunoglobulin Fc region or variant thereof are expressed in the same isolated cell or population of cells and/or the same cell culture thereof, they may be brought into contact during the recovery step, thereby making the binding protein.
- Alternatively, when the said first antigen-binding domain and/or said second antigen-binding domain and/or said all or part of immunoglobulin Fc region or variant thereof are expressed in different isolated cells or population of cells, they may be brought into contact after the recovery step.
- The recovery step may consist of any method known in the Art. In a non-exhaustive manner, the recovery of the expressed polypeptides bearing all or part of the antigen-binding domain(s) and Fc region or variant thereof (e.g. the expressed one or more polypeptide chain(s)) may comprise the following steps:
-
- (b1) recovering the isolated cell or cell culture thereof,
- (b2) optionally centrifugating, depth filtering, membrane filtering, ultrafiltering and/or diafiltering the isolated cell or cell culture thereof.
- In the protein sequences notation used herein, the left-hand direction is the amino terminal direction (the “N terminus” or “N-term”) and the right-hand direction is the carboxyl-terminal direction (the “C terminus” or “C-term”), in accordance with standard usage and convention.
-
SEQ ID NO: Name Sequence 1 VH1 CDR-H1 GYSFTDYYMK Anti-CD123 CD123-1 2 VH1 CDR-H2 DIIPSSGATF Anti-CD123 CD123-1 3 V H1 CDR-H3 SHLLRASWFAY Anti-CD123 CD123-1 4 Anti-CD123 GFTFSHYN CD123-2 5 V H1 CDR-H2 ITYDDHST Anti-CD123 CD123-2 6 V H1 CDR-H3 ARLVNYAFAY Anti-CD123 CD123-2 7 VL1 CDR-L1 ESSQSLLSSGNQKNYLT Anti-CD123 CD123-1 8 V L1 CDR-L2 WASTRES Anti-CD123 CD123-1 9 V L1 CDR-L3 QNDYSYPYT Anti-CD123 CD123-1 10 V L1 CDR-L1 QTVGNN Anti-CD123 CD123-2 11 V L1 CDR-L2 YAS Anti-CD123 CD123-2 12 V L1 CDR-L3 QRMYNSPT Anti-CD123 CD123-2 13 VH2 CDR-H1 DYVIN Anti-NKp46 NKp46-1 14 VH2 CDR-H2 EIYPGSGTNYYNEKFKA Anti-NKp46 3D9 and NKp46-1 15 VH2 CDR-H3 RGRYGLYAMDY Anti-NKp46 3D9 and NKp46-1 16 VH2 CDR-H1 SDYAWN Anti-NKp46 NKp46-2 13G4 17 VH2 CDR-H2 YITYSGSTSYNPSLES Anti-NKp46 NKp46-2 18 VH2 CDR-H3 GGYYGSSWGVFAY Anti-NKp46 NKp46-2 19 VH2 CDR-H1 EYTMH Anti-NKp46 NKp46-3 20 VH2 CDR-H2 GISPNIGGTSYNQKFKG Anti-NKp46 NKp46-3 21 VH2 CDR-H3 RGGSFDY Anti-NKp46 NKp46-3 22 VH2 CDR-H1 SFTMH Anti-NKp46 NKp46-4 23 VH2 CDR-H2 YINPSSGYTEYNQKFKD Anti-NKp46 NKp46-4 24 VH2 CDR-H3 GSSRGFDY Anti-NKp46 NKp46-4 25 VH2 CDR-H2 YITYSGSTNYNPSLKS Anti-NKp46 13G4 26 VH2 CDR-H3 CWDYALYAMDC Anti-NKp46 13G4 27 VL2 CDR-H1 RASQDISNYLN Anti-NKp46 3D9 and NKp46-1 28 VL2 CDR-H2 YTSRLHS Anti-NKp46 3D9 and NKp46-1 29 VL2 CDR-H3 QQGNTRPWT Anti-NKp46 3D9 and NKp46-1 30 VL2 CDR-H1 RVSENIYSYLA Anti-NKp46 NKp46-2 31 VL2 CDR-H2 NAKTLAE Anti-NKp46 NKp46-2 13G4 32 VL2 CDR-H3 QHHYGTPWT Anti-NKp46 NKp46-2 33 VL2 CDR-H1 RASQSISDYLH Anti-NKp46 NKp46-3 34 VL2 CDR-H2 YASQSIS Anti-NKp46 NKp46-3 35 VL2 CDR-H3 QNGHSFPLT Anti-NKp46 NKp46-3 36 VL2 CDR-H1 RASENIYSNLA Anti-NKp46 NKp46-4 37 VL2 CDR-H2 AATNLAD Anti-NKp46 NKp46-4 38 VL2 CDR-H3 QHFWGTPRT Anti-NKp46 NKp46-4 39 VL2 CDR-H2 RTSENIYSYLA Anti-NKp46 13G4 40 VL2 CDR-H3 QHHYDTPLT Anti-NKp46 13G4 41 VH-full length-anti- EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKG CD123 LEWMGDIIPSSGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDT AMYYCARSHLLRASWFAYWGQGTMVTVSS 42 VH-full length-anti- EVqLVESGGGLVQPGRSLKLSCAASGFTFSHYNMAWVRQAPK CD123 KGLEWVATITYDDHSTYYRDSVKGRFTISRDTAKSTLYLQMDS LRSEDTATYYCARLVNYAFAYWGQGTLVTVSS 43 VL-full length-anti- DIVMTQSPDSLAVSLGERATINCESSQSLLSSGNQKNYLTWYQQKP CD123 GQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY CONDYSYPYTFGQGTKLEIK 44 VL-full length-anti- NIVMTQSPKSMSISVGDRVTMNCKASQTVGNNIAWYQQKPGLSPQ CD123 LLIDYASNRYTGVPNRFTGGGYGTDFILTINSVQAEDAAFYYCQR MYNSPTFGGGTKLELK 45 VH-full length-anti- QVQLVQSGAEVKKPGSSVKVSCKASGYTFSDYVINWVRQAPGQG NKp46 LEWMGEIYPGSGTNYYNEKFKAKATITADKSTSTAYMELSSLRSED TAVYYCARRGRYGLYAMDYWGQGTTVTVSS 46 VH-full length-anti- QVQLQQSGPELVKPGASVKMSCKASGYTFTDYVINWGKQRSGQG NKp46 LEWIGEIYPGSGTNYYNEKFKAKATLTADKSSNIAYMQLSSLTSED NKp46-1 SAVYFCARRGRYGLYAMDYWGQGTSVTVSS 47 VH-full length-anti- EVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKL NKp46 EWMGYITYSGSTSYNPSLESRISITRDTSTNQFFLQLNSVTTEDTAT NKp46-2 YYCARGGYYGSSWGVFAYWGQGTLVTVSA 48 VH-full length-anti- EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSL NKp46 EWIGGISPNIGGTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDS NKp46-3 AVYYCARRGGSFDYWGQGTTLTVSS 49 VH-full length-anti- QVQLQQSAVELARPGASVKMSCKASGYTFTSFTMHWVKQRPGQG NKp46 LEWIGYINPSSGYTEYNQKFKDKTTLTADKSSSTAYMQLDSLTSDD NKp46-4 SAVYYCVRGSSRGFDYWGQGTLVTVSA 50 VH-full length-anti- QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDYAWNWIRQPPGKGL NKp46 EWIGYITYSGSTSYNPSLESRVTISRDTSKNQFSLKLSSVTAADTAV 10B8 YYCARGGYYGSSWGVFAYWGQGTLVTVSS 51 VH-full length-anti- QVQLVQSGAEVKKPGASVKVSCKASGYTFTSFTMHWVRQAPGQG NKp46 LEWIGYINPSSGYTEYNQKFKDRVTITADKSTSTAYMELSSLRSED 12E12 TAVYYCVRGSSRGFDYWGQGTLVTVSS 52 VH-full length-anti- QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDYAWNWIRQPPGKGL NKp46 EWIGYITYSGSTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAV 13G4 YYCARCWDYALYAMDCWGQGTTVTVSS 53 VL-full length-anti- DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKL NKp46 LIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQGNTRP 3D9 WTFGGGTKVEIK 54 VL-full length-anti- DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKL NKp46 LIYYTSRLHSGVPSRFSGSGSGTDYSLTINNLEQEDIATYFCQQGNT NKp46-1 RPWTFGGGTKLEIK 55 VL-full length-anti- DIQMTQSPASLSASVGETVTITCRVSENIYSYLAWYQQKQGKSPQL NKp46 LVYNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHY NKp46-2 GTPWTFGGGTKLEIK 56 VL-full length-anti- DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRL NKp46 LIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSF NKp46-3 PLTFGAGTKLELK 57 VL.full length-anti- DIQMIQSPASLSVSVGETVTITCRASENIYSNLAWFQQKQGKSPQLL NKp46 VYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGIYYCQHFWG NKp46-4 TPRTFGGGTKLEIK 58 VL-full length-anti- DIQMTQSPSSLSASVGDRVTITCRVSENIYSYLAWYQQKPGKAPKL NKp46 LVYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHY 10B8 GTPWTFGGGTKVEIK 59 VL-full length-anti- DIQMTQSPSSLSASVGDRVTITCRASENIYSNLAWFQQKPGKAPKL NKp46 LVYAATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFW 12E12 GTPRTFGGGTKVEIK 60 VL-full length-anti- DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWCQQKPGKAPKL NKp46 LIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLqPEDFATYYCQHHYD 13G4 TPLTFGQGTKLEIK 61 Polypeptide chain MSVPTQVLGLLLLWLTDARCDIVMTQSPDSLAVSLGERATINCESS (I) QSLLSSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGS GSGTDFTLTISSLQAEDVAVYYCONDYSYPYTFGQGTKLEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL SSPVTKSFNRGECDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK 62 Polypeptide chain MEWSWVFLFFLSVTTGVHSEVQLVQSGAEVKKPGESLKISCKGSG (II) YSFTDYYMKWARQMPGKGLEWMGDIIPSSGATFYNQKFKGQVTI SADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGT MVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGSTGSQVQLVQSGAEVKKPGSSVKVSCK ASGYTFSDYVINWVRQAPGQGLEWMGEIYPGSGTNYYNEKFKAK ATITADKSTSTAYMELSSLRSEDTAVYYCARRGRYGLYAMDYWG QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDKRVEPKSCDKTHS 63 Polypeptide chain MSVPTQVLGLLLLWLTDARCDIQMTQSPSSLSASVGDRVTITCRAS (III) QDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFT FTISSLQPEDIATYFCQQGNTRPWTFGGGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC 64 F25 polypeptide DIVMTQSPDSLAVSLGERATINCESSQSLLSSGNQKNYLTWYQQKP chain (I) GQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVY Cleaved (without YCONDYSYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV leader peptide) VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 65 F25 polypeptide EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKG chain (II) LEWMGDIIPSSGATFYNQKFKGQVTISADKSISTTYLQWSSLKASD Cleaved (without TAMYYCARSHLLRASWFAYWGQGTMVTVSSASTKGPSVFPLAPS leader peptide) SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGSTG SQVQLVQSGAEVKKPGSSVKVSCKASGYTFSDYVINWVRQAPGQ GLEWMGEIYPGSGTNYYNEKFKAKATITADKSTSTAYMELSSLRS EDTAVYYCARRGRYGLYAMDYWGQGTTVTVSSASTKGPSVFPLA PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC DKTHS 66 F25 polypeptide DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKL chain (III) LIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQGNTR Cleaved (without PWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY leader peptide) PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 67 Cκ RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGEC 68 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK VDKRV 69 (CH2-CH3)A APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 70 (CH2-CH3)B APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 71 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAK 72 CH3 of (CH2-CH3)A GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK 73 C-term truncated GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG CH3 of (CH2-CH3)B QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG 74 Hinge1 DKTHTCPPCP 75 Hinge2 EPKSCDKTHTCPPCP 76 Linker1 STGS 77 Hinge3 EPKSCDKTHS 78 HingeALT1 EPKSCDKTH 79 HingeALT2 EPKSCDKTHT 80 Single guide RNA CUUGAGGUGUCAUGCGUGGA 81 Single guide RNA AAGCAUCGCUACACAUCAGC 82 DNA primer 1 TACGACTCACAAGCTTGCCGCCACCATGTCTTCCACACTCCCTG C 83 DNA primer 2 CCGCCCCGACTCTAGATCAATGGTGATGGTGGTGATGATTCTGG GCAGTGTGATCCC 84 Human NKp46 MSSTLPALLCVGLCLSQRISAQQQTLPKPFIWAEPHFMVPKEKQVT extracellular ICCQGNYGAVEYQLHFEGSLFAVDRPKPPERINKVKFYIPDMNSRM domain (ECD) AGQYSCIYRVGELWSEPSNLLDLVVTEMYDTPTLSVHPGPEVISGE KVTFYCRLDTATSMFLLLKEGRSSHVQRGYGKVQAEFPLGPVTTA HRGTYRCFGSYNNHAWSFPSEPVKLLVTGDIENTSLAPEDPTFPAD TWGTYLLTTETGLQKDHALWDHTAQN 85 Cynomolgus MSSTLRALLCLGLCLSQRISAPKQTLPKPIIRAESTYMVPKEKQATL NKp46-FlagM2 CCQGSYGAVEYQLHFEGSLFAVERPKPPERINGVKFHIPDMNSRKA extracellular GRYSCIYRVGELWSERSDLLDLVVTEMYDTPTLSVHPGPEVTSGE domain (ECD) KVTFYCRLDTATSMFLLLKEGRSRDVQRSYGKVQAEFPMGPVTTA HRGSYRCFGSYNNYAWSFPSEPVKLLVTGDIENTSLAPTDPTFPDS WDTCLLTRETGLQKDLALWDHTAQNDYKDDDDK 86 Human CD123 TKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSMPA extracellular VNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAE domain (ECD) NLTCWIHDVDFLSCSWAVGPGAPADVQYDLYLNVANRRQQYECL HYKTDAQGTRIGCRFDDISRLSSGSQSSHILVRGRSAAFGIPCTDKF VVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYELQIQK RMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQR FECDQEEGANTRAWR 87 Human Fc-gamma- MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVT receptor 3A LKCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQ (CD16A). TNLSTLSDPVQLEVHIGWLLLQAPRWVFKEEDPIHLRCHSWKNTA LHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLVGSKN VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFS VKTNIRSSTRDWKDHKFKWRKDPQDK 88 Human Fc-gamma- MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVT receptor 3A LKCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQ (CD16A) (V176F TNLSTLSDPVQLEVHIGWLLLQAPRWVFKEEDPIHLRCHSWKNTA polymorphic LHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN variant) VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFS VKTNIRSSTRDWKDHKFKWRKDPQDK 89 DNA primer 3 TACGACTCACAAGCTTGCCGCCACCATGTCTTCCACACTCCGTG C 90 DNA primer 4 CCGCCCCGACTCTAGATCACTTGTCATCGTCATCTTTGTAATCAT TCTGGGCAGTGTGGTCC 91 NKp46-IC_F25 EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRL Fragment 1 LFSDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYRY SPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 92 NKp46-IC_F25 EVQLVESGGGLVQPGRSLRLSCAASGFTFDNYAMHWVRQAPGKG Fragment 2 LEWVSGISRSSGDIDYADSVKGRFTISRDNAKNSLYLQMNSLRAED TALYYCARGGVGSFDTWGQGTMVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGSTGSQV QLVQSGAEVKKPGSSVKVSCKASGYTFSDYVINWVRQAPGQGLE WMGEIYPGSGTNYYNEKFKAKATITADKSTSTAYMELSSLRSEDT AVYYCARRGRYGLYAMDYWGQGTTVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT HS 93 NKp46-IC_F25 DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKL Fragment 3 LIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQGNTR PWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 94 moNKp46- DIVMTQSPDSLAVSLGERATINCESSQSLLSSGNQKNYLTWYQQKP huCD123_F25 GQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVY Fragment 1 YCQNDYSYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 95 moNKp46- EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKG huCD123_F25 LEWMGDIIPSSGATFYNQKFKGQVTISADKSISTTYLQWSSLKASD Fragment 2 TAMYYCARSHLLRASWFAYWGQGTMVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGSTG SEVQLVESGGGLVKPGGSLKLSCAASGFTFSDYGMHWVRQAPEK GLEWVAYISSGSSTIYYADTVKGRFTISRDNAKNTLFLQMTSLRSE DTAMYYCARGTTIFNYFEYWGQGTSVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH S 96 moNKp46- DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQK huCD123_F25 PGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVY Fragment 3 YCQQYYEIPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVV CLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 97 NKp46-CD123_F5 DIVMTQSPDSLAVSLGERATINCESSQSLLSSGNQKNYLTWYQQKP Fragment 1 GQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVY YCQNDYSYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 98 NKp46-CD123_F5 EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKG Fragment 2 LEWMGDIIPSSGATFYNQKFKGQVTISADKSISTTYLQWSSLKASD TAMYYCARSHLLRASWFAYWGQGTMVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGSTG SQVQLVQSGAEVKKPGSSVKVSCKASGYTFSDYVINWVRQAPGQ GLEWMGEIYPGSGTNYYNEKFKAKATITADKSTSTAYMELSSLRS EDTAVYYCARRGRYGLYAMDYWGQGTTVTVSSRTVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC 99 NKp46-CD123_F5 DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKL Fragment 3 LIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQGNTR PWTFGGGTKVEIKASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKRVEPKSCDKTHS 100 IC-CD123_F5 DIVMTQSPDSLAVSLGERATINCESSQSLLSSGNQKNYLTWYQQKP Fragment 1 GQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVY YCONDYSYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 101 IC-CD123_F5 EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKG Fragment 2 LEWMGDIIPSSGATFYNQKFKGQVTISADKSISTTYLQWSSLKASD TAMYYCARSHLLRASWFAYWGQGTMVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGSTG SEVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKG LEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASD TAMYYCARRRNWGNAFDIWGQGTMVTVSSRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE C 102 IC-CD123_F5 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPR Fragment 3 LLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYG SSTWTFGQGTKVEIKASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKRVEPKSCDKTHS 103 IC-hIGg1-ADCC- EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRL enh LFSDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYRY Light Chain SPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 104 IC-hIGg1-ADCC- EVQLVESGGGLVQPGRSLRLSCAASGFTFDNYAMHWVRQAPGKG enh LEWVSGISRSSGDIDYADSVKGRFTISRDNAKNSLYLQMNSLRAED Heavy Chain TALYYCARGGVGSFDTWGQGTMVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTC PPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK - The sequences encoding each polypeptide chain of NKp46-CD123_F25 binding proteins of the present disclosure were inserted into the pTT-5 vector between the HindIII and BamHI restriction sites. The three vectors (made as endotoxin-free midipreps) were used to cotransfect EXPI-293F cells (Life Technologies) in the presence of PEI (37° C., 5% CO2, 150 rpm). The cells were used to seed culture flasks at a density of 1×106 cells per ml (EXP1293 medium, Gibco). As a reference, for the NKp46-CD123_F25 binding protein, we used a DNA ratio of 0.1 μg/ml (polypeptide chain I), 0.4 μg/ml (polypeptide chain II), or 0.8 μg/ml (polypeptide chain III). Valproic Acid (final concentration 0.5 mM), glucose (4 g/L) and tryptone N1 (0.5%) were added. The supernatant was harvested after six days after and passed through a Stericup filter with 0.22 μm pores.
- The NKp46-CD123_F25 binding proteins of the present disclosure were purified from the supernatant following harvesting using rProtein A Sepharose Fast Flow (GE Healthcare, reference 17-1279-03). A Cation Ion Exchange Chromatography (CIEX) purification was then performed after dialysis of the sample in a Na2HPO4/KH2PO4 50 mM pH 6.2 phosphate buffer. Prior to injection to the two «in series» column HiTrap SP-
HP 1 mL from GE Healthcare (ref 17-1151-01), the sample was filtered on a 0.22 μm device. The starting and the elution buffers were respectively Na2HPO4/KH2PO4 50 mM pH 6.2 and Na2HPO4/KH2PO4 25 mM pH 6.2; 1M NaCl. The elution was performed using a linear gradient from 0% to 50% (elution buffer) on 100 CV. The peak of interest is finally dialyzed against PBS1X, overnight at 4° C. under agitation. - Healthy Human buffy coats were provided by the Etablissement Frangais du Sang (EFS, Marseille; AC-2019-3428). Peripheral mononuclear cells (PBMC) were isolated from buffy coats by using Ficoll density gradient centrifugation. Human NK cells were purified from PBMC by using beads-based negative selection kit from StemCell or Miltenyi.
- Acute myeloid leukemia (AML) samples from patients were provided by Institut Paoli-Calmettes (Marseille, SA-IPH-MImAbs Contract).
- CD123 expressing Acute myeloid leukemia (AML) cell line: MOLM-13 and THP-1 were purchased at ATCC. Cells were cultured in complete RPMI medium (RPMI-1640 containing 10% FBS, 2 mM L-Glutamine, 1 mM Sodium pyruvate and non-essential amino-
acids 1×). 25 mM HEPES were added in the culture medium for THP-1 cells. - THP-1 CD64KO and THP-1 CD32KO cells were generated with CRISPR/Cas endonucleases. THP-1 cells were cultured in RPMI-1640, 10% SVF, 2 mM L-Glu, 1 mM sodium pyruvate, 0.1 mM non-essential amino acid. To generate CD64 deficient THP-1 cells, 2,5.106 cells were nucleofected (Neon Transfection System, 100 ul tip, 1700V, 20 ms, 1 pulse) with two sgRNAs (CD64.1: CUUGAGGUGUCAUGCGUGGA (SEQ ID NO: 80); CD64.2: AAGCAUCGCUACACAUCAGC (SEQ ID NO: 81; Synthego) at a CAS9:sgRNA ratio of 1:9 (Alt-R™ S.p. Cas9 Nuclease 3NLS, Integrated DNA Technology). Lack of CD64 expression was monitored by flow cytometry and cells were either sorted or sub-cloned.
- To generate CD32-knockout (KO) THP-1 cells, 2.5·106 cells were nucleofected (Neon Transfection System, 100 μL tip, 1700 V, 20 ms, 1 pulse) with a couple of sgRNAs (CD32A: AUGUAUGUCCCAGAAACCUG (SEQ ID NO: 105); CD32B: AAGCAUAUGACCCCAAGGCU (SEQ ID NO: 106) (Integrated DNA Technologies)) at a CAS9:sgRNA ratio of 1:9 (Alt-R™ S.p. Cas9 Nuclease 3NLS, Integrated DNA Technology). The THP-1 CD32KO cells were cell sorted only. Following cell sorting, absence of CD32 expression was monitored by flow cytometry.
- Target cells were loaded with 51Cr (for MOLM-13, THP-1 or THP-1 CD64KO, THP-1 CD32KO cells) or with CalceinAM (Life technologies, ref: C3100MP or equivalent) for AML blasts from patient samples. Tested antibodies, labelled target cells and fresh or overnight-rested human NK cells from healthy donors were successively added in each well of round bottom 96-well plates to obtain a 10:1 (E:T) ratio. After 4 h of co-incubation, the supernatant was transferred into a Lumaplate (for 51Cr) or into a flat bottom culture plate (for CalceinAM).
- For 51Cr-based cytotoxic assay, the 51Cr released from dead target cells was dosed using a TopCount NXT™ (Microplate Scintillation and Luminescence Counter; Perkin Elmer). Radioactivity was measured by counting γ-emission during 60 s for each well and these results was expressed in cpm=count per minute.
- For Calcein-based cytotoxic assay, the CalceinAM released from dead target cells was dosed by measuring relative fluorescence units (RFU) with a Luminoter (EnSpire® Multimode Plate Reader (Perkinelmer): fluorescence emission at λ=516 nm after an excitation at λ=495 nm).
- For the analysis, the percent specific lysis was calculated using the following formula:
-
- with ER=experimental release, SR=spontaneous release and MR=maximal release
EC50 of each antibody are determined with drawing appropriate non-linear regression curve (choice of “log(agonist) vs. response—Variable slope (four parameters)” model) by using Graphpad Prism Software. - The expression of CD32, CD64 and CD123 on AML samples derived from patient blood and on AML cell lines was controlled by flow cytometry using Anti-human CD33-BB515 (BD Biosciences 564588 Clone WM53), Anti-human CD45-Viogreen (Miltenyi 130-096-906 Clone 5B1), Anti-human CD123-AF647 (BD Biosciences 563599 Clone 9F5), Anti-human CD32-PE (Beckman Coulter IM1935 Clone 2E1), Anti-human CD64-PE (Beckman Coulter IM3601U Clone 22), Anti-human CD123-PE (Biolegend 306006 Clone 6H6), and cognate isotype control antibodies mIgG1-PE (IC-1; BD Biosciences 555749 Clone MOPC-21), and mIgG2a-PE (IC-2a; Beckman Coulter A09142 Clone 7T4-1F5). Target cells were saturated with normal mouse serum diluted at 1/10e in staining buffer (SB) and then mix with antibodies coupled to dyes. Cells were fixed in BD Cellfix diluted at 1/10e in H2O during 30 min after staining and analyzed by flow cytometry with a FACS Canto II. FSC-A, FSC-H, SSC-A, SSC-H, FL2-A, FL4-A and FL7-A or FSC-A, FSC-H, SSC-A, SSC-H, FL1-A, FL2-A, FL3-A, FL5-A and FL8-A (for AML samples derived from patient blood) parameters were recorded and the analyses were done with FlowJo software. The phenotyping results are shown in
FIG. 6A ,FIG. 6B , andFIG. 14B . - A.6. NK Cell Degranulation Assay with AML Samples
- In order to test NK cell activation as in
FIG. 7 , tested antibodies, AML blast and autologous NK cells derived from AML patients were successively added in each well of round bottom 96-well plates. After overnight co-incubation with the NKp46-CD123_F25 binding proteins of the present disclosure, anti-human CD107a and CD107b antibodies were added in each well for 4 hours. Cells were then washed and stained with the following mix: markers of viability, APC-coupled anti-human CD45, BB515-coupled anti-human CD33, PeCy7-coupled anti-human CD56, BV510-coupled anti-human CD3 antibodies. Cells were then washed, fixed and analyzed by flow cytometry. Obtained data were analyzed by using Flowjo Software to analyze NK cell degranulation through the expression of CD107 on NK cells identified as alive CD45+CD33−CD56+CD3− cells. - In order to test NK cell activation and cytokine/chemokine production towards MOLM-13 cells viaNKp46-CD123_F25 binding proteins as in
FIG. 17 , flow cytometric analysis was performed using the following antibody markers: CD69, CD107a/b, IFNα, TNFα, MIP1β. - First, purified primary human NK cells from three separate donors were co-incubated with or without MOLM-13 cells at a 1:1 ratio (seeded at 50,000 cells/well; U bottom 96-well plate) for 4 h at 37° C., in the presence of increasing concentrations of NKp46-CD123_F25 or controls (NKp46-IC_F25 and no antibody). Concomitantly, BD GolgiSTOP™ was added to both experimental and control samples at a final dilution of 1/6000 in each well. A positive control of NK cell activation was performed by using 125 ng/mL final of PMA and 1 μg/mL final of IONO added on 50,000 resting NK cells by well (data not shown).
- After the 4 hr incubation, cells were washed in staining buffer (PBS with 0.2% BSA, 2 mM EDTA, and 0.02% sodium azide and stained with the following extracellular antibody mixture: anti-human CD3-Pacific Blue, anti-human CD56-Pe-Vio770, anti-human CD69-FITC, anti-human CD107a (LAMP-1)-APC, anti-human CD107b-APC according to manufacturer's recommended incubation and dilution ratios. After a fixation and permeabilization step, intracellular staining was performed using the following intracellular antibody mixture: anti-human IFNγ-BV605, anti-human TNFα-BUV395, and anti-human MIP1β-PE. To eliminate aggregates, antibody mixtures were centrifuged at 16,000 g for 10 min at 4° C., washed, and resuspended in sample buffer.
- Flow cytometry was performed on a LSR Fortessa™ X-20, equipped with BD FACSDiva acquisition software measuring FSC-A, FSC-H, SSC-A, SSC-H, FL-1, FL-3, FL-6, FL-7, FL-9, FL-13 and FL-16 parameters. All data were analyzed with FlowJo software.
- Marker percent of NK cell sample was done using GraphPad prism. Top of activation values corresponded to the observed maximum activation. Half maximal effective concentration (EC50) values were calculated using 4 parameter logistics non-linear regression model corresponding to the following equation:
-
- Calculated bottom of activation, calculated top of activation, slope and 95% confidence interval (CI) values were calculated using the same model as EC50.
- These parameters were calculated for each activation marker (CD69, CD107a/b), cytokine (IFNα, TNFα) and chemokine (MIP1β).
- The sequence encoding the Extracellular Domain (ECD) of human NKp46 (Gln22-Asn255, NCBI Reference: NM_004829.5) was inserted into the SLX192 vector (Selexis) between the HindIII and XbaI restriction sites. A C-terminal 6×His tag (SEQ ID NO: 107) was added for purification. The following primers were used for PCR on human PBMCs: 5′
TACGACTCACAAGCTTGCCGCCACCATGTCTTCCACACTCCCTGC 3′ (SEQ ID NO: 82) and 5′CCGCCCCGACTCTAGATCAATGGTGATGGTGGTGATGATTCTGGGCAGTGTGA TCCC 3′ (SEQ ID NO: 83). The sequence of the amplicon was checked. The vector was then used to transfect a CHO cell line and a clone producing the protein was selected. The protein was purified from the culture supernatant with Ni-NTA beads (Qiagen, #1018244) and 5200 size exclusion chromatography was performed to ensure the elimination of aggregates prior to characterization of binding kinetics with surface plasmon resonance (SPR). The recombinant human NKp46-derived polypeptide sequence is reported herein as SEQ ID NO: 84; which includes part of the extracellular domain of NKp46. - The sequence encoding the ECD of Cynomolgus NKp46 (Gln17-Asn254, NP_001271509.1) was cloned into the SLX192 vector between the HindIII and XbaI restriction sites. A C-terminal Flag-M2 tag was added for purification. The primers used to amplify the expected sequence from cynomolgus PBMC were: 5′
TACGACTCACAAGCTTGCCGCCACCATGTCTTCCACACTCCGTGC 3′ (SEQ ID NO: 89) and 5′CCGCCCCGACTCTAGATCACTTGTCATCGTCATCTTTGTAATCATTCTGGGCAG TGTGGTCC 3′ (SEQ ID NO: 90). After sequence validation, the vector was used to transfect the CHO-KlSV cell line and a producing cell clone was selected. The recombinant Cynomolgus NKp46-FlagM2 protein sequence is reported herein as SEQ ID NO: 85; which includes part of the extracellular domain of NKp46 (GenBank number: CAC41080.1). The first three batches (150602CCe batch 1,150618CCe batch 2 and 150715CCe batch 3) were purified by M2 affinity chromatography. The beads were incubated with the supernatant containing the recombinant protein overnight. The beads were then washed with PBS1X and the elution is performed with elution peptide at 150 ng/μl in PBS1X. The proteins are then dialyzed against PBS1X. The next batches (161003CDe batch 1 and 161116CDe batch 2) were purified by affinity chromatography by coupling the anti-NKp46 antibody HUX1-M-H46-17E1 to the AminoLink Coupling Resin according to the manufacturer's instructions (GE Healthcare, #20381, batch QB213815). The beads were then incubated with the supernatant containing the recombinant protein overnight. The beads were then washed with PBS1X and the elution is performed using Glycine 0.1M pH2.5. The proteins are then dialyzed against TBS buffer pH7.5 and concentrated to perform a preparative size exclusion chromatography on aSuperdex 200Increase 10/300 GL column. - A recombinant human CD123 from ACRO Biosystems (catalog no. ILA-H52H6), recombinant Human Fc gamma RIIIA/CD16a (V176) (Biotechne, catalog no. 4325-FC), and recombinant Human Fc gamma RIIIA/CD16a (V176F) (Biotechne, catalog no. 8894-FC) were further used.
- A Biacore T200 instrument (Cytiva, Uppsala, Catalog No. 28975001) was used with a Series S CM5 sensor chip (Cytiva, Uppsala, Catalog No. 29149603).
- For binding kinetics measurements with NKp46 and CD123, HBS-EP+ buffer (Cytiva, Uppsala, Catalog No. BR1006-69) was prepared by mixing 100
mL 10× HBS-EP+ buffer with 900 mL of purified water. Affinity capture of the bispecific Ab sample was achieved using the human antibody capture kit (Cytiva, Uppsala, Catalog No. BR1008-39). The anti-Fc capture antibody was diluted in running buffer 1:20 and coupled to the CM5 chip (Cytiva, Uppsala, Catalog No. 29149603) using standard amine coupling to yield approximately 8000 response units (RU) using the amine coupling kit (Cytiva, Uppsala, Catalog No. BR-100-50). Seven serial 1:1 dilutions of either human NKp46 (Innate Pharma) or human CD123 (ACRO Biosystems) in HBS-EP+ assay buffer were prepared to concentrations of 1.56 nmol/L, 3.13 nmol/L, 6.25 nmol/L, 12.5 nmol/L, 25 nmol/L, 50 nmol/L and 100 nmol/L. The bispecific antibody was diluted with HBS-EP+ buffer to a concentration of 0.06 μg/mL and used at this concentration in the experiments. The antibody was captured at a flow rate of 10 μL/min for 90 sec to yield maximal response (Rmax) values of approximately 30 RU. Measurements were performed in multicycle kinetics experiments for both antigens. In each multicycle experiment the antibody was captured via an anti-human Fc antibody immobilized on a series S CM5 sensor chip (human antibody capture kit, Cytiva, Uppsala, Catalog No. BR1008-39). Human and cynomolgus NKp46 (Innate Pharma) or human CD123 (ACRO Biosystems), diluted into HBS-EP+ buffer, were injected in a 1:1 dilution series from 1.56 nmol/L to 100 nmol/L for 240 sec at a flow rate of 30 μL/min followed by a dissociation phase of 1200 sec. All analyte concentrations were run in duplicate together with multiple buffer blanks for double referencing. Regeneration of the capture surface was performed with regeneration solution (3 mol/L MgCl2) for 60 sec at 30 μL/min. Binding kinetics data were evaluated with the Biacore T200 Evaluation Software version 3.0 (Cytiva, Uppsala) for all other antibodies using a 1:1 binding model with mass transport limitation. - For binding affinity measurements with CD16a, HBS-EP+ buffer (Cytiva, Uppsala, Catalog No. BR1006-69) was prepared by mixing 100
mL 10× HBS-EP+ buffer with 900 mL of purified water. Affinity capture of the human CD16a proteins was achieved using the His capture kit (Cytiva, Uppsala, Catalog No. 28995056). The anti-His capture antibody was diluted in running buffer 1:20 and coupled to the CM5 chip (Cytiva, Uppsala, Catalog No. 29149603) using standard amine coupling to yield approximately 8000 response units (RU) using the amine coupling kit (Cytiva, Uppsala, Catalog No. BR-100-50). Ten serial 1:1 dilutions of the bispecific antibody in HBS-EP+ assay buffer were prepared to concentrations of 5.8 nmol/L, 11.7 nmol/L, 23.4 nmol/L, 46.8 nmol/L, 93.75 nmol/L, 187.5 nmol/L, 375 nmol/L, 750 nmol/L, 1500 nmol/L and 3000 nmol/L. The CD16a (V/F) proteins were diluted with HBS-EP+ buffer to a concentration of 0.1 ng/mL and used at this concentration in the experiments. CD16a (V176) and CD16a (V176F) were captured at a flow rate of 10 μL/min for 30 sec onflow cells - The efficacy of muNKp46-huCD123_F25 a murine surrogate version of the NKp46-CD123_F25 was evaluated in severe-combined-immunodeficient (SCID) mice engrafted with disseminated human MOLM-13 cells. This surrogate is different from NKp46-CD123_F25 for the arm targeting the NKp46 protein (as it targets the murine protein instead of the human one) and is similar to NKp46-CD123_F25 for the other arms (human CD123 binding arm and human IgG1 competent Fc domain able to bind to all activating murine FcγRs, to recruit murine effector cells and to induce ADCC with murine NK cells).
- The muNKp46-huCD123_F25 activity was compared to an anti-CD123 ADCC-enhanced antibody (Reference-1) able to bind murine FcγRs and to recruit murine effector cells. The muNKp46-huCD123_F25 activity was also compared to an isotype control binding of muNKp46 and murine FcγRs but not to bind to huCD123 (muNKp46-IC).
- Mice were intravenously inoculated with tumor cells (5×106) on
day 0. Treatments were administered by intraperitoneal route onday 1 post tumor implantation. - In the first experiment (
FIG. 8 ), mice were randomized in 4 groups (n=10 mice in treated groups and 20 mice in control group) onday 1 post tumor implantation. muNKp46-huCD123_F25 was administered at 0.5, 0.25 and 0.05 mg/kg following intra-parenteral administrations onday 1. - In the second experiment (
FIG. 18 ), muNKp46-IC was administered at 0.5 mg/kg. muNKp46-huCD123_F25 and Reference-1 were administered at 5, 0.5, 0.25 and 0.05 mg/kg. The control group was left untreated. - In the third experiment (
FIG. 19 ), mice were randomized into the 4 groups (untreated control group; untreated control group+anti-asialoGM1; NKCE control; or NKCE+anti-asialoGM1). A day before tumor implantation (day −1) as well as atday 5 post-tumor implantation the experimental groups received NK cell depletion antibody, anti-asialo GM1. Treatments (Vehicle or NKCE) were administered intraperitoneally onday 1 post tumor implantation at a single dose of 0.5 mg/kg. NKCE included Nkp46-CD123_F25, muNKp46-IC, an isotype control antibody binding huCD123 and murine FcγRs but not murine NKp46 (IC-huCD123). - Mice were checked and adverse clinical reactions noted. Individual mice were weighed daily until the end of the experiment (day 70). Mice were euthanized when turning moribund according to predefined criteria in order to avoid animal suffering. Clinical signs related to the pathology, considered as critical are limb paralysis, ascites, palpable internal tumor mass, morbidity or weight loss superior or equal to 20%.
- The primary efficacy endpoints were the Median Survival Time (MST) in day, the percent Increased Lifespan (% ILS), and the long-term survivor rate.
- Individual days of death (if any) of each mouse was reported. MST was determined for each group and the ratio ILS was calculated and expressed as percentage:
-
% ILS=100×(T−C)/C -
- Where T=MST of treated group and C=MST of control group.
- For the purpose of this example, a dose was considered as therapeutically active when % ILS is superior to 25% and highly active when % ILS is superior to 50% (Johnson J I, Decker S, Zaharevitz D, Rubinstein L V, Venditti J M, Schepartz S, Kalyandrug S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer. 2001 May; 84(10):1424-31).
- Long term survivor rate is defined as the number of mice with survival duration superior or equal to 2 times the MST of control group on the total number of mice in the group expressed in percentage.
- A qualified flow cytometry panel used for evaluating in monkey cynomolgus blood samples, the phenotyping and count of Basophils and total CD123 immune cells. The panel was composed by the antibodies against the antigen CD45 (Clone D058-1283), CD14 (clone REA599), CD203c (clone NP4D6), CD193 (clone 5E8), IgE (clone REA1049), CD123 (clone CD123), CD33 (clone AC104.3E3) and the viability marker Zombie Nir (Biolegend 423106). 100 μL of whole blood sample collected into a 3K-EDTA anticoagulated air-vacuum sampling were incubated with a lysis solution (Biocytex CP025) during 10 min following by a centrifugation step at 300 g at room temperature during 5 min with DPBS (Sigma D8537). The resuspended cells were stained during 10 min at room temperature with the antibodies and viability marker. A third step of centrifugation were done in order to eliminate non-fixed antibodies. Cells were resuspended into 250 μL of fixative solution (Biocytex CP026) and were incubated during one hour at room temperature. 100 μL of Flow count beads (Beckman A91346) were added into cells tube and were acquired on a Gallios Beckman coulter instrument equipped by 3 lasers and 10 colors.
- PBMCs from human healthy donors (N=10) were seeded in 96-well U-bottom plates (Ultra low binding Costar ref #CLS7007) in 190 μL complete culture medium (500,000 cells per well). and incubated at 37° C. in the presence of 5% CO2 for 20 hours with serial dilutions of CD123-NKCE, IC-NKCE control and CD123-TCE molecules. The basophil population, defined as TCRαβ negative, CD14 negative and IgE receptor positive viable cells, was analyzed by flow cytometry and cytokine absolute concentrations released in the supernatant were analyzed by meso scale discovery (MSD) assay.
- Flow Cytometry—Assay
- Cell pellets were suspended in cold 50 μL Stain Buffer (AutoMACS Running Buffer Miltenyi Ref #130-091-221) completed with 1 μL FcR Blocking reagent, human (Miltenyi Ref #130-059-901). A mix of PBMC subsets specific labelling antibodies and the viability reagent were added into the PBMC suspension following supplier recommendations. As Fluorescence Minus One (FMO) control, further points were performed by labelling PBMC with the same mix in which each labelling antibody was replaced by its corresponding isotype control Cells with mixed antibodies were incubated 1 hour at 4° C. in the dark. Then, cell suspensions were centrifuged twice at 300 g during 5 minutes at 4° C., with the supernatant discarded and 200 μL of Stain buffer added between each centrifugation. Cells were analyzed using the MACSQuant® Analyser, Miltenyi flow cytometer. Analysis of raw data (fcs-files) exported from the flow cytometer was performed using the VenturiOne@ software (AppliedCytometry inc.). The populations were gated from forward scatter/sideward scatter dotplot, single cells and further viable cells were gated on Iodure Propidium viable negative gate. Gates were set according to FMO controls.
- Cytokine MSD Assay
- Cell supernatant was collected and diluted in MSD buffer following purchaser recommendations. Diluted samples or pre-diluted multi-analyte calibrators samples are added in pre-coated plate supplied in the kit. After adding a solution of detection antibodies conjugated with electrochemiluminescent labels (MSD SULFO-TAG), the plates were incubated at room temperature for 2 hours. Then, MSD buffer creating the appropriate chemical environment for elctrochemiluminescence (ECL) was added and the plates loaded into an MSD instrument where a voltage applied to the plate electrodes causes the captured labels to emit light. The instrument measures the intensity of emitted light and provide a quantitative measure of each analyte in the samples.
- Analysis of raw data exported from the MSD instrument was performed using Excel software. Concentrations of IL-6, IL-1b, IFNγ and TNFα are determined from ECL signals by back-fitting to a calibration curve established with a 4-parameter logistic model with 1/Y2 weighting.
- An ECLIA (Electrochemoluminescence Assay) method using Mesoscale (MSD) Proinflammatory Panell (NHP) kit (ref. K15056D) was developed and validated to quantify IL-2, IFN-γ, IL-6, and IL-10 in monkey K3-EDTA plasma. It is a quantitative sandwich enzyme immunoassay using anti-human IL-2, IL-6, IL10 and IFN-γ antibodies immobilized on the working electrode surface and a Ruthenium anti-human IL-2, IL-6, IL-10 and IFN-γ antibodies. 50.0 μL of diluted samples were dispensed into the 96 microplate wells coated with the human anti-human IL-2, IL-6, IL-10 and IFN-γ antibodies. After an overnight period of incubation at room temperature and 3 steps of washing, 25.0 μL of sulfotag conjugated anti-human IL-2, IL-6, IL-10 and IFN-γ antibodies were added. After 3 steps of washing, 150 μL of read buffer (2×) were added that creates the appropriate chemical environment for the electrochemiluminescence. The instrument measures the intensity of emitted light to provide a quantitative measure of analytes in the sample. Analyses were performed in duplicate.
- CD123-NKCE solutions for administration were prepared extemporaneously by dilution of the stock solution in the vehicle and were kept at room temperature before and during administration. To avoid adsorption, PolyPropylene, PolyCarbonate or PETG containers were used for dilutions and these containers were coated with a solution of NaCl 0.9% containing 100 ppm of PS80 before use. Tubing used for each intravenous dosing (syringe/winged needle) were coated by successive flushes with a solution of NaCl 0.9% containing 100 ppm of PS80.
- Animals were identified as M1 and M2 for males dosed at 0.1 mg/kg/administration, F3 and F4 for females dosed at 0.1 mg/kg/administration, M5 and M6 for males dosed at 3 mg/kg/administration, and F7 and F8 for females dosed at 0.1 mg/kg/administration, respectively. Dosing was performed on
Days Day 29. - Parameters were evaluated for each treated animal:
-
- in blood
- on pretest (predose)
-
Day 1 at 1.5, 5, 24, 72 hours after the start of infusion -
Day 8 at 24 hours after the start of infusion -
Day 15 at 1.5 and 24 hours after the start of infusion -
Day 22 at 24 hours after the start of infusion - Day 29 (1 week after the last administration; all animals)
- Day 50 (4 weeks after the last administration; recovery animals).
- in bone marrow
- Pretest (predose)
-
Day 9 - Day 29 (1 week after the last administration; all animals)
- Day 50 (4 weeks after the last administration; recovery animals)
- Blood samples (serial sampling) were withdrawn from brachial or saphenous vein into K3-EDTA polypropylene tubes. Blood samples were placed on wet ice and centrifuged. Plasma samples obtained were frozen at −80° C. pending their analyses. CD123-NKCE concentrations were determined in plasma using a dedicated immunoassay method where CD123-NKCE were captured by biotin-coupled CD123 recombinant proteins and revealed by a monkey absorbed alexa-goat anti-human IgG, with a Lower Limit of Quantification (LLOQ) value of 0.250 ng/mL.
- The F25 format, or its variants, is illustrated in
FIGS. 1 and 2 , and comprises three polypeptide chains. The NKp46-CD123_F25 binding protein comprises three polypeptide chains including a human CD123 binding domain and a human NKp46 binding domain, respectively including hypervariable regions comprising polypeptide sequences SEQ ID NO: 1, 2, 3, 7, 8, 9 and SEQ ID NO: 13, 14, 15, 27, 28, 29. - Each polypeptide chain (I, II, and III) is expressed with a signal (or “leader”) sequence that is cleaved intracellularly before assembly.
- The first polypeptide chain (or “polypeptide chain (I)” or “Fragment I” or “
Fragment 1”) comprises from N-term to C-term, the VL (CD123-binding) domain corresponding to the amino sequence of SEQ ID NO:43, a native CK (or Cκ) domain derived from human IgG1, a modified human IgG1 hinge region (“DKTHTCPPCP (SEQ ID NO: 74)”) wherein residue D (position according to EU numbering) is connected to the C-terminal cysteine of the human CK domain. The Fc region or variant thereof is further derived from a native human IgG1 antibody comprising a CH2-C H3 domain. Disulfide bridges are potentially formed extracellularly with the second polypeptide chain (“chain II”) with native cysteines. - The second polypeptide chain (“polypeptide chain (II)” or “Fragment II” or “
Fragment 2”) comprises, from N-term to C-term, the VH (CD123-binding) domain corresponding to the amino sequence of SEQ ID NO:41, anative C H1 domain derived from human IgG1, an unmodified human IgG1 hinge region (“EPKSCDKTHTCPPCP (SEQ ID NO: 75)”), and a Fc region or variant thereof derived from a human IgG1 including a CH2-C H3 domain wherein the last residue of theC H3 domain is removed and replaced by a small four amino-acid “STGS (SEQ ID NO: 76)” linker, a VH (NKp46-binding) domain corresponding to the amino sequence of SEQ ID NO:45, asecond native C H1 domain which is identical to theC H1 domain of the first polypeptide chain, and a C-terminal hinge sequence from human IgG1. - The third polypeptide chain (“polypeptide chain (III)” or “Fragment III” or “
Fragment 3”) comprises a VL (NKp46-binding) domain corresponding to the amino sequence of SEQ ID NO: 53 and a CK domain terminated with a Cysteine. - The
C H2 domains of the Fc part of the NKp46-CD123_F25 binding protein of the present disclosure are glycosylated at position N297 to ensure binding to CD16 (FcγR). - Overall, the NKp46-CD123_F25 binding protein comprises four predicted interchain disulfide bridges:
-
- (i) one disulfide bridge connecting the C-term CK cysteine of the first polypeptide chain to the first hinge cysteine of the second polypeptide chain;
- (ii) two disulfide bridges formed with two cysteines of the hinge region of the first and second polypeptide chains;
- (iii) one disulfide bridge connecting the last C-term cysteine of the second polypeptide chain to the C-
terminal C H1 domain of the second polypeptide chain.
- The results related to binding, in-vitro, ex-vivo and in-vivo activity and safety profile showed in section B3 to B11 were obtained with NKp46-CD123_F25 binding protein of the present disclosure comprising polypeptide (I), (II) and (III); wherein the polypeptide (I) consists of an amino acid sequence of SEQ ID NO: 64, the polypeptide (II) consists of an amino acid sequence of SEQ ID NO: 65, and the polypeptide (III) consists of an amino acid sequence of SEQ ID NO: 66.
- The NKp46-CD123_F25 binding protein (NKp46-CD123_F25) was tested by SPR in order to confirm its affinity toward a set of human Fcγ receptors, including CD64 and two variants of the CD16a receptor.
-
hFcγR1 hFcγR3a-V hFcγR3a-F Kd (nM) hCD64* hCD16a-V hCD16a-F NKp46-CD123_F25 6.9 462 2606 - The human CD16a-V receptor, or CD16aV, refers to a polypeptide construct comprising a fragment of the CD16 human receptor binding to a Fc region of a natural antibody, mediating antibody-dependent cellular cytotoxicity and bearing a Valine (V) on position 158, which is also reported in the literature as allotype CD16a V158.
- The human CD16a-F receptor, or CD16aF, refers to a polypeptide construct comprising a fragment of the CD16 human receptor binding to a Fc region of a natural antibody, mediating antibody-dependent cellular cytotoxicity and bearing a Phenylalanine (F) on position 158, which is also reported in the literature as allotype CD16a F158.
- The conclusion of this experiment is that the constant regions which compose NKp46-CD123_F25 retains their affinity toward a plurality of human Fc-γ receptors, including human CD16 and human CD64.
- The same experiment was performed with human and monkey versions of NKp46. The results are summarized in the two tables hereafter (Table 1 and Table 2).
-
TABLE 1 HUMAN (hNKp46) MONKEY (CynoNKp46) ka kd KD ka kd KD NKp46 (1/Ms) (1/S) (nM) (1/Ms) (1/S) (nM) NKp46- 5.38E+04 9.43E−04 17.5 3.64E+04 2.47E−03 67.9 CD123_F25 -
TABLE 2 HUMAN (hCD123) MONKEY (CynoCD123) ka kd KD ka kd KD CD123 (1/Ms) (1/S) (nM) (1/Ms) (1/S) (nM) NKp46- 1.19E+05 2.85E−05 0.24 1.83E+05 5.29E−05 0.29 CD123_F25 - The conclusion of this experiment is that the NKp46-CD123_F25 binding protein related to the present disclosure (NKp46-CD123_F25) retains affinity for NKp46 and CD123 targets, which applies both to human and monkey isoforms.
-
FIG. 4 reports in vitro cytotoxicity against MOLM-13 AML cells (FIG. 4A ). The same experiment is reproduced against ex vivo patient blast samples as target cells (FIG. 4B ). Cytotoxicity is assessed as a function of the tested NKp46-CD123_F25 binding protein (NKp46-CD123_F25) concentration in the experiment. - Overall, the experiments show that NKp46-CD123_F25 is responsible for dose-dependent cytotoxicity in both in vitro and ex vivo tested samples. For a similar concentration, the observed cytotoxicity is also higher than the one observed with an anti-CD123 antibody ADCC-enhanced with no specificity for NKp46 (Reference-1). Conversely, a negative control variant of format F25 binding NKp46 only (NKp46-IC_F25) shows little cytotoxicity under the tested conditions. Hence, the experiments support a synergistic effect of the dual binding toward both CD123 and NKp46 in a Fc-competent construct (F25) to lead to cytotoxicity against CD123-positive tumor cells.
-
FIG. 5 provides data based on EC50 on a MOLM-13 cell line. Improvement of in vitro cytotoxicity (which translates into a decreased EC50) is observed with the NKp46-CD123_F25 binding protein (NKp46-CD123_F25). In contrast, the F6 control (NKp46-CD123_F6), which lacks N-glycosylation on residue 297, provides a decreased cytotoxicity since it activates NK cells by engaging NKp46 only and not CD16a. Hence, this second experiment provides evidence of the synergistic effect observed through binding and activation of NKp46 and CD16a NK cell markers. - Accordingly, specific lysis was illustrated with NKp46-CD123_F25, and with an anti-CD123 antibody ADCC-enhanced with no specificity for NKp46 (Reference-1) in the presence of human NK cells against CD123-positive MOLM-13 AML cells. The EC50 value is established based on the variation of cell lysis over the concentration of binders. The results are shown hereafter.
-
EC50 (pM) Molecules Mean +/− sem (4 donors) NKp46-CD123_F25 80.3 ± 44.9 Reference-1 85.3 ± 41.3 - Hence, it is shown that the NKp46-CD123_F25 binding protein (NKp46-CD123_F25) exhibits a cytotoxic activity which is at least equal or superior to the anti-CD123 ADCC-enhanced antibody (Reference-1).
- Reference-1 is a fully-humanized monoclonal antibody indicated for the treatment of AML, which targets the alpha chain of the
interleukin 3 receptor (IL3Rα; also known as CD123) and is optimized for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells. - B.6. CD64 Expression on AML does not Impact NKCE Cytotoxic Activity while it Negatively Impacts REFERENCE-1 Activity
- To further document and compare the activity of NKp46-CD123_F25 and Reference-1 antibody, cytotoxicity experiments were performed using different AML cell lines expressing CD123 as targets. Surprisingly, even though THP-1 and MOLM-13 cells express comparable level of CD123 at the cell surface, Reference-1 antibody efficiently killed MOLM-13 cells but was not active against THP-1 cells (
FIG. 6A -upper panels). Contrary to Reference-1 antibody, NKp46-CD123_F25 demonstrated comparable killing activity on both AML cell lines (FIG. 6A -upper panels).FIG. 6A -lower panels show that MOLM-13 and THP-1 cells differ for the expression of CD32a/b and CD64 FcγRs at the cell surface as analyzed by flow cytometry. MOLM-13 cells had much lower CD64 levels, and also lower levels of CD32a/b, than THP-1 cells (FIG. 6A —lower panels). CD64 (FcγRI) is a high affinity receptor for human IgG expressed on healthy monocytes and macrophages and found expressed on AML blasts in about one third of patients which may be considered as CD64-positive Acute Myeloid Leukemia. To investigate the role of CD64 expression on cytotoxicity for the NK Cell engager (NKCE), compared to the humanized monoclonal antibody Reference-1, the expression of CD32a/b and CD64 was selectively knocked down in THP-1 cells. - Killing experiments performed on THP-1 sub-clones expressing CD32a/b but not CD64 or expressing CD64 but not CD32a/b (
FIG. 6B ) demonstrated that CD64 expression on THP-1 was responsible for the inhibition of Reference-1 ADCC activity as killing of this antibody was restored only on sub-clones inactivated for CD64 expression. Accordingly, these results indicate that cis capture of antibody FC by FcγR, CD64, at the surface of AML cells interfere with ADCC probably by competing with the binding of CD16a to NK cells. - Interestingly, NKp46-CD123_F25 demonstrated consistent killing activity on all AML cell lines and all THP-1 sub-clones emphasizing that the NKp46-CD123_F25 binding proteins related to the present disclosure are more efficient for inducing NK cell-mediated cytotoxicity of AML blasts, as compared to Reference-1, whatever the CD64 expression status.
-
FIG. 14A-B confirm that Reference-1 activity is negatively impacted by expression of CD64 on AML cells. -
FIG. 14A reports the NKp46-CD123_F25 and Reference-1-mediated cytotoxicity of primary malignant AML blasts from four representative patients (AML # 1, #2, #5 and #6; N=8) which were evaluated ex vivo using healthy donor NK cells as effectors. As observed with MOLM-13 and THP-1 cell lines, Reference-1 antibody mediated the killing of CD64-negative patient samples (AML # 1 and #2;FIG. 14A ) but was barely active against blasts from CD64-positive AML patient samples (AML # 5 and #6;FIG. 14A ). Accordingly, AML #5-AML # 6, (Reference-1-non-responders) have higher staining levels of CD32 and CD64 thanAML # 1 and AML #2 (Reference-1 responders)(FIG. 14B , right panels, compare peak shifts in CD64 and CD32 from controls in both groups). - In contrast, trifunctional NKp46-NKCEs targeting CD123 had strong anti-tumor effects on both CD64-positive and CD64-negative AML patient samples (
FIG. 14 ).FIGS. 6 and 14 demonstrate that CD123-NKp46_F25 was equally potent against the parental THP-1 cell line, THP-1 subclones, and MOLM-13 cells, regardless of FcγR expression status, and, more specifically, CD64 expression on target cells. Moreover, trifunctional NKCE molecules also display killing activity against all primary malignant AML cells, promoting significant antitumor activity in CD64-positive AML patient samples (AML # 5 and 6) against which Reference-1 was completely inactive (FIG. 14A ). - Regarding experiments using MOLM-13 cells, trifunctional molecules (CD123-NKp46_F25) were more potent than the bispecific reagents activating NKp46 (CD123-NKp46_F6) or CD16a (CD123-IC_F25) separately (
FIG. 15A ), demonstrating potent killing activity (geometric mean EC50 of 4.2 [95% CI: 2.7, 6.3] pM, a mean observed maximum specific lysis of 71±5%) and good consistency between healthy NK cell donors (FIG. 15B ). - The properties of NKp46-CD123_F25 binding proteins of the present disclosure (NKp46-CD123_F25) to induce NK degranulation against primary CD64(+) or CD64(−) AML blasts were established in
FIG. 7 through measurement of the percentage of CD107-positive NK cells. - Overall, this experiment provides evidence that the NKp46-CD123_F25 binding proteins of the present disclosure are able to activate NK cells in primary samples from AML patients in an autologous assay, e.g., with primary blasts and NK cells from the same patient.
- These results were further consolidated in a dedicated autologous NK-cell activation assay with two additional AML patient samples without (sample 10) and with (
sample 8 and 9) CD64 expression (FIG. 16A ). Again, NKp46-CD123-NKCEs mediated the autologous activation (see shift in CD107 staining) of the patients' NK cells against their own malignant cells regardless of CD64 expression status on blasts, whereas Reference-1 was active only against the CD64-negative sample (sample 10) (FIG. 16B ). - Accordingly, this experiment supports the capacity of the NKp46-CD123_F25 binding protein of the present disclosure to activate NK cells ex vivo, both with respect to CD64(+) and CD64(−) AML cells.
- Besides, in this autologous assay, NKp46-CD123_F25 binding protein of the present disclosure are able to engage NK cells in the presence of CD64(+) cells at a much lower concentration than what is observed in the presence of Reference-1.
- In addition, mean EC50 were also quantified for NKp46-CD123_F25 and Reference-1, in a blast killing assay using six NK healthy donors against four AML samples (2 CD64(+) and 2 CD64(−), and the results are reproduced here below.
-
Mean EC50 Mean EC50 CD64(−) AML CD64(+) AML blasts +/− SD (pM) blasts +/− SD (pM) NKp46-CD123_F25 27.9 +/− 14.1 18.6 +/− 1.9 Reference-1 48.0 +/− 36.3 inactive - Overall, these experiments again demonstrate that the blast killing activity of the NKp46-CD123_F25 binding proteins related to the present disclosure is superior to the Reference-1 antibody, even for CD64(−) AML samples, with Reference-1 being inactive against CD64(+) AML blasts.
-
FIG. 8 reports dose-dependent anti-tumor activity with a muNKp46-huCD123_F25 binding protein (muNKp46-huCD123_F25) inducing 50% mice survival at 0.5 mg/kg, 70 days after tumor implantation, using a SCID mouse model. More specifically, the control group treated showed an MST of 27.5 days and 5% of long-term survivors. - X-axis marks the number of days after tumor implantation, consisting of an intravenous injection of human MOLM-13, including a single compound administration on day one by the intraperitoneal (i.p.) route. Y-axis marks the percentage of survival based on ten mice for the treated group and twenty mice for the control group. *** marks a p value<0.001 vs. control group.
- The group treated with muNKp46-huCD123_F25 at 0.5 mg/kg showed a MST of 66 days, an increased lifespan of 140% and 50% of long term survivors, muNKp46-huCD123_F25 at 0.5 mg/kg was statistically significantly active as compared to the control group (p<0.0001). For the dose of 0.25 mg/kg, the group showed an MST of 36 days, an increased lifespan of 31% and 10% of long-term survivors, muNKp46-huCD123_F25 inducing at 0.25 mg/kg was not statistically different to the control group. For the dose of 0.05 mg/kg, the group showed an MST of 33 days, an increased lifespan of 20% and no long-term survivors, muNKp46-huCD123_F25 at 0.05 mg/kg was not statistically different to the control group.
- The NKp46-CD123_F25 binding protein related to the present disclosure showed a dose-dependent anti-tumor in-vivo activity with a robust activity at 0.5 mg/kg. Those results are summarized in the following Table 3:
-
TABLE 3 Long term Median Survival Increase Group survivors Time in days of lifespan F25 at 0.5 mg/ kg 50% 66 140% F25 at 0.25 mg/ kg 10% 36 31% F25 at 0.05 mg/ kg 0% 33 20 % Control 5% 27.5 — - Hence, this confirms that the NK cell engagers are efficient for the treatment of proliferative disorders in-vivo in an animal model.
- Additionally, for further evaluation of efficacy, the experiment described above and reported in
FIG. 8 was repeated but including a 5 mg/kg of muNKp46-huCD123_F25 NKCE or control as well as with an additional group administered that was Reference-1. The results are presented inFIG. 18 . - Consistent with the
FIG. 8 study, in theFIG. 18 study the surrogate muNKp46-huCD123_F25 induced a statistically significant activity at the doses of 5, 0.5, 0.25 and 0.05 mg/kg in human MOLM-13 disseminated model, with an ILS compared to control of 100% and 60% of long-term survivors for the doses of 5, 0.5 and 0.25 mg/kg and an ILS of 30% and 10% of long-term survivors for the dose of 0.05 mg/kg. - Reference-1 induced a statistically significant activity at the dose of 5 mg/kg in human MOLM-13 disseminated model, with an ILS of 70% and 40% of long-term survivors. It was not active at the doses of 0.5, 0.25 and 0.05 mg/kg.
- The muNKp46-huCD123_F25 was statistically significantly more active than Reference-1 at the doses of 0.5 and 0.25 mg/kg.
- Tabular results for
FIG. 18 are summarized as follows: -
Long term Median Survival Increase Group survivors Time in days of lifespan muNKp46- 60% >70 >97% huCD123_F25 at 5 mg/kg muNKp46- 60% >70 >97% huCD123_F25 at 0.5 mg/kg muNKp46- 60% >70 >97% huCD123_F25 at 0.25 mg/kg muNKp46- 10% 46 30% huCD123_F25 at 0.05 mg/kg Reference-1 at 5 mg/ kg 40% 60.5 70 % Reference 1 at 0.5 mg/ kg 0% 32 0 % Reference 1 at 0.25 10% 37 4% mg/ kg Reference 1 at 0.05 20% 40.5 14% mg/ kg Control 0% 35.5 - In conclusion, muNKp46-huCD123_F25 surrogate showed a dose-dependent activity with a robust activity from 0.25 mg/kg. These data demonstrated the benefit of co-engaging NK cells with NKp46/FcγRs leading to an improved in vivo efficacy relative to an anti-CD123 antibody (Reference-1).
- The absence of pro-inflammatory cytokine release of NKCE in human PBMCs in vitro was further confirmed in two dedicated pharmacokinetic, pharmacodynamic and safety studies performed on NHPs. Cynomolgus monkeys were selected as a relevant species for preclinical pharmacokinetics, pharmacodynamics and toxicological studies on (1) the basis of their tissue distributions of NKp46 and CD123, which are similar to those in humans (Walzer et al. PNAS; 2007; 104:3384-3398 and ChiChili et al. Sci Transl Med; 2015; 7:289) and (2) because the antibodies and Fc fragment constituting the CD123-NKCE molecule bind to cynomolgus antigens and FcγRs with affinities similar to those for human molecules as shown in the Table 4 below. Specifically, CD16a (FcγRIIIA) has a monovalent KD of 0.46±0.01 μM and 2.61±0.09 μM for its 158V and 158F isoforms, respectively, and anti-NKp46 and anti-CD123 antibody moieties bind to human NKp46 and human CD123 with monovalent KD of 16.3±2.9 nM and 0.40±0.04 nM, respectively.
-
TABLE 4 KD (nM) Mean +/− SD (n = 3) Human IgG1 NKp46-CD123_F25 control Human molecules CD123 0.40 ± 0.02 NA Nkp46 16.6 ± 1.1 NA Human FcRn 109 +/− 28 94 +/− 25 Human FcγRI 0.2 +/− 0.0 0.2 +/− 0.0 Human FcγRIIa 1222 +/− 99 1574 +/− 108 Human FcγRIIb 3196 +/− 375 4232 +/− 483 Human FcγRIIIaF 2606 +/− 91 2820 +/− 58 Human FcγRIIIaV 462 +/− 12 575 +/− 16 Human FcγRIIIb 6688 +/− 413 7541 +/− 838 Cynomolgus molecules CD123 1.2317 ± 0.132 NA NKp46 29.038.9 ± 1.74 NA Cynomolgus FcRn 282 +/− 41 237 +/− 22 Cynomolgus FcγRI 12 +/− 1 18 +/− 2 Cynomolgus FcγRIIa 5177 +/− 290 6336 +/− 377 Cynomolgus FcγRIIb 1891 +/− 130 2320 +/− 165 Cynomolgus FcγRIII 466 +/− 36 580 +/− 56 Displayed results in table 4 were performed at 25° C. pH5.6 ; default condition : 25° C. pH7.4. NA: not applicable. SD: standard deviation. KD: Dissociation constant. -
FIG. 9 further shows a complete and sustained CD123-positive basophil depletion at 3 μg/kg for up to 20 days after the injection of the NKp46-CD123_F25 binding protein related to the present disclosure (NKp46-CD123_F25), and up to 5 hours at 0.5 μg/kg for non-human primates. - Accordingly, this result demonstrates that the in vitro, ex vivo and in vivo results previously obtained, including those observed in the SCID mouse model, can be extrapolated to non-human primates for NK cell engagers.
- Overall, CD123-positive immune cell depletion is a hallmark of in vivo activity of the NKp46-CD123_F25 binding proteins in non-human primate. It is found that rapid and sustained depletion of CD123-positive basophils is observed, which occurs at about 1.5 hours from start of infusion, and is maintained up to
Day 7, with cell number returning to baseline onDay 28. -
FIGS. 10A and 10B illustrate that NKp46-CD123_F25 and NKp46-CD123_F5 binding proteins show the same cytotoxic activity against both MOLM-13 and THP-1 AML cell lines, by engaging NK cells from healthy donors (D648). - The main difference between MOLM-13 and THP-1 cells relates to their level of expression of the CD64 marker. MOLM-13 cells do not express CD64(−), whereas THP-1 cells express high level of CD64(+). Both cells express CD32a.
- Thus, this example reports the variation of specific lysis for three distinct binding proteins: (i) a NKp46-CD123_F5 binding protein in the F5 format (NKp46-CD123_F5), (ii) a NKp46-CD123_F25 binding protein in the F25 format (NKp46-CD123_F25), and (iii) a negative isotype control variant of format F5 binding CD123 only (CD123-IC_F5).
- Overall, those results demonstrate that cytotoxic activity is maintained with two Fc competent NKp46-CD123 binding proteins in F5 and F25 formats. In Contrast, the negative controls do not lead to detectable cytotoxic activity.
- B.11. NKp46-CD123 NKCEs-Induced CD123-Positive Basophil Depletion is Associated to Low Cytokine Release when Compared to T-Cells Engager Tool
- Potent cytotoxicity may be associated with toxicity in patients. To investigate the cytokine release from human PBMCs induced by CD123-NKCE in vitro, as a predictive assay of potential cytokine release syndrome (CRS) in patients, the following experiment was performed.
- Human PBMCs (N=10 samples) were cultured for 20 hours in the presence of a NKp46-CD123_F25 (CD123-NKCE; dose of 0.1, 1, or 10 μg/mL; 0.68-68 nM), a negative isotype control variant of format F25 binding NKp46 only (NKp46-IC_F25; dose of 0.1, 1 or 10 μg/mL; 0.68-68 nM), or with an anti-CD123 T-cell engager antibody tool with specificity for CD3 and no specificity for NKp46 (CD123-TCE, Reference-1; 0.1 μg/mL; 1.6 nM) over a concentration gradient (10−3 to 101 μg/mL).
- Amongst human PBMCs, CD123 is constitutively expressed on a subset of circulating basophils and plasmacytoid dendritic cells (pDC). Given that basophils have higher CD123+ expression than pDCs, the percent depletion of basophils was monitored for each treatment group indicated above.
FIG. 11 shows the treatment of human PBMCs with CD123-NKCE promoted a dose-dependent partial depletion of CD123+ basophils with a median maximum depletion of 37% [31; 50], and a geometric mean EC50 value of 38 μM (95% CI [12.9; 401]), calculated with six of 10 donor samples. In contrast, basophil depletion did not occur in a considerable amount in the presence of a F25 binding molecule lacking a CD123 binding site (NKp46-IC_F25). From the human PBMCs treatment groups indicated above, the supernatant was collected to quantify the amount of cytokine release.FIG. 12 demonstrates that the in vitro IL-6, and IL-1β pro-inflammatory cytokine and TNF-α and IFN-γ cytokine release associated to the administration of the NKp46-CD123_F25 binding protein related to the present disclosure (NKp46-CD123_F25) was much lower than the corresponding IL-6 release associated with the administration of a positive control known to induce cytokine release syndrome (CRS), Reference-1, at a 100-fold lower dose (0.1 μg/ml). - CD123-NKCE induced much lower levels of cytokine release than CD123-TCE, even at concentrations 42-times higher.
-
FIGS. 11 and 12 demonstrate that the treatment of PBMCs with CD123-NKCEs promoted a depletion of CD123′ basophils but induced much lower levels of IL-6, IL-1β, TNF-α and IFN-γ release than treatment with CD3-CD123 antibody molecule. - In conclusion, the NKp46-CD123_F25 binding protein related to the present disclosure (NKp46-CD123_F25) has shown its ability to engage primary NK cells to target and kill CD123+ primary normal mononuclear blood cells associated with minor cytokine release and may have a better benefit/risk profile than TCEs for the treatment of AML.
- Regardless of the dose level and up to a high dose of 3 mg/kg,
FIG. 13A -FIG. 13F show that very low cytokine release (IL6 and IL10) was observed in all treated animals (male Cynomolgus monkeys) after the start of the injection of NKp46-CD123_F25 binding protein related to the present disclosure (NKp46-CD123_F25), without any associated clinical signs. No IL-2 nor IFNγ cytokine release were detected. More particularly, transient IL6 and IL10 peaks are detected in non-human primates after a single intravenous injection of F25 constructs at 3 mg/kg. This transient peak occurs from 1 hour to 5 hours and returns to baseline within 1 or 2 days. - Also, those very low levels of IL-6 and IL-10 cytokine release are not associated with clinical signs up to 3 mg/kg dose. This indicates that such NK cell engagers possess a good safety profile in non-human primates.
- B.12. NKp46-CD123 NK Cell Engagers Promote NK-Cell Activation In Vitro that is Commensurate with Cytokine/Chemokine Production
- Flow cytometric analysis corresponding to
FIG. 17 demonstrate that NKp46-CD123_F25 binding proteins promoted NK-cell activation only when CD123 expressing target cells are present. - Primary donor NK cells (N=3) incubated in the presence of NKp46-CD123_F25 displayed higher expression levels of NK cell activation markers, CD107 and CD69, as well as cytokines, TNF-α, IFN-γ, and chemokine, MIP-10, in a dose-dependent manner, when MOLM-13 target cells were present (
FIG. 17 , comparing NK alone vs NK+MOLM-13 condition). - Overall, this experiment provides evidence that the NKp46-CD123_F25 binding proteins of the present disclosure activate and commensurately promote cytokine/chemokine production in primary NK cells towards CD123+ AML cells with no off-target activation of NK cells.
- To test whether the efficacy of the NKp46-CD123_F25 depended on NK cells anti-tumor activity against MOLM-13 human AML injected in a SCID mouse model, mice underwent an NK cell depletion regimen during the experimental set-up outlined in B.8.
- The results are presented on
FIG. 18 andFIG. 19 and corresponding tabular results are shown in table 5 below. -
TABLE 5 Long term Median Survival Increase of Group survivors Time in days lifespan muNKp46- IC 0% 31 7% muNKp46-IC + 10% 23.5 ≤0% anti-aGM1 IC- huCD123 20% 37 28% IC- huCD123 + 0% 25 ≤0% anti-aGM1 muNKp46- 40% 53.5 84% huCD123_F25 muNKp46- 0% 33 14% huCD123_F25 + anti-aGM1 Control 0% 29 — - The control group treated showed a median survival time (MST) of 29 days and no long-term survivors.
- The muNKp46-IC isotype control did not show activity with an ILS of 7% and no long-term survivors. No impact of the NK depletion is observed on the group treated with muNKp46-IC isotype control with no increased lifespan and 10% of long-term survivors. The IC-huCD123 isotype control was statistically significantly active with an ILS of 28% and 20% of long-term survivors. A statistically significant impact of the depletion was observed on the group treated with IC-huCD123 isotype control with no increased lifespan and no long-term survivors.
- The muNKp46-huCD123_F25 was statistically significantly active with an ILS of 84% and 40% of long-term survivors. A statistically significant impact of the depletion was observed on the group treated with muNKp46-huCD123_F25 with an ILS of 14% and no long-term survivors.
- In conclusion, the NK depletion impacted the anti-tumoral activity of muNKp46-huCD123_F25 confirming the NK involvement as effector cells in muNKp46-huCD123_F25 NKCE in vivo efficacy.
- To confirm the safety profile of the Nkp46-CD123 cell engagers in the NHP study conducted in
FIG. 9 andFIG. 13 interrogating the pharmacokinetics and pharmacodynamics of CD123-NKCEs administered by a single i.v. injection of a high (3 mg/kg) or low (3 μg/kg and 0.5 μg/kg) doses in male cynomolgus monkeys (2 animals each for the 3 mg/kg and 3 μg/kg doses and 1 animal for the 0.5 μg/kg dose). - Treatment with CD123-NKCE promoted a sustained and complete depletion of CD123+ cells in the blood of all monkeys, for more than 10 days, at both the 3 mg/kg and 3 μg/kg doses (as exemplified for CD123+ basophils and total CD123+ cells in
FIG. 20A andFIG. 20B ), with only very small amounts (<50 μg/mL) of the pro-inflammatory cytokines IL-6 and IL-10 released (FIG. 20C ) without any associated clinical signs. - A transient and partial depletion of CD123+ cells was observed in the monkey treated at the lowest dose (0.5 μg/kg, data not shown), but 3 μg/kg was considered to be the lowest effective dose in this species. The PK profiles of the two monkeys treated at the highest dose (3 mg/kg) were marked by an anti-drug antibody (ADA) response (data not shown) occurring 12-14 days after treatment (
FIG. 20D ) and associated with the recovery of CD123+ cells from the blood at later timepoints. - The preclinical safety profile of CD123-NKCE was further interrogated through an exploratory repeat-dose toxicity study in which four monkeys (2/sex/dose) were treated weekly, for four weeks, at a dose of 3 mg/kg/administration or 0.1 mg/kg/administration, administered by intravenous infusion for one hour (
FIG. 21 ). In all monkeys (except one of the monkeys, monkey M5, male No. 5;FIG. 21 ), exposure to CD123-NKCEs lasted for at least two weeks, at both tested doses, with the presence of Anti-Drug Antibody (ADA) detected (data not shown) from the third administration (Day 15) (Table 6). - Table 6 below displays individual CD123-NKCE plasma concentration values after a weekly repeat 1-hour intravenous infusion at 0.1 and 3 mg/kg/administration for 4 weeks (on
Days -
TABLE 6 Concentration in plasma (ng/mL) 0.1 mg/kg/administration 3 mg/kg/administration Day Sampling M1♂ M2♂ F3♀ F4♀ M5♂ M6♂ F7♀ F8♀ 1 Predose <LLOQ <LLOQ <LLOQ <LLOQ 2.27 <LLOQ <LLOQ <LLOQ 1 1 h 1750 1200 1550 1870 37000 68700 100000 46200## 1 1.5 h 1100 1520 1390 1750 78600 67000 98600 48300## 1 5 h 736 1350 986 469 64100 72200 76300 47500## 2 24 h 160 381 250 448 221000# 30800 55200 41500## 4 72 h 1.66 9.17 7.83 14.8 31600 31100 27500 29100## 8 168 h/Predose <LLOQ 0.484 0.698 1.18 16000 17300 20100 37800 8 1 h 1340 3.32 1980 1610 92000 91900 137000 87500 8 1.5 h 1250 29.6 1680 1460 89900 88400 110000 82500 8 5 h 892 132 1280 1210 38600 72900 74800 88300 9 24 h 239 78.2 554 512 64500 61200 46100 65200 11 72 h 1.17 35.7 43.8 20.8 46300 47100 23000 30500 15 168 h/Predose <LLOQ <LLOQ 2.45 <LLOQ 45000 51.8 <LLOQ <LLOQ 15 1 h 19.3 205 256 5.61 124000 21600 2310 11900 15 1.5 h 5.53 105 190 3.30 75900 33600 497 9800 15 5 h <LLOQ 22.2 157 <LLOQ 85400 10600 246 1170 16 24 h <LLOQ 0.333 35.1 <LLOQ 51700 300 <LLOQ 37.9 18 72 h US US US US US US US US 22 168 h/Predose <LLOQ <LLOQ <LLOQ <LLOQ 9120 <LLOQ <LLOQ 1.09 22 1 h 0.998 <LLOQ <LLOQ <LLOQ 61600 365 <LLOQ 149 22 1.5 h <LLOQ <LLOQ <LLOQ <LLOQ 55500 228 <LLOQ 53.7 22 5 h <LLOQ <LLOQ <LLOQ <LLOQ 44000 26.3 <LLOQ <LLOQ 23 24 h <LLOQ <LLOQ <LLOQ <LLOQ 26100 <LLOQ <LLOQ <LLOQ 25 72 h US US US US US US US US 29 168 h <LLOQ <LLOQ <LLOQ <LLOQ 110 <LLOQ <LLOQ 0.525 # Values are rounded to 3 significant figures. LLOQ (Lower Limit Of Quantification) 0.250 ng/ml; # aberrant value excluded for TK analysis; US: unscheduled sampling; ##Given as indicative due to a technical issue during 1-hour infusion on Day 1 (i.e., 50% of the dose received subcutaneously) - Transient minimal increases in IL-6 concentration were observed after each weekly administration, for both doses (Table 7 maximum levels of 25 and 160 μg/mL for doses of 0.1 and 3 mg/kg/administration, respectively). Table 7 displays individual IL-6 plasma concentration values after a weekly repeat 1-hour intravenous infusion of CD123-NKCE at 0.1 and 3 mg/kg/administration for 4 weeks (on
Days -
TABLE 7 Sampling IL-6 concentration in plasma (pg/mL) Time pre or 0.1 mg/kg/administration 3 mg/kg/administration Day post dose M1♂ M2♂ F3♀ F4♀ M5♂ M6♂ F7♀ F8♀ 1 Predose <LLOQ <LLOQ 0.84 0.54 <LLOQ <LLOQ <LLOQ 2.09 1 1 h 1.52 1.92 3.12 4.65 1.49 1.61 2.63 7.99 1 1.5 h 2.99 4.54 5.09 6.79 2.17 2.98 5.61 14.37 1 5 h 1.83 3.00 3.17 3.55 1.57 8.92 11.41 15.86 2 24 h <LLOQ <LLOQ 0.66 1.98 0.79 1.96 2.15 1.61 8 72 h <LLOQ <LLOQ <LLOQ <LLOQ 0.73 1.63 1.52 0.57 8 168 h/Predose 1.42 2.12 5.04 2.60 1.65 2.35 2.74 4.48 8 1 h 2.97 18.84 9.85 2.46 1.90 2.5 3.92 8.50 8 1.5 h 2.15 18.89 7.69 1.39 1.53 38.04 2.34 2.71 9 5 h 0.92 4.23 1.18 1.56 0.68 3.98 11.58 1.03 15 24 h <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ 0.62 1.58 15 72 h 1.20 1.98 2.93 1.63 2.17 3.14 7.67 68.51 15 168 h/Predose 1.47 1.88 5.72 1.65 2.35 5.02 12.19 85.36 15 1 h 2.33 1.33 1.57 1.33 5.53 2.01 4.09 7.11 16 1.5 h <LLOQ <LLOQ 1.48 6.47 2.76 <LLOQ 1.40 0.71 22 5 h <LLOQ <LLOQ <LLOQ <LLOQ 1.16 <LLOQ 1.34 1.11 22 24 h 2.22 2.79 1.35 4.07 3.12 123.36 27.39 150.97 22 72 h 3.54 3.52 2.23 5.08 2.83 121.88 51.43 159.71 22 168 h/Predose 2.68 4.42 2.89 22.72 2.56 4.07 6.35 22.23 23 1 h <LLOQ 1.53 <LLOQ 0.81 4.52 <LLOQ 1.10 1.29 29 1.5 h 0.79 <LLOQ <LLOQ <LLOQ <LLOQ 0.74 <LLOQ 0.69 LLOQ (Lower Limit Of Quantification): 0.53 pg/mL - In particular, no significant IL-6 release was observed in monkey M5 treated at the high dose (3 mg/kg/administration) which did not exhibit ADA response and was exposed to CD123-NKCE throughout the study (
FIG. 21A andFIG. 21B ), whereas strong PD effects of CD123+ cell depletion were observed in both blood and bone marrow of this monkey (Table 8 andFIG. 21C ). -
TABLE 8 displays the individual absolute counts of basophils and total CD123- positive cells in blood and bone marrow after a weekly repeat 1-hour intravenous infusion of CD123-NKCE at 0.1 and 3 mg/kg/administration for 4 weeks to cynomolgus monkeys. Sampling 0.1 mg/kg/administration 3 mg/kg/administration Day Time M1♂ M2♂ F3♀ F4♀ M5♂ M6♂ F7♀ F8♀ Absolute count of CD123-positive basophils in blood (cells/μL) Predose 1.16 2.79 8.60 2.25 5.65 11.6 15.1 <DL 1 1.5 h <DL <DL <DL <DL <DL <DL <DL <DL 1 5 h <DL <DL <DL <DL <DL <DL <DL <DL 2 <DL <DL <DL <DL <DL <DL <DL <DL 4 <DL <DL <DL <DL <DL <DL <DL <DL 9 <DL <DL <DL <DL <DL <DL <DL <DL 15 1.5 h <DL <DL <DL <DL <DL <DL <DL <DL 16 1.90 <DL <DL <DL <DL <DL 1.87 <DL 23 1.56 <DL <DL 7.61 <DL 10.4 34.7 9.58 29 11.8 3.30 <DL 34.5 <DL 24.9 62.3 17.0 50 4.19 nd 6.30 nd 13.1 nd 12.9 nd Absolute count of total CD123-positive cells in blood (cells/μL) Predose 6.26 6.32 21.9 4.02 9.72 22.8 19.3 1.59 1 1.5 h 5.90 1.83 3.01 3.74 1.50 <DL 1.18 1.24 1 5 h 4.06 1.40 <DL 1.90 <DL <DL <DL <DL 2 3.79 2.00 <DL 2.47 <DL 2.08 2.30 1.48 4 10.3 1.95 2.47 2.43 1.54 1.32 1.84 2.80 9 1.44 <DL <DL <DL <DL <DL <DL <DL 15 1.5 h 5.77 2.16 2.40 3.25 1.15 8.14 12.9 12.3 16 17.7 3.77 2.97 6.42 1.43 7.16 10.2 8.91 23 18.5 8.33 9.52 12.2 1.28 58.5 49.7 32.4 29 33.9 18.2 29.5 47.0 4.15 82.9 72.1 38.1 50 8.81 nd 14.5 nd 16.8 nd 17.3 nd Absolute count of CD123-positive basophils in bone marrow (cells/μL) Predose 439 11.5 30.2 30.0 21.4 14.7 155 21.3 9 <DL <DL <DL <DL <DL <DL <DL <DL 29 74.5 25.6 50.2 89.2 <DL 50.0 235.6 131 50 54.0 nd 185 nd 29.6 nd 43.9 nd Absolute count of total CD123-positive cells in bone marrow (cells/μL) Predose 914 19.8 45.9 51.1 61.6 28.9 218 41.6 9 5.85 <DL <DL <DL <DL <DL <DL <DL 29 140 49.6 192 142 68.4 98.1 311 200.8 50 112 nd 402 nd 50.9 nd 71.6 nd DL (detection limit): 1.15 cells/μL (blood) or 2.10 cells/μL (bone marrow); nd: not done - In all the other animals, a sustained depletion of CD123-expressing cells was observed in the blood 1.5 hours after the first administration and up to 24 hours after the 3rd administration, with a rebound (above baseline) observed on
days 22 to 29 (Table 8). Moreover, all the treated monkeys presented a complete depletion of CD123-positive cells from the bone marrow on day 9 (24 hours after the second administration), for both doses (Table 8; values below the detection limit onday 9 for most of animals), with a restoration of CD123-positive populations atday 29, one week after the last administration. - No clinical signs, changes in body weight or body temperature, and no effects on ECG potentially attributable to treatment with CD123-NKCE were observed, whatever the dose. No compound-related adverse effects on hematological, coagulation, clinical chemistry, or urinary parameters were observed either. Microscopic examination of the tissues sampled revealed no evidence of organ targeting, and all observations noted were considered to lie within the background range of variation and to be unrelated to the administration of the CD123-NKCE.
- Overall, these results thus constitute proof-of-principle for the efficacy of CD123-NKCE in vivo, with no signs of toxicity.
- B.15. NKp46-CD123 NK Cell Engager Tumor Cell Killing with Healthy Donor NK Cells
- NKp46-CD123_F25 and its isotype control IC-CD123_F6 were tested in an in vitro tumor cell killing assay with NK cells taken from 2 different healthy donors (HD).
- NK Cells Purification and AML Cell Line
- Human peripheral blood mononuclear cells (PBMC) from anonymous healthy donors (HD) were isolated by Ficoll density gradient centrifugation. NK cells were purified from these PBMCs with MACSxpress® Whole Blood NK cells isolation kit (Miltenyi Biotec). The NK cells were rested overnight in RPMI1640 (Gibco) supplemented with 10% SVF (BioWest) and 1% L-Glutamine (Gibco).
- THP1 cells (CD123+. CD64+) were chosen for this study based on their expression of CD123. Before the experiment, THP1 cells were infected with Incucyte® Nuclight Green Lentivirus (Sartorius) to express the Green Fluorescent Protein (GFP).
- NK Functional Assay in Presence of NKp46-CD123_F25 Over Time
- NK cells and THP1 GFP target cells were incubated in presence of NKp46-CD123_F25 or its isotype control IC-CD123_F6 at 0.1, 1, 10 and 100 ng/mL at 37° C. The ratio effector:target cells was 1:1. The medium used was the same as for NK cell culture. The target cells were monitored by florescence imaging over 74 h using Incucyte Live Cell Analysis system (EssenBioscience). The number of live target cells was quantified using IncucyteS3 software (2020B version).
- As shown in
FIG. 22 , NKp46-CD123_F25 at different concentrations (1, 10 and 100 ng/mL) enhances the cytotoxic activity of HD NK cells against THP1 GFP AML cells over time at the effector:target cells ratio of 1:1.
Claims (22)
V1A-C1A-Hinge1-(CH2-CH3)A (I)
V1B-C1B-Hinge2-(CH2-CH3)B-L1-V2A-C2A-Hinge3 (II)
V2B-C2B (III)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/308,778 US20230416383A1 (en) | 2020-12-31 | 2023-04-28 | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20306717 | 2020-12-31 | ||
EP20306717.8 | 2020-12-31 | ||
US202163256950P | 2021-10-18 | 2021-10-18 | |
US17/566,142 US11692039B2 (en) | 2020-12-31 | 2021-12-30 | Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123 |
US18/308,778 US20230416383A1 (en) | 2020-12-31 | 2023-04-28 | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/566,142 Division US11692039B2 (en) | 2020-12-31 | 2021-12-30 | Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230416383A1 true US20230416383A1 (en) | 2023-12-28 |
Family
ID=79316794
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/566,142 Active US11692039B2 (en) | 2020-12-31 | 2021-12-30 | Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123 |
US18/308,778 Pending US20230416383A1 (en) | 2020-12-31 | 2023-04-28 | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/566,142 Active US11692039B2 (en) | 2020-12-31 | 2021-12-30 | Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123 |
Country Status (11)
Country | Link |
---|---|
US (2) | US11692039B2 (en) |
EP (1) | EP4271709A1 (en) |
JP (1) | JP2024501539A (en) |
KR (1) | KR20230127306A (en) |
AU (1) | AU2021414400A1 (en) |
CA (1) | CA3206883A1 (en) |
CO (1) | CO2023008958A2 (en) |
IL (1) | IL304124A (en) |
MX (1) | MX2023007901A (en) |
TW (1) | TW202241952A (en) |
WO (1) | WO2022144836A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6840682B2 (en) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Multispecific antigen binding protein |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
WO1997024373A1 (en) | 1995-12-29 | 1997-07-10 | Medvet Science Pty. Limited | Monoclonal antibody antagonists to haemopoietic growth factors |
US7435549B1 (en) | 1997-11-17 | 2008-10-14 | Micromet Ag | Method of identifying binding site domains that retain the capacity of binding to an epitope |
CA2362264C (en) | 1999-02-08 | 2012-05-08 | Medvet Science Pty. Ltd. | Cytokine-binding domain |
EP1161453A4 (en) | 1999-02-08 | 2005-01-05 | Medvet Science Pty Ltd | Cytokine-binding domain |
GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
ATE510855T1 (en) | 2000-03-06 | 2011-06-15 | Univ Kentucky Res Found | USE OF AN ANTIBODIES OR AN IMMUNOTOXIN THAT RESPECTIVELY THAT SELECTIVELY BINDS TO CD123 TO IMPAIR HEMATOLOGICAL CANCER PROGENIC CELLS |
FI117667B (en) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | A pharmaceutical composition suitable for use in orthopedics and dentistry |
RU2005137325A (en) | 2003-05-31 | 2006-09-10 | Микромет Аг (De) | PHARMACEUTICAL COMPOSITION CONTAINING A DESIGN SPECIFIC TO ERS |
FR2879605B1 (en) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | PRODUCTION OF ANTIBODY FORMATS AND IMMUNOLOGICAL APPLICATIONS OF THESE FORMATS |
JP2011505386A (en) | 2007-12-06 | 2011-02-24 | シーエスエル、リミテッド | Methods for inhibiting leukemic stem cells |
US20100209341A1 (en) | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
PT2426148E (en) | 2009-04-27 | 2015-10-26 | Kyowa Hakko Kirin Co Ltd | Anti-il-3ra antibody for use in treatment of blood tumor |
JP5808052B2 (en) | 2009-05-29 | 2015-11-10 | 中外製薬株式会社 | Pharmaceutical composition comprising antagonist of EGF family ligand as ingredient |
NZ601760A (en) | 2010-02-17 | 2013-10-25 | Csl Ltd | Compositions and methods for targeting type 1 interferon producing cells |
CN103068225B (en) | 2010-06-07 | 2015-12-16 | 斯蒂潘公司 | Dilutable biocidal composition and using method |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
CN103153299A (en) | 2010-10-06 | 2013-06-12 | 国立大学法人东京大学 | Prophylactic and/or therapeutic agent against lymphedema |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
CA2816520C (en) | 2010-11-01 | 2017-11-21 | Symphogen A/S | Anti-her3 antibodies and compositions |
EP2658869B1 (en) | 2010-12-30 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
DK2670847T3 (en) * | 2011-02-03 | 2017-01-16 | Xoma Technology Ltd | Methods and Materials for Improving Functional Protein Expression in Bacteria |
US20160046718A1 (en) | 2013-03-14 | 2016-02-18 | Csl Limited | Agents that neutralize il-3 signalling and uses thereof |
WO2014138805A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
MX370272B (en) | 2014-03-19 | 2019-12-09 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy. |
PL3148579T3 (en) | 2014-05-28 | 2021-07-19 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
CA2949325A1 (en) | 2014-06-17 | 2015-12-23 | Cellectis | Cd123 specific multi-chain chimeric antigen receptor |
WO2015197598A2 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
EP3161002A1 (en) | 2014-06-27 | 2017-05-03 | Innate Pharma | MULTISPECIFIC NKp46 BINDING PROTEINS |
CN110642952B (en) | 2014-08-14 | 2021-05-25 | 上海生物制品研究所有限责任公司 | anti-HER 3 antibody, preparation method and application thereof |
EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
EA037647B1 (en) | 2014-09-05 | 2021-04-27 | Янссен Фармацевтика Нв | Cd123 binding agents and uses thereof |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
ES2941897T3 (en) | 2014-11-12 | 2023-05-26 | Seagen Inc | Compounds that interact with glycans and procedures for use |
CN107428835B (en) | 2015-01-23 | 2021-11-26 | 赛诺菲 | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 |
US11014989B2 (en) | 2015-01-26 | 2021-05-25 | Cellectis | Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy |
EP3292149B1 (en) | 2015-05-04 | 2021-12-01 | CytomX Therapeutics, Inc. | Activatable anti-cd71 antibodies, and methods of use thereof |
TW201709932A (en) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | CD123 antibodies and conjugates thereof |
EP3313524A1 (en) | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies |
JP6840682B2 (en) | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Multispecific antigen binding protein |
EP3313881A1 (en) | 2015-06-23 | 2018-05-02 | Innate Pharma | Multispecific nk engager proteins |
CN108495641A (en) | 2015-08-11 | 2018-09-04 | 塞勒克提斯公司 | The cell for immunotherapy for targeting CD38 antigens and the engineering inactivated for CD38 genes |
IL258768B2 (en) | 2015-11-12 | 2023-11-01 | Siamab Therapeutics Inc | Glycan-interacting compounds and methods of use |
MA43389A (en) | 2015-12-02 | 2021-05-12 | Agenus Inc | ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE |
WO2017096276A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
MA43387A (en) | 2015-12-02 | 2018-10-10 | Agenus Inc | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE |
US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
CN108779175B (en) | 2015-12-28 | 2022-07-08 | 依奈特制药公司 | Variable regions of NKp46 binding proteins |
US11027021B2 (en) | 2016-03-15 | 2021-06-08 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors |
US11191771B2 (en) | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
EP3713959A1 (en) * | 2017-11-21 | 2020-09-30 | Innate Pharma | Multispecific antigen binding proteins |
MX2021010281A (en) | 2019-02-26 | 2021-09-23 | Sorrento Therapeutics Inc | Antigen binding proteins that bind bcma. |
WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
JP2024521405A (en) | 2021-06-09 | 2024-05-31 | イナート・ファルマ・ソシエテ・アノニム | Multispecific proteins that bind to NKP46, cytokine receptors, tumor antigens and CD16A |
-
2021
- 2021-12-30 WO PCT/IB2021/062494 patent/WO2022144836A1/en active Application Filing
- 2021-12-30 CA CA3206883A patent/CA3206883A1/en active Pending
- 2021-12-30 EP EP21840696.5A patent/EP4271709A1/en active Pending
- 2021-12-30 US US17/566,142 patent/US11692039B2/en active Active
- 2021-12-30 TW TW110149620A patent/TW202241952A/en unknown
- 2021-12-30 JP JP2023539973A patent/JP2024501539A/en active Pending
- 2021-12-30 KR KR1020237025940A patent/KR20230127306A/en unknown
- 2021-12-30 MX MX2023007901A patent/MX2023007901A/en unknown
- 2021-12-30 AU AU2021414400A patent/AU2021414400A1/en active Pending
-
2023
- 2023-04-28 US US18/308,778 patent/US20230416383A1/en active Pending
- 2023-06-28 IL IL304124A patent/IL304124A/en unknown
- 2023-07-05 CO CONC2023/0008958A patent/CO2023008958A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022144836A1 (en) | 2022-07-07 |
KR20230127306A (en) | 2023-08-31 |
CA3206883A1 (en) | 2022-07-07 |
TW202241952A (en) | 2022-11-01 |
US11692039B2 (en) | 2023-07-04 |
JP2024501539A (en) | 2024-01-12 |
EP4271709A1 (en) | 2023-11-08 |
IL304124A (en) | 2023-09-01 |
MX2023007901A (en) | 2023-07-11 |
US20220213202A1 (en) | 2022-07-07 |
CO2023008958A2 (en) | 2023-08-18 |
AU2021414400A1 (en) | 2023-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022507295A (en) | Therapeutic SIRPα antibody | |
CN113412279A (en) | Humanized anti-SIRP alpha antibodies | |
CN115023441A (en) | Heavy chain antibodies that bind to CD38 | |
CN114007699A (en) | Antagonist anti-CD7 antibodies | |
US20230416383A1 (en) | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 | |
US20220315663A1 (en) | TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3 | |
TW202309088A (en) | New stable anti-vista antibody | |
JP2022537703A (en) | Antibodies and directions for use | |
CN117255807A (en) | Multifunctional Natural Killer (NK) cell adaptor binding to NKp46 and CD123 | |
JP2024521408A (en) | Multispecific antibodies binding to CD20, NKP46, CD16 and conjugated to IL-2 | |
JP2021501583A (en) | Antibodies and usage | |
JP2022553927A (en) | Treatment of cancer with ILT-2 inhibitors | |
US20240084014A1 (en) | Multispecific binding compounds that bind to pd-l1 | |
US12030951B2 (en) | Anti-OX40 antibody and uses thereof | |
US20230151105A1 (en) | Anti-ox40 antibody and uses thereof | |
WO2022098910A1 (en) | Icos antibodies for treatment of lymphomas | |
WO2023245097A2 (en) | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof | |
TW202336033A (en) | Novel combination and use of antibodies | |
CN116964091A (en) | Human CCR8 binding agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AMARA, CELINE;CHIRON BLONDEL, MARIELLE;DUFFIEUX, FRANCIS;AND OTHERS;SIGNING DATES FROM 20211123 TO 20211208;REEL/FRAME:063479/0936 Owner name: SANOFI, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT;REEL/FRAME:063480/0056 Effective date: 20211215 Owner name: SANOFI, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENINGA, JOCHEN;REEL/FRAME:063480/0020 Effective date: 20211124 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |